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THESIS ABSTRACT 
Proton magnetic resonance spectroscopy ( 'H MRS) was used to assess chronic liver disease 
non-invasively. 'H MRS was optimised to study intact liver tissue in vitro and used to derive 
hepatic metabolic profiles in murine models of non-alcoholic fatty liver disease. The technique 
was applied to liver biopsy specimens from 47 patients with chronic hepatitis C. In vitro MRS 
data were used to inform analysis and aid interpretation of in vivo MR spectra. Findings were 
validated in a separate cohort of 59 patients in vivo. Diagnostic performance of other emerging 
non-invasive techniques, ultrasound and serum markers, were compared with histology in 67 
patients with chronic hepatitis C. Finally, 38 patients underwent comparative 'H MRS, transient 
elastography and AST to platelet ratio index (APRI). 
Multivariate pattern recognition enabled distinction of murine liver tissue by strain and diet. 
There was correct prediction of histologically-defmed steatohepatitis from steatotic and normal 
samples. 
Disease severity was correctly predicted in 46 of 47 human liver samples. Lipid and choline 
resonances contributed predominantly to statistical models. 'H MRS indices of total lipid, lipid 
saturation and polyunsaturation, and choline were derived in vitro and validated in vivo. Total 
lipid assessed by 'H MRS was higher in patients with genotype 3 than genotype 1. The degree 
of fatty acid polyunsaturation decreased with fibrosis stage and steatosis. 
In 67 patients with hepatitis C, APRI combined with either transient elastography or the serum 
panel marker, ELF, effectively predicted fibrosis stage, while three or more tests combined led 
to redundancy of information. Microbubble ultrasound performed least well. In the smaller 
cohort, 'H MRS improved prediction of hepatic fibrosis when combined with transient 
elastography or APRI. 
In conclusion, assessment of hepatic lipid composition by 'H MRS is of biological importance 
in chronic liver disease and complements data conveyed by other modalities. 
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1 INTRODUCTION 
1.1 The clinical problem 
Chronic liver disease is a major cause of morbidity and mortality worldwide. The presence of 
chronic inflammation and consequent fibrosis leads to the development of cirrhosis and its 
complications. End-stage liver disease accounts for one in 40 deaths worldwide, according to 
World Health Organisation estimates from 2002 (Perz et al, 2006). In the United States, 
cirrhosis accounted for 25 000 deaths in 1998 and the worldwide prevalence of cirrhosis has 
been estimated at up to 1% (Schuppan and Afdhal, 2008). 
Chronic liver disease has a varied aetiology, including viruses, such as hepatitis B (HBV) and 
hepatitis C (HCV). Worldwide, over half a billion people may be chronically infected with 
either of these viruses (World Health Organisation, 2000; World Health Organisation, 2008). 
Metabolic causes include the increasingly prevalent non-alcoholic fatty liver disease (NAFLD). 
Toxic causes, such as excess alcohol consumption, and autoimmune disorders, such as primaiy 
biliary cirrhosis and autoimmune hepatitis, contribute to the disease burden. Over half of the 
deaths attributable to cirrhosis and nearly 80% of those attributable to primary liver cancers 
occur in those who have chronic HBV and HCV infection (Perz et al., 2006), while in many 
developed nations excess alcohol consumption is the commonest cause. 
Chronic liver disease takes many years to progress from inflammation, associated with 
hepatocellular injury, to fibrosis and requires long-term exposure to the causative agent. 
Progressive scarring or fibrosis develops during the period of time between initiation and end-
stage disease. The resulting pre-cirrhotic fibrosis is a target for therapies aimed at reducing the 
rate of progression to cirrhosis, or even reversal of fibrosis (Friedman, 2003). 
Effective antiviral therapies and the advent of antifibrotic drugs have led to increasing demand 
for non-invasive, accurate and reliable biomarkers of hepatic disease severity. It is recognised 
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that the current "gold standard", histological analysis of liver biopsy, has limitations and 
engenders risk to the patient. Sampling variability and the subjective interpretation of scoring 
systems means that consistency and the representation of the true disease state is questionable. 
The procedure frequently causes discomfort and there is a risk of morbidity and a small, but 
significant, mortality rate (Gilmore et al., 1995). These risks preclude frequent serial biopsies in 
most cases. Emerging non-invasive imaging-based technologies, particularly using ultrasound 
and nuclear magnetic resonance (NMR), allow a quantitative assessment of different aspects of 
disease from metabolic markers of inflammation, through assessment of fibrotic load, markers 
of portal hypertension and prognostic indicators of the complications of cirrhosis (Cobbold et 
al., 2006). 
There is a clear need for safe and effective non-invasive markers of hepatic fibrosis, both for the 
management of individual patients and for the development of new antifibrotic therapies. 
Imaging modalities have the potential to fulfil this role. 
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1,2 Chronic liver disease 
Chronic liver disease occurs over months and years. Resultant morbidity and mortality are 
largely associated with the development of end-stage liver disease. Cirrhosis is defined as the 
histological development of regenerative nodules surrounded by fibrous bands in response to 
chronic liver injury, leading to portal hypertension and end-stage liver disease (Schuppan and 
Afdhal, 2008). The condition is indolent and frequently asymptomatic until the development of 
complications, occurring late in the disease process. Such complications include variceal 
haemorrhage, ascites, spontaneous bacterial peritonitis and hepatic encephalopathy. Cirrhosis is 
a risk factor for the development of hepatocellular carcinoma (Fattovich et al., 2004). 
1.2.1 The natural history of chronic liver disease 
Chronic liver injury may lead to fibrosis as a result of accumulation of "scar" tissue. Liver 
injury leads to initiation and perpetuation of inflammatory processes, which, by a cascade of 
inter-related processes and pathways, leads to deposition of fibrous proteins, such as collagens 
(Figure 1-1). By convention, fibrosis has been considered potentially reversible, while the end-
stage, cirrhosis, has been considered irreversible. However, with elimination of the cause of 
liver injury, a number of studies have demonstrated regression of all stages of fibrosis in animal 
models and in humans (Hammel et al., 2001; Iredale et al., 1998; Iredale, 2001; Kweon et al., 
2001; Poynard et al., 2002). Elucidation of the process of fibrogenesis enables markers of 
disease severity and potential targets for therapeutic intervention to be developed. 
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Figure 1-1. Histology of normal liver, fibrosis and cirrhosis 
Representative histological images (magnification x200, Masson 's trichrome staining) of A, normal liver, 
B, mild to moderate fibrosis (META VIR F=2, Ishak stage i j ; C, moderate "bridging" fibrosis (META VIR 
F=3, Ishak stage 4)\ D, cirrhosis (META VIR F=4, Ishak 5 or 6). Adapted from www. PHEONIXCME. org 
1.2.2 Normal liver 
Normal liver consists of rows of hepatocytes surrounded by fenestrated endothelium within 
sinusoids containing venous blood. Kupffer cells (tissue macrophages) are present within 
sinusoids. The space of Disse lies between the hepatocytes and the endothelial layer and 
contains a basement membrane-like matrix (extracellular matrix- ECM), which is essential for 
maintainance of functioning liver cells. Hepatic stellate cells (HSC), also called Ito cells or 
perisinusoidal cells, are present in the space of Disse and are thought to be the principal cell 
type involved in hepatic fibrogenesis (Figure 1-2) (Friedman, 2003). 
1.2.3 Anatomy of liver fibrosis 
In chronic liver disease, the composition of the ECM is altered with increasing fibrosis to 
contain higher quantities of collagens, and a change in conformation from low-density basement 
membrane-like lattice matrix, through which solutes and growth factors are freely diffusible, to 
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a disordered interstitial type matrix, which interferes with hepatic function (Figure 1-2) 
(Friedman, 2003). 
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Figure 1-2. Schematic of sinusoidal structure in health and fibrotic liver disease. 
Panel A shows the sinusoidal space in healthy liver, while panel B shows some of the changes that occur 
with the development offibrosis, resulting in deterioration of hepatic function. Adapted from Friedman 
2000. 
1.2.4 Mechanism of flbrogenesis (Friedman, 2003; Friedman, 2008) 
The HSC has a central role in the pathogenesis of liver fibrosis. These cells comprise 15% of 
liver cells and are thought to be derived from neural crest tissue, on account of the expression of 
neural crest markers, including glial fibrillary acidic protein and nestin (Niki et al., 1999). 
HSCs are activated following liver injury from a relatively quiescent lipid and vitamin A-storing 
phenotype to a myofibroblastic phenotype capable of proliferation, contraction and fibrogenesis. 
Recently, other myofibroblastic cell populations have also been shown to be involved in 
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fibrogenesis, including portal fibroblasts (Beaussier et al, 2007) and bone marrow-derived cells 
(Forbes et al., 2004). 
HSC activation occurs through two stages; initiation and perpetuation, each of which involves 
characteristic pathways, as described by Friedman. 
1.2.4.1 Initiation 
Initiating events may consist of any chronic perturbation of hepatic homeostasis, which is often, 
but not always, associated with the presence of inflammatory cells. Such perturbations of 
hepatic homeostasis may lead to the net over-production of unstable reactive oxygen species 
(ROS) derived from hepatocytes, macrophages, stellate cells and inflammatory cells. ROS are 
potent mediators of the initiation and perpetuation of liver injury, and cause lipid peroxidation 
of cellular membranes. The importance of lipid peroxidation extends beyond the activation of 
stellate cells and is also of considerable importance to the development of insulin resistance and 
hepatic steatosis, as described in more detail in section 1.5.3. 
Cell death is both a cause and a consequence of altered hepatic homeostasis that leads to the 
upregulation of the inflammatory response and activation of fibrogenic pathways. Cell death 
occurs in two modes, apoptosis and necrosis, with differing mechanisms and local responses. 
Apoptosis, or programmed cell death, of parenchymal cells represents an important 
inflammatory stimulus, which can activate HSCs (Jaeschke, 2002). Necrosis, which is often 
found to coexixt with apoptosis in histological sections, is also a potent activator of 
inflammation and fibrogenesis, associated with redox imbalance (Poli, 2000). 
During initiation (or the pre-inflammatory phase), there is immediate early gene expression 
leading to changes in the phenotype of HSCs, which results in increased responsiveness to 
cytokines and other local stimuli. Injury to cells nearby causes changes in cellular homeostasis 
and to ECM composition. Release of reactive oxygen intermediates from damaged hepatocytes 
stimulates local HSCs and the activity of HSCs in culture has been shown to increase upon 
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depletion of antioxidants. In addition, culture medium taken from hepatocytes undergoing 
oxidative stress results in increased proliferation and collagen synthesis, when applied to 
cultured HSCs (Svegliati et al, 1998). Damage to endothelial cells also contributes to HSC 
activation by the production of a splice variant of cellular fibronectin (Jarnagin et al., 1994) and 
by converting transforming growth factor (31 (TGF(3) to its active form through activation of 
plasmin (Friedman, 1999). Furthermore, the infiltration and activation of Kupffer cells (KCs) is 
temporally associated with expression of HSC activation markers. TGpp and other cytokines 
from KCs stimulate the synthesis of ECM and KCs also release ROS in response to injury. 
1.2.4.2 Perpetuation 
Perpetuation of HSC activation is comprised of a number of cellular responses, which lead to 
increase expression of, and responsiveness to, growth factors. Perpetuation is a dynamic 
process, occuring along a number of pathways associated with different HSC responses. These 
responses include release of largely proinflammatory cytokines, proliferation and increased 
contractility of HSCs, chemotaxis of inflammatory cells and the net deposition of pathological 
ECM. 
1.2.4.2.1 Cytokine release 
A large number of autocrine and paracrine cytokines are released during activation, including 
TGF(3, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), platelet 
activating factor and endothelin-1 (ET-1) (Pinzani et al., 1994; Pinzani and Marra, 2001). 
Neutrophil and monocyte chemoattractants are also released leading to increased local 
inflammatory infiltration (Marra et ah, 1998). 
1.2.4.2.2 Proliferation 
The expression of a number of mitogenic factors and upregulation of their tyrosine kinase 
receptors (TKRs) leads to proliferation of HSCs. PDGF is a potent stimulator of proliferation 
that, together with its receptor, has been shown to be up-regulated following liver injury 
(Pinzani et al, 1994). A TKR, discoidin domain receptor-2 (DDR-2) binds to fibrillar collagen 
as its ligand, provoking a biochemical cascade, leading to activation of matrix 
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metalloproteinase-2 (MMP-2), which is itself a HSC mitogen (Olaso et al, 2001; Olaso et al, 
2002^ 
1.2.4.2.3 Contractility 
Activation of HSCs also leads to increased contractility of the myofibroblastic phenotype and 
impedence of portal blood flow by constriction of sinusoids and overall contraction of the 
cirrhotic liver. This is mediated by endothelin-1 (ET-1) (Racine-Samson et al., 1997), the action 
of which is opposed by nitric oxide (NO), also produced by a number of liver cell types. 
Progressive development of intrahepatic shunts occurring in concert with the constriction of 
hepatic sinusoids has been postulated to require angiogenic responses. 
1.2.4.2.4 Chemotaxis 
Activated HSCs migrate to areas of hepatic injury and a number of growth factors have been 
identified within the liver that have chemoattractant as well as mitogenic properties. These 
include PDGF, IGF-1, ET-1, monocyte chemoattractant protein 1 and the chemokine receptor 
CXCR3 (Bonacchi et al., 2001; Gentilini et al., 2000; Marra et al., 1998; Tangkijvanich et al., 
2001^ 
1.2.4.2.5 Matrix accumulation and degradation 
HSCs, platelets and KCs secrete TGppi , which is activated by MMPs and tissue plasminogen 
activator (tPA). TGF(3 receptors are upregulated upon activation of HSCs leading to increased 
responsiveness and increased manufacture of ECM components (Gressner et al., 2002). The 
build up of pathological ECM or scar tissue is a dynamic process with competition between 
accumulation and degradation. Degradation may be divided into that of the normal, low density 
ECM, termed "pathological matrix degradation", which is associated with worsening liver 
disease and degradation of the higher density fibrotic ECM, termed "restorative matrix 
degradation" which is associated with improvement in fibrosis and restoration of normal hepatic 
architecture (Friedman, 2003). 
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Matrix-metalloproteinases (MMP) are calcium dependent enzymes, which degrade collagens 
and other substrates. MMPs may be divided into categories dependent on their specific 
substrate, for example: collagenases, stromelysins, gelatinases and membrane-type MMPs (Poli, 
2000). Activated HSCs express latent proenzymes of MMPs, which are then activated by 
proteolytic cleavage by urokinase or tissue plasminogen activator (He et al., 1989). The hepatic 
tissue expresses tissue inhibitors of metalloproteinases (TIMP) specific to each MMP type, 
which inhibit MMP activity and help to localize MMP activity where it is required (Benyon and 
Arthur, 2001). Protein structures determine the binding of MMPs and their respective TIMPs 
according to strict ratios and determine the resultant activity. Accordingly, net quantities of 
these enzymes determine local collagenase activity. 
In the progression from fibrotic to cirrhotic liver, there appears to be a relative deficiency in 
collagenase activity, such that degradation of type 1 collagen, the main component of 
pathological ECM is impaired. Marked increases in TIMP-1 and TIMP-2 have been observed in 
progressive fibrosis leading to decreased MMP activity. HSCs are thought to be the major 
source of these inhibitors, representing another role for HSCs in the pathogenesis of fibrosis 
(Iredale, 2001). 
1.2.4.3 Extracellular matrix 
The interaction between HSCs and the ECM also appears to be important in the initiation and 
perpetuation of fibrogenic processes by a number of positive feedback pathways. These include 
changes in membrane receptors, such as integrins, which promote migration and contraction, 
activation of cellular MMPs, and increases in matrix stiffness. It appears that a number of 
hepatic cell types are mechanosensitive, leading to stellate cell activation and upregulation of 
profibrogenic receptors, associated with increased matrix stiffness (Wells, 2008). 
1.2.4.4 Resolution of fibrosis 
For resolution of fibrosis to occur, removal of the injurious agent is prerequisite. Activation of 
HSCs has been shown to be crucial for the development of fibrosis, while in recovery and 
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resolution of fibrosis, the number of activated HSCs is reduced. The latter may occur as a result 
of reversion to the quiescent form or by apoptosis. Return to the quiescent form has been 
observed in vitro (Sohara et ai, 2002), but not in vivo. Apoptosis has been postulated as the 
predominant mechanism for removal of HSC activity. It has been shown that spontaneous 
apoptosis of HSCs occurs in vitro. Conversely, it has also been shown that MMP-2 levels 
correlate with apoptosis and may be stimulated by apoptosis (Preaux et al., 2002) and that 
TIMP-1, by inhibition of MMP, leads to inhibition of activated HSC apoptosis (Murphy et ah, 
2002y 
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1.3 Hepatic steatosis 
Liver fibrosis is the key pathological feature of progressive liver disease. However, the 
accumulation of excessive hepatic triglyceride, hepatic steatosis, is increasingly recognised as 
an important factor in the pathogenesis of a number of chronic liver diseases, not simply an 
"innocent bystander". 
1.3.1 Definitions 
Hepatic steatosis is a pathological lesion, defined as the presence of large and small vesicles of 
fat, predominantly triglycerides, accumulating within hepatocytes (Clark et ah, 2002). Hepatic 
steatosis is frequently associated with obesity, insulin resitance and dyslipidaemia in those who 
do not drink excessive alcohol, when it is termed non-alcoholic fatty liver disease (NAFLD) 
(Angulo, 2002). Hepatic steatosis may also be a result of secondary causes, which include 
alcoholism, hepatitis C virus, severe weight loss, total parenterol nutrition and drugs (such as 
amiodarone, diltiazem, tamoxifen, steroids and highly active antiretroviral therapy) (Sanyal, 
2002). NAFLD may thus be considered a syndrome of various aetiologies, excluding alcohol 
and, by convention, hepatitis C. 
1.3.2 Epidemiology 
As there is no simple non-invasive test for NAFLD, the prevalence of NAFLD has been 
estimated by extrapolation from other studies. Angulo estimated the prevalence of NAFLD in 
the U.S. population to be around 30 million (or 21% of adults) in 2000 on the basis of the 
prevalence of obesity in the US population, multiplied by the proportion of those found to have 
hepatic steatosis in studies of obese people (Angulo, 2002). Clark and colleagues estimated the 
prevalence to be 31 million (or 23% of adults) in the U.S on the basis that 79% of patients with 
mildly abnormal liver function tests and no other cause described are likely to have NAFLD 
(Clark et ah, 2002). 
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1.3.3 Pathophysiology 
The development of hepatic steatosis occurs when the rate of synthesis or import of fatty acids 
by hepatocytes exceeds the rate of export or catabolism. Such an imbalance can occur in a 
number of ways: 
1.3.3.1 Increased uptake of fatty acids by hepatocytes 
Hepatic steatosis is strongly associated with obesity. Adipose tissue is a metabolically active 
tissue and is a source of a number of mediators of carbohydrate and lipid metabolism, including 
leptin, adiponectin, apolipoprotein E, and lipoprotein lipase. It is also a source of a number of 
cytokines, including TNFa, IL-6 and TGF|3 (Brunt, 2004). TNFa levels rise in obesity, and 
TNFa activates IKB kinase P, which inhibits phosphorylation of insulin receptor subtrates, one 
of the mechanisms leading to insulin resistance. This reduces the insulin-mediated suppression 
of hormone sensitive lipase, increasing the release of fatty acids into the circulation (Day, 
2002). TNFa also mediates upregulation of hepatic fatty acid translocase, increasing hepatic 
uptake of fatty acids (Memon et aL, 1998). 
1.3.3.2 Increased hepatic fatty acid and triglyceride synthesis 
Insulin resistance leads to hyperinsulinaemia, and consequently to increased fatty acid synthesis 
by glycolysis and decreased levels of apolipoprotein B-lOO, reducing triglyceride export. 
Increased fatty acid synthesis is promoted by the transcription factor, sterol regulatory element-
binding protein-Ic (SREBP-lc). SREBPs are also activated by hepatitis C viral proteins 
(section 1.5.2.2). Higher glucose levels lead to increased de novo fatty acid synthesis via 
carbohydrate response element-binding protein (ChREBP). 
1.3.3.3 Impairedfatty acid mitochondrial /3-oxidation 
Saturation of mitochondrial P-oxidation of fatty acids exacerbates hepatic steatosis and is 
associated with mitochondrial dysfunction and the release of ROS (Angulo, 2002). As 
mitochondrial oxidative capacity becomes overwhelmed, alternative oxidative pathways are 
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used, including peroxisomal P-oxidation and endoplasmic reticular ©-oxidation, both of which 
lead to the increased production of ROS (Reddy, 2001). 
1.3.3.4 Reduced VLDL synthesis and triglyceride secretion 
The rate limiting step for the export of hepatic triglycerides is the lipidation of apolipoprotein 
BlOO by microsomal triglyceride transfer protein (MTP) at the endoplasmic reticulum. 
Mutations in the gene for MTP lead to the autosomal recessive abetalipoproteinaemia, 
characterised by severe hepatic steatosis, while a number of drugs which cause hepatic steatosis, 
including amiodarone, have been shown to have deleterious effects on MTP activity (Anstee 
and Goldin, 2006). Importantly, HCV core protein has been shown to inhibit this process, 
providing a direct route to hepatic steatosis in HCV infection (section 1.5.2.2). 
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1.4 Hepatitis C as a relevant model of chronic liver disease 
Cohorts of patients with hepatitis C virus (HCV) infection provide an appropriate disease model 
for the study of chronic liver disease. The natural history of the disease and its histological 
classification are well established, the prevalence of the disease is high in many countries and 
effective treatment options are available (Bedossa and Poynard, 1996; Ishak et al., 1995; 
Poynard et aL, 1997). HCV is a single stranded RNA virus from the Flaviviridae family, with an 
estimated 170 million people infected worldwide (World Health Organisation, 2000). There are 
a number of HCV genotypes, the most prevalent being genotypes 1 to 4, which are 
geographically-related and which differ in terms of response to treatment and, controversially, 
disease progression (Esteban et al., 2008; Zein, 2000). Transfer of blood and blood products is 
the most common mode of transfer. The median time from infection with HCV to development 
of cirrhosis has been calculated to be 30 years (Poynard et al., 1997). Within the population, 
slow, intermediate and rapid fibrosers have been identified, leading to estimates of 33% of those 
infected developing cirrhosis within 20 years and 31% taking longer than 50 years (Ghany et 
al., 2003). Viral, host and environmental factors have all been implicated in the variation in 
progression of fibrosis between individuals (Feld and Liang, 2006). Histologically determined 
improvement in fibrosis takes between 2 and 3 years, which necessitates follow-up times of this 
order in longitudinal studies, although a slowing of progression in those responding to treatment 
compared to those not responding may be detected at earlier timepoints (Dienstag et aL, 2003; 
Poynard et al., 2002). 
While many mechanisms of hepatic injury in chronic hepatitis C infection (CHC) are common 
to other causes of liver disease, some are specific. HCV has a number of receptors on 
hepatocytes, including CD81 (Stamataki et al., 2008), the LDL receptor and Clq, which are also 
expressed on stellate cells (Friedman, 2008). Furthermore, hepatitis C viral proteins (non-
structural and core) induce stellate cell proliferation and the release of proinflammatory 
cytokines, which may initiate or augment fibrogenic pathways (Dataller et al., 2004). CHC is 
also associated with hepatic steatosis, as will be discussed in section 1.5.2. 
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1.5 Hepatitis C and hepatic steatosis 
1.5.1 Epidemiology 
In a review of studies of patients with CHC, the prevalence of steatosis overall ranged from 40-
86% (mean around 55%), while the mean prevalence of steatosis in patients with HCV genotype 
3 was 73% (Asselah e/ al., 2006). This prevalence far exceeds that seen in non-infected western 
populations (Clark et al., 2002; Sanyal, 2002) (section 1.3.2). 
Steatosis is thus more common in patients with hepatitis C than in the general population. 
Aetiological factors associated with hepatic steatosis, such as obesity, high alcohol 
consumption, type-2 diabetes and hyperlipidaemia may also be coexistent in CHC, but the 
increased prevalence points to specific mechanisms related to the HCV itself, or to the host 
response to the virus. 
1.5.2 Steatosis in HCV 
The steatosis score has been shown to correlate with the viral load in patients with genotype 3, 
but with insulin resistance in genotype 1 (Fartoux et al., 2005). In another study, steatosis in 
CHC did not correlate with BMI in a cohort of patients with CHC of mixed genotypes, but the 
grade of steatosis was associated with high visceral fat in patients with genotype 1, but not in 
those with genotype 3 (Adinolfi et al., 2001). This genotype-related nature suggested that, in 
patients with CHC, steatosis could have "metabolic" origins, particularly in patients with 
genotype 1, and "viral" origins, associated most with genotype 3. The relationship between 
hepatic steatosis, insulin resistance, HCV and liver injury is summarised in Figure 1-3. 
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Figure 1-3. Hepat ic steatosis, l iver injury, insulin resistance and hepatitis C 
Panel A summarises some mechanisms associated with the development of simple hepatic steatosis. Panel 
B summarises interactions of hepatitis C virus on hepatic steatosis, insulin resistance, oxidative stress 
and hepatocellular injuiy. Arrows signify increases or activation; blunt ends, inhibition. Abbreviations: 
(F)FA, (free) fatty acid, TG, triglyceride; Apo B, apolipoprotein B; MTP, microsomal triglyceride 
transfer protein; IR, insidin resistance; HCV core, HCV core protein; HCV NS5A, HCV non-structural 
protein 5 A; SREBP, steroid responsive binding protein; ECM, extracellular matrix. 
1.5.2.1 "Metabolic" steatosis is associated with insulin resistance in a cytokine-mediated 
host response to the hepatitis C virus 
Epidemiological evidence from a case cohort study suggested that patients with HCV were 12 
times more likely to be at high risk of type-2 diabetes (T2DM) (Mehta et al., 2003). This 
suggested that HCV accelerates the onset in those already at risk of T2DM, but that young 
people with low BMI were not subject to an increased risk. Accordingly, HCV might be 
considered a conditional risk factor for T2DM. 
A number of studies have documented a relationship between HCV and insulin resistance 
(Asselah et al., 2006). Patients with HCV have greater insulin resistance than healthy controls 
(Hui et al., 2003), and the presence of insulin resistance is associated with moderate to severe 
steatosis (Camma et al., 2006). However such clinical studies are susceptible to confounding by 
obesity and alcohol use, although, in vitro studies have demonstrated specific mechanisms. 
Mice transgenic for the HCV core protein displayed high serum insulin levels and increased 
insulin resistance, compared to controls. Feeding a high-fat diet caused diabetes in the 
transgenic animals but not in controls. Tumour necrosis factor alpha (TNFa) was found to be 
raised in the transgenic mice and anti-TNFa restored insulin sensitivity (Shintani et al., 2004). 
Molecular pathways leading to insulin resistance in CHC have recently been reviewed, and 
include the release of TNFa, lL-6 and TGF(3 as a consequence of the release of reactive oxygen 
species (ROS), as part of the Kupffer cell-mediated, pro-inflammatoiy immune response against 
the HCV (Sheikh et al., 2008). TNFa modulates adipocytes affecting cytokine, adiponectin and 
leptin production, which can lead to insulin resistance. TNFa causes down-regulation of 
glucose transporter gene expression and, consequently, the reduced uptake of glucose into 
hepatocytes promotes hyperglycaemia and hyperinsulinaemia. Increased IL-6 is part of the 
virally-induced pro-inflammatory state found in patients with HCV and promotes insulin 
resistance by means of an acute phase response. 
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1.5.2.2 " Viral" steatosis is directly mediated by viral proteins 
In cell culture, the non-structural gene, NS5A, associates with the endoplasmic reticulum and 
stimulates mitochondrial ROS production and activating nuclear factor-KB, upregulating 
cytokine production (including TNFa) . The HCV core protein has been shown to interact with 
lipid droplets (Barba et at., 1997) and studies have demonstrated that the lipid droplet is 
involved in the production of infectious viral particles, whereby core protein recruits a 
replication complex to the lipid droplet-associated membranes (Miyanari et al., 2007). In 
murine models, HCV core protein was seen to inhibit activity of MTP within the endoplasmic 
reticulum. MTP stabilises apoliprotein B (apoB) by lipidation. Lipidated apoB associates with 
triglycerides to form very low density lipoproteins (VLDL), so decreased MTP activity leads to 
intracytoplasmic lipid accumulation (Perlemuter et al., 2002). ApoB levels were inversely 
correlated with the steatosis score and correlated with decreased cholesterol levels in a cohort of 
male patients with CHC (Serfaty et al., 2001). Furthermore, MTP mRNA expression in liver 
biopsies from patients with CHC was inversely correlated with the degree of steatosis and with 
serum insulin levels. In addition, MTP-activity was significantly lower in genotype 3 than in 
genotype 1 (Mirandola et al., 2006). Cell culture experiments have shown that the production of 
low density lipoviral particles occurs in the endoplasmic reticulum and is dependent on MTP 
and apoB, a mechanism closely related to the production of VLDL. These studies demonstrated 
that HCV coopts VLDL assembly, maturation, degradation and secretory pathways within the 
cell, providing a possible mechanism for hepatocyte tropism and immune evasion (Gastaminza 
et al., 2008). Elegent studies by Kapadia and Chisari demonstrated that, in cell lines, HCV 
RNAs express enzymes involved in cholesterol and fatty acid biosynthesis. These authors 
showed that the fatty acid content of the cell and the levels of geranylgeranyl pyrophosphate (a 
post-transcriptionally modified protein originating within the cholesterol biosynthetic pathway) 
determine HCV RNA replication (Kapadia and Chisari, 2005). Whereas saturated and 
monounsaturated fatty acids induced HCV RNA replication in vitro, polyunsaturated fatty acids 
(PUFAs) inhibited HCV RNA replication. Furthermore, 3-hydroxy-3-methy 1 glutary 1 coenzyme 
A (HMG-CoA) reductase inhibitors ("statins") have been shown to display antiviral effects 
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when combined with interferon-a in vitro and this effect is reversed by the addition of 
geranylgeraniol (Ikeda et al., 2006). Core protein may also act indirectly to cause mitochondrial 
dysfunction by inhibition of peroxisome proliferator-activated receptor alpha (PPARa). This 
leads to decreased circulating levels of adiponectin, associated with insulin resistance (Sheikh et 
aA,2008^ 
Further studies implicate sterol regulatory binding protein (SREBP), which promotes fatty acid 
synthesis, in the development of HCV-related steatosis (Mengshol et al., 2007). Cell lines 
transfected with HCV genotype lb core protein demonstrated increased SREBP levels and 
activity (Kim et al., 2007), while HCV (genotype 2a) infection was shown to cause proteolytic 
cleavage of sterol regulatory binding proteins (SREBP). Core protein and NS4b from genotype 
3a were shown to induce proteolytic processing of SREBP. The mechanism for the cleavage and 
activation of SREBP is thought to arise from oxidative stress and such activation results in the 
up-regulation of genes involved in lipogenesis and cellular uptake of lipoproteins (Waris et al., 
2007y 
HCV induces hepatic steatosis through a number of routes and further work is required to 
elucidate further the mechanisms which may yield targets for future therapy (Mengshol et al., 
2007; Sheikh et al., 2008). While a number of direct pathways have been described for the 
development of "viral" steatosis, "metabolic" steatosis may be considered the result of 
virus/host interaction and, in particular, the inflammatory response, promoting insulin resistance 
and hepatic steatosis. 
1.5.3 Oxidative stress 
A common factor in many pathways for the development of hepatic steatosis and hepatic injury 
in CHC is the presence of oxidative stress (Figure 1-3). Oxidative stress may be defined as an 
unbalanced increase of ROS with predominantly pro-oxidant activity exerted on different 
molecules, potentially able to affect their structure and function (Poli, 2000). ROS include 
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superoxide, hydrogen peroxide and hydroxyl radicals, all of which may directly cause cellular 
injury and genetic mutations. Lipid cell membrane constituents, particularly PUFA, are the main 
substrate for peroxidation within the liver and membrane lipid peroxidation end-products, such 
as covalently-bonded malondialdehyde (MDA) and 4-hydroxy-2,3-nonenal (HNE) adducts, 
have been detected by immunohistochemistry in chronic hepatitis C, correlating with fibrosis 
score and histological activity (Paradis et al., 1997b). Although lipid peroxidation products have 
been documented histologically in a number of chronic liver diseases (Paradis et al., 1997a), 
higher levels of MDA and activation of glutathione turnover have been demonstrated in patients 
with hepatitis C than in those with hepatitis B (Farinati et al., 1995). A further study 
investigated the presence of lipid peroxidation products and antioxidants in a cohort of patients 
with hepatitis C, finding that levels of peroxidation markers, such as the ratio of oxidized to 
reduced glutathione and 8-isoprostane were significantly increased, and the levels of 
antioxidants significantly decreased in patients with both cirrhotic and precirrhotic disease 
compared to controls (Jain et al., 2002). Oxidative stress is central to a number of mechanisms 
of hepatic injury and the development of hepatic steatosis. 
1.5.3.1 Oxidative stress is caused by the hepatitis C virus and other insults 
The HCV components, core protein, NS3 and NS5a, can interact with mitochondria and the 
endoplasmic reticulum to increase the fonnation of ROS (Okuda et al., 2002) and as described 
in section 1.5.2.2. Ethanol metabolism and the presence of iron overload are also potent 
sources of ROS, which may exacerbate liver injury. 
1.5.3.2 Oxidative stress is a consequence of immune activation 
Hepatocellular injury, whether by viral, metabolic or toxic insults, leads to immune activation 
(section 1.2.4). HCV causes liver damage by diverse mechanisms including direct cytopathic 
effects and through an immunological response to virally-infected or necrotic cells. Cytokine 
release and the activation of macrophages lead to the further production of ROS (Poli, 2000). 
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1.5.3.3 Oxidative stress is a cause of steatosis and insulin resistance 
ROS induce cytokine formation by hepatocytes and Kuppfer cells (including TNFa, TGPP and 
IL-6), which leads to increased insulin resistance and, indirectly, to hepatic steatosis, as 
described in section 1.5.2.1. 
1.5.3.4 Oxidative stress is a consequence of steatosis 
Steatosis in hepatocytes is considered a source of ROS, as the presence of excess triglyceride 
provides "fuel on raging flames" (Koike, 2005). However, hepatic lipid per se is not a cause of 
progressive disease, so other sources of oxidative stress are required (Day and James, 1998). 
1.5.3.5 Oxidative stress is a cause of hepatocellular injury and hepatic fibrosis 
ROS are destructive molecules, causing cellular and genetic damage, which leads to necrosis 
and immune activation, both potent triggers of oxidative stress. ROS are one of a number of 
activators of HSCs. It has been shown that activation of HSCs by oxidative stress is a paracrine 
reaction, mediated by hepatocytes (Bedossa et al., 1994; Svegliati et al, 1998). As liver disease 
progesses, the disruption of hepatic tissue architecture and sinusoidal function may impair local 
homeostatic processes and the clearance of toxic metabolites, and cause depletion of 
antioxidants (Friedman, 2000). Thus, a destructive cycle may be initiated. 
1.5.4 Hepatic steatosis, insulin resistance and hepatic fibrosis 
A number of cross-sectional studies have found a weak association between the presence of 
steatosis and a higher degree of fibrosis (Asselah et al., 2006). Conflicting evidence has been 
presented as to whether the relationship between steatosis and fibrosis is genotype-dependent. In 
a large European cohort, steatosis was associated with fibrosis only in patients with genotype 3 
(Rubbia-Brandt et al., 2004), while in another cohort, fibrosis stage was related to the severity 
of steatosis in genotype 1 (Patton et al., 2004). 
A study comparing factors associated with fibrosis in patients with NAFLD and patients with 
CHC (genotype 3) found that, while advanced fibrosis was associated with steatosis grade in 
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NAFLD, steatosis grade was not associated with fibrosis in the cohort of patients with hepatitis 
C. Insulin resistance was associated with advanced fibrosis in both cohorts (Bugianesi et al., 
2006). These observations were extended to patients with CHC, genotypes 1 and 4, in which 
insulin resistance was independently associated with significant fibrosis and significant fibrosis 
was associated with severe steatosis (Moucari et al, 2008). In a further study, insulin resistance 
was an independent predictor of both the severity of fibrosis and the rate of fibrosis progression 
in CHC (Hui et al., 2003). 
1.5.5 Hepatic steatosis in CHC and response to antiviral treatment 
The effect of insulin resistance on response to antiviral therapy in patients with CHC, genotypes 
2 and 3, has been examined. High insulin resistance was associated with reduced response to 
treatment (Poustchi et al., 2008). Conversely, in patients with CHC who responded to antiviral 
therapy, steatosis improved (Castera et al., 2004). Attempts to reduce insulin resistance, such as 
exercise, weight loss and use of metformin were proposed to lead to improved response to 
antiviral treatment. Indeed, metformin added to antiviral therapy increased the rapid viral 
response, although longer term data are awaited (Romero-Gomez et al., 2008a). 
1.5.6 Summary 
Section 1.5 describes how hepatic steatosis is an important co-factor in chronic liver disease 
and, in particular, chronic hepatitis C. Steatosis is both a direct and indirect consequence of 
HCV infection, and a result and a cause of oxidative stress. Epidemiological and clinical studies 
have shown the co-existence of these conditions to be of importance with respect to the severity 
and rate of progression of subsequent fibrosis and, particularly in terms of insulin resistance, 
response to antiviral therapy. Moreover, the intimate relationship between viral replication and 
cellular lipid metabolism provides the basis for novel approaches to therapy. 
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It is essential, then, that methods for the clinical assessment of hepatic lipid in chronic liver 
disease be developed and validated in addition to the development of non-invasive tools for the 
assessment of hepatic fibrosis. 
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1.6 Current approaches to the assessment of chronic liver disease 
The assessment of patients with chronic liver disease is largely based on assessment of the 
clinical history and physical examination. Most pre-cirrhotic chronic liver disease is 
asymptomatic, while clinical signs are subtle and non-specific. Clinical chemistry, so-called 
"liver function tests" (aminotransferases, alkaline phosphatase, bilirubin and gamma-glutamyl 
transferase) and haematological indices (cell-counts and the prothrombin time) may be deranged 
in cirrhotic and pre-cirrhotic disease, but alone, their sensitivity and specificity for the diagnosis 
and staging of chronic liver disease is limited (Schuppan and Afdhal, 2008). 
1.6.1 Liver biopsy is still considered the "gold standard" for disease assessment 
Histological assessment of liver biopsy is the mainstay for the diagnosis and staging of chronic 
liver disease. Epidemiological and pathophysiological data support fibrosis being the hallmark 
of chronic liver disease and a predictor of outcome (Poynard et al., 1997). Inflammatory and 
metabolic processes are central to fibrogenesis and information regarding these features is also 
conveyed by histology. Inherent to liver biopsy is the risk of discomfort, significant morbidity 
and a small, but important mortality rate, described in section 1.6.4.1. As such, it is not optimal 
for repeated measures, as required by clinical longitudinal interventional studies. 
1.6.2 Liver biopsy 
Most liver biopsies for the assessment of chronic liver disease are performed percutaneously, by 
passing the biopsy needle between the ribs into the right lobe of the liver. Guidelines for safe 
and effective liver biopsy have been published by the British Society of Gastroenterology 
(Neuberger et al., 2004). 
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1.6.3 The validity of histological scoring systems 
1.6.3.1 Fibrosis and inflammation 
The interpretation of the histology of liver tissue in chronic liver diseases is based on 
categorization or scoring of inflammatory features (grade) and fibrosis and architectural 
disruption (stage) (Standish et al., 2006). The first major scoring system was developed in 1981, 
and based on the identification of periportal necrosis, intralobular necrosis, portal inflammation 
and fibrosis, assessed separately and assigned a score (Knodell et al., 1981). This histological 
activity index was modified subsequently to include extra scores (Ishak et al., 1995). The first 
three components of the score contribute to the necroinflammatory grade, while the fibrosis 
score, from 0-6, is based on architectural changes in the pattern and expansion of fibrous bands. 
Cirrhosis is represented by stage 5 (incomplete cirrhosis) and 6 (probable or definite cirrhosis). 
The METAVIR scoring system was developed to look specifically at hepatitis C-related liver 
disease. Here, the histological activity is based on piecemeal and lobular necrosis, while the 
fibrosis stage is scored from 0-4, with 4 representing cirrhosis (Bedossa and Poynard, 1996). 
All scoring systems are designed to place a numeric value to architectural features. They consist 
of ordered categorical data representing qualitative and semi-quantitative descriptions, so are 
not quantitative measures of fibrosis. Studies of liver tissue using digital image analysis have 
shown that the area of fibrous tissue is not linearly related to the fibrosis score. Moreover, 
inflammation may cause expansion of fibrous tracts (Standish et al., 2006). Nevertheless, 
histological fibrosis assessment has been validated by successive clinical studies, making the 
features clinically relevant (Poynard et al., 1997). 
1.6.3.2 Steatosis 
Scoring systems quantify fat on the basis of visible hepatic lipid droplets within hepatocytes. 
The grade of steatosis is based on the proportion of hepatocytes containing visible lipid and is 
expressed semi-quantitatively on a scale of 0-3 (0, <5%; 1, 5% - 33%; 2, >33% - 66%; 3, >66%) 
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(Brunt et al., 1999; Kleiner et al., 2005). Grading is considered in the context of other 
histopathological lesions, such as inflammatory infiltration and ballooning of hepatocytes. 
However, there are considerable limitations to liver biopsy for the quantification of hepatic 
lipid. Quantification of lipid is based only on visible lipid droplets, so invisible (for example, 
membrane) lipid is not included. The assessment is only semi-quantitative, being a two-
dimensional estimation of the proportion of hepatocytes including lipid, and not considering the 
volume of droplets. Finally, the composition of the fatty acid components is not assessed, 
although, using immunohistochemical techniques, the presence of lipid peroxidation products 
may be determined (Paradis et al., 1997a). 
1.6.4 Limitations of liver biopsy 
The limitations of liver biopsy have been well-documented but warrant re-iteration in studies 
that use histology as a reference standard. 
1.6.4.1 Morbidity and mortality 
Percutaneous liver biopsy has a small, but quantifiable, risk of mortality, quoted as between 1 in 
1000 and 1 in 10000 patients (Gilmore et al., 1995; Lindor et al., 1996; Perrault et al., 1978). 
Minor complications, such as post-procedural pain or localised haematoma, occur in between 
3% and 30% of cases. More severe complications, including intraperitoneal haemorrhage 
(requiring transfusion) or perforation of a viscus (including pneumothorax) may occur in 0.3% 
to 0.6% of cases (Cadranel et ah, 2000; Neuberger et al., 2004). Good management of clotting 
disorders and the appropriate use of the transjugular approach may improve outcome 
(Neuberger et al., 2004). 
1.6.4.2 Sampling variability 
Percutaneous liver biopsy typically samples less than 1/50000"' of the liver, so any 
heterogeneity of pathological features may lead to sampling variability (Bedossa et al., 2003). 
Autopsy studies have demonstrated that cirrhosis may be missed on a single pass liver biopsy in 
between 10% and 30% of cases (Maharaj et al., 1986; Poniachik et ah, 1996), while a study 
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using laparoscopic biopsy of both left and right lobes of the liver found a difference of at least 
one fibrosis stage between lobes in over 30% of patients (Regev et al., 2002). 
The size of the liver biopsy specimen influences sampling variability. Smaller biopsy sizes (in 
length and breadth) were shown to lead to a lower probability of observing characteristics of 
more severe diseases and, consequently, led to underestimation of disease severity (Colloredo et 
al., 2003). The authors recommended that biopsies be longer than 20mm and contain 11 or more 
complete portal tracts. Nevertheless, even in major centres, as few as 1/6"' of samples exceeded 
this length in a study of over 500 patients (Poynard et al., 2004). A study using digital image 
analysis of large sections of liver tissue (given a reference score) and "virtual" biopsies of small 
areas showed that a sample length of 25mm had a 25% error, which reduced to a minimum at 
40mm (Bedossa et al., 2003). The type of needle used is also a factor, with Tru-Cut considered 
superior to Menghini (Colombo et al., 1988). While the size of sample is clearly important for 
correct interpretation, the number of passes taken to obtain the specimen is correlated with the 
rate of complications (Tobkes and Nord, 1995). 
1.6.4.3 Subjectivity and inter-observer variation 
Histological scoring systems are designed to be objective and reproducible, but interpretation is 
still a source of error. Interobserver variability is low for the assessment of fibrosis, but higher 
for the assessment of activity or inflammation (Goldin et al., 1996). hi a study of intra- and 
inter-observer variability, agreement was better for fibrosis than activity and among experienced 
pathologists than more junior pathologists (Rousselet et al., 2005). These authors concluded that 
the experience of the pathologist had more influence on agreement than the characteristics of the 
biopsy itself. 
Histology of liver biopsy specimens is still the mainstay for the definitive diagnosis of liver 
diseases and for investigation of co-existing pathology. Nevertheless, there are risks inherent in 
the technique and scoring systems should be interpreted in the knowledge of the limitations. 
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1.7 Non-invasive techniques 
Non-invasive techniques are suited to clinical and longitudinal studies as the risk to patients is 
limited. In addition, problems related to sampling variability are greatly reduced. Finally, non-
invasive techniques may measure clinically relevant parameters not adequately assessed by liver 
biopsy. Non-invasive tests of chronic liver disease may be broadly divided into serum (or blood) 
markers and imaging-based technologies. Other approaches include the use of breath tests 
(Lalazar et ai, 2008) and the developing "-omics" technologies, genomics, proteomics (Morra 
et al., 2007) and metabonomics of biofluids (Lindon et al., 2004). The focus of this thesis is on 
imaging techniques for the assessment of chronic liver disease and, in particular, 'H MRS. 
1.7.1 Magnetic resonance spectroscopy 
Nuclear magnetic resonance (NMR) is a non-destructive technique which allows the study of 
molecular composition and structure. The term encompasses both in vivo magnetic resonance 
spectroscopy (MRS) and in vitro MRS at high magnet field strengths (Gadian, 1995). 
1.7.2 Proton magnetic resonance spectroscopy 
The 'H MR spectrum represents resonances (peaks) pertaining to protons in differing physico-
chemical environments, with the position of each resonance determined by the chemical shift. 
The area under the peak is proportional to the number of protons contributing to that resonance. 
The width of the peak is determined, in part, by the T? (transverse) relaxation time. Free or 
unbound protons in smaller, mobile molecules are represented as narrow peaks. Glucose, 
glycogen subunits, choline-containing compounds, fatty acids and free amino acids are thus all 
represented, since they are MR-visible. Fats are usually represented by prominent, but relatively 
broad peaks. The linewidths of the lipid resonances are dependent on molecular mobility and 
vary according to whether the lipid is free or membrane-bound. Water, being the most abundant 
compound in most biological tissues leads to a prominent resonance, which, on account of 
strong hydrogen bonds, is typically a broad peak. Larger macromolecules, such as proteins, and 
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the amino acids contained therein, are poorly represented, as T? relaxation times are very short, 
leading to very broad and essentially MR-invisible components. In addition, the large broad 
resonances of fat and water often dominate spectra, obscuring the smaller resonances. These 
characteristics are important for the interpretation of the spectra. The principles of NMR, where 
relevant to this study, are considered in more detail in Chapter 2. 
MRS provides a "snapshot" overview of metabolism in a particular region of interest or sample. 
Spatial resolution of MRS is of the order of a few cubic centimetres, thus reducing the sampling 
error inherent in liver biopsy, and while there is low specificity for the analysis of specific 
pathways, a global assessment may be achieved. These properties make 'H MR spectroscopy a 
potentially useful tool for the assessment of chronic liver disease and an adjunct to imaging 
modalities, for example ultrasound or MRI, which enable assessment of the structural changes 
associated with chronic liver disease. 
1.7.3 Imaging-based modalities assess features of chronic liver disease 
Imaging modalities are site-specific; while serum markers may potentially be confounded by 
extra-hepatic disease, imaging markers are anatomically-defined. Imaging techniques detect a 
number of signs or physical parameters, which are of relevance to chronic liver disease. 
1.7.3.1 Morphological changes 
The later stages of chronic liver disease are characterized by a number of intra- and extra-
hepatic structural changes. A number of these structural changes are manifestations, or 
consequences of other pathological processes, which will be addressed below. 
The cirrhotic liver is typically small, with an uneven border or perimeter. These features are 
caused by the contraction of thick bands of fibrous tissue interspersed by regenerative nodules. 
Ultrasound-visible features, such as liver surface nodularity, caudate lobe hypertrophy and the 
presence of detectable hepatic venous blood flow have been shown to identify those with severe 
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fibrosis or cirrhosis from a cohort of patients with chronic liver disease, although it is doubtful 
that the severe fibrosis group alone would be identifiable by such a technique (Colli et al., 
2003y 
Routine MRl, computed tomography (CT) and ultrasound indices can detect gross 
morphological changes associated with cirrhosis, but none is sensitive or specific. Moreover, 
pre-cirrhotic disease is not adequately discriminated (Aube et al., 1999; Awaya et al., 2002; Ito 
et al., 1999). However, dynamic superparamagnetic iron oxide (SPIO) -enhanced and 
gadolinium-enhanced MRI demonstrates reticular-nodular patterns, thought to represent septal 
hepatic fibrosis, the presence of which, taken with an overall (subjective) qualitative 
assessment, allows the discrimination of moderate and severe from mild fibrosis (Figure 1-4) 
(Aguirre et al., 2006). Digital image processing of unenhanced CT scans has enabled 
assessment of the distribution of high-attenuation patterning, again presumed to represent 
fibrosis and distinction between moderate and severe fibrosis (Romero-Gomez et al., 2008b). 
However, these techniques do not provide a quantitative measure of disease severity, and a 
number of the techniques remain unvalidated by other centres. 
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Figure 1-4. Transverse MR images of cirrhotic liver in vivo. 
A, SPIO-enhanced two-dimensional spoiled gradient echo (SPGR) image with echotime of 2.65ms\ B, 
double-enhanced SPGR image at the same level, showing hyperintense reticulations and hypointense 
nodules (arrows), thought to represent fibrous septal bands surrounding regenerative nodules. Adapted 
from Aguirre 2006. 
Water molecules are tightly bound in the fibrotic extracellular matrix, providing the rationale 
behind the application of diffusion-weighted MR imaging (DWI) to chronic liver disease. An 
apparent diffusion coefficient (ADC) is derived, representing proton, and hence water, mobility. 
A reduced ADC is observed in cirrhosis and with increasing fibrosis stage, and has been 
interpreted as being due to restriction of water diffusion in fibrotic tissue (Aube et al., 2004; 
Lewin et al., 2007), or, possibly, by reduced capillary perfusion (Taouli et al., 2007). However, 
the precise relationship between the ADC and fibrosis is currently unclear. 
1.7.3.2 Portal hypertension 
Portal hypertension is the cause of much morbidity and mortality associated with chronic liver 
disease, through development of varices of porto-systemic anastomoses and through activation 
of vasodilatory pathways and development of ascites and the hepato-renal syndrome. Increased 
portal pressure is caused by increased intrahepatic resistance to flow, according to Ohm's law. 
The increased intrahepatic resistance results from both vascular factors and fibrosis (Langer and 
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Shah, 2006). The structural results of portal hypertension, such as splenomegaly, ascites and the 
presence of venous collaterals are also readily assessed by conventional imaging techniques, but 
these features tend to be associated with decompensated cirrhosis and not pre-cirrhotic disease 
stages. 
A number of ultrasound-based studies have aimed to assess portal pressure indirectly as a 
surrogate for disease severity (Vilgrain, 2001). However ultrasound Doppler indices of portal 
flow were found not to correlate reliably with increasing severity of disease (Bernatik et al., 
2002; Lim et al., 2005a). 
Liver stiffness, as discussed below, is a physical parameter that represents the result of a number 
of biological processes (Cobbold and Taylor-Robinson, 2008). A number of studies have 
pointed to a relationship between portal hypertension and liver stiffness measurement (LSM). 
Foucher and colleagues demonstrated a correlation between liver stiffness measurement and 
splenomegaly, the presence of oesophageal varices and a history of bleeding varices (Foucher et 
al., 2006). A relationship between LSM and presence of varices has also been described, 
although evidence for the relationship between LSM and size of varices is mixed (Kazemi et al., 
2006; Vizzutti et al., 2007). Vizzutti and colleagues went on to demonstrate coiTelation between 
LSM and the hepatic venous pressure gradient (HVPG), particularly at lower HVPG values 
(<10-12mmHg). This represents a complex relationship, which was less apparent at higher 
HVPG values (Vizzutti et al., 2007). It has been stated that the "progressive rise in portal 
pressure...[is]...due mainly to an increase in intrahepatic vascular resistance from the 
accumulation of fibrillar extracellular matrix" (Lim and Groszmann, 2007). However, increased 
arterial and portal inflow may contribute directly to the liver stiffness, while haemodynamic 
changes characteristic of advanced portal hypertension, including extrahepatic haemodynamic 
changes, may not be detected by changes in liver stiffness. 
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] .7.3.3 Intrahepatic vascular changes 
Vascular remodeling is increasingly seen as a pathological feature of chronic liver disease. In 
the development of fibrosis, obliteration of the small hepatic and portal veins may lead to a 
congestive hepatopathy, which is exacerbated by a co-existant hyperdynamic circulation 
(Wanless et al., 1995). This results in inflammation and oxidative stress, both triggers for 
flbrogenesis (section 1.5.3). Intrahepatic vascular remodeling within the fibrotic liver is 
performed by the contractile HSCs, mediated by changes in levels of nitric oxide (NO), 
consequent to derangement of endothelial NO synthase. This contributes to high resistance, 
constricted sinusoidal vessels (Lee et al., 2007). Such mechanisms may also contribute to the 
development of intrahepatic vascular shunts. Dynamic microbubble contrast-enhanced studies 
are thought to exploit the intra- and extra-hepatic vascular changes that generate shortening of 
hepatic vein transit times with increasing disease severity (Albrecht et ah, 1999; Lim et al., 
2005b). Microvascular remodeling and hepatic congestion may also contribute to changes in 
water diffusion within a region of interest, measured by DWI (Taouli et al., 2007). 
Imaging techniques assess changes in physical properties consequent to vascular alteration. 
While vascular changes occur with increasing fibrosis, imaging techniques do not assess fibrosis 
directly, so may be considered surrogate markers in this context. 
1.7.3.4 Liver stiffness 
Liver stiffness measurement by ultrasound-based transient elastography and, more recently, by 
magnetic resonance elastography (MRE), has proved a promising approach for the assessment 
of chronic liver disease. Clinically, a cirrhotic liver is hard on palpation, and experimentally, 
stiffness (elastic modulus) has been correlated with the histopathological fibrosis score in ex 
vivo hepatic samples (Yeh et ah, 2002). Biologically, the stiffness of the extracellular matrix has 
been shown to activate hepatic stellate cells, partly through integrin signalling (Wells, 2008). 
However, it has been stressed that "biological tissue is a composite material and it is difficult to 
separate the influence of each component of the tissue on the total in modulus estimates" (Yeh 
et al., 2002). Therefore, liver stiffness cannot be considered a measure of hepatic fibrosis alone. 
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The development of transient elastography enabled the rapid acquisition of objective liver 
stiffness measurements in vivo (Sandrin et al., 2003). Multiple regression analysis in early 
studies demonstrated a relationship between elasticity measurements and fibrosis stage, but not 
to the disease activity (or necroinfiammatory score), nor to the degree of steatosis (Sandrin et 
ah, 2003; Ziol et al., 2005). 
A number of studies have confirmed the correlation between liver stiffness and hepatic fibrosis 
in hepatitis C (Castera et al., 2005; Ziol et al., 2005), and other chronic hepatic conditions 
(Corpechot et al., 2006; Ganne-Carrie et al., 2006; Yoneda et al., 2007). Recently, meta-
analyses and systematic reviews have also been published (Castera et al., 2008; Friedrich-Rust 
et al., 2008). However, studies have also indicated the presence of co-existing factors that may 
contribute to liver stiffness, including inflammation (section 1.7.3.5), portal hypertension 
(section 1.7.3.2) and, possibly, steatosis (section 1.7.3.6). 
While ultrasound-based transient elastography measures liver stiffness in a defined region 
(about 5cm\ right lobe of the liver), MRE has recently been shown to predict fibrosis stage 
effectively in patients with chronic liver disease, while producing a "map" of liver stiffness, 
potentially of use to investigate the distribution of pathology (Huwart et al., 2008; Yin et al., 
2007y 
1.7.3.5 Inflammation and cell turnover 
The effects of hepatic inflammation have been studied using a number of imaging-based 
technologies, including MR and ultrasound applications. Hepatic inflammation is associated 
with cellular inflammatory infiltrate, tissue oedema and hepatocyte swelling. Each of these is 
likely to affect the physical properties of liver tissue and, as such, can be measured by imaging 
modalities. These properties include: nuclear relaxation (T?), assessed by MR techniques; water 
perfusion and diffusion, as assessed by DWI; liver stiffness; changes in attenuation, assessed by 
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CT and echogenicity, assessed by B-mode ultrasound. The effect of inflammation on ^'P MRS 
and transient elastography is discussed below. 
1.7.3.5.1 Phosphorus MRS 
Phosphorus (^'P) MRS allows the quantification of ^'P-containing moieties in tissues. These 
include energy intermediates (inorganic phosphate, ATP subunits) and phospholipid membrane 
metabolites (phosphomonoester (PME), thought, broadly, to represent membrance precursors, 
and phosphodiester (PDE), thought to represent membrance degradation products). Studies in 
tumour tissue (Ruiz-Cabello and Cohen, 1992), chronic liver disease in vitro (Bell et al., 1993; 
Taylor-Robinson et al., 1995) and in vivo (Lim et al., 2003b; Menon et al., 1995) have 
demonstrated a correlation between the ratios of these resonances and disease state or severity. 
A study in patients with acute hepatitis A demonstrated an acute rise in PME/PDE, which 
decreased with resolution of disease (Yamane et al., 1994). Moreover, in patients with hepatitis 
C, the PME/PDE decreased significantly in those responding to antiviral treatment but did not 
change in non-responders (Lim et al., 2007). 
1.7.3.5.2 Transient elastography 
The association between liver stiffness and disease activity or necroinflammatory score has been 
shown by a step-wise increase of LSM with necroinflammatory activity in a cohort of patients 
with disease of varied aetiology (Fraquelli et al., 2007). Others examined the relationship 
between LSM and biochemical activity in patients with chronic viral hepatitis. The LSM was 
lower, stage-for-stage, in those with biochemical remission (as assessed by ALT) than those 
with a higher ALT (Coco et al., 2007). Recent papers have specifically addressed the effect of 
hepatic inflammation on LSM. In one, 18 patients without a past history of liver disease, but 
with acute viral hepatitis, were studied. The LSM at the peak aminotransferase level exceeded 
12kPa (the cut-off for prediction of cirrhosis) and furthermore, in all but one subject, the LSM 
returned to within normal range (below 7kPa). In addition, the LSM correlated with the 
aminotransferases at onset and with the AST at follow-up (Arena et al., 2008). In another paper, 
20 patients with acute hepatitis of vaiying aetiology (including drug-induced hepatitis) were 
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studied. In those followed up longitudinally, the aminotransferases returned to a level 
commensurate with the fibrosis stage at biopsy (Sagir et ah, 2008). While it is known that acute 
hepatitis is associated with an inflammatory infiltrate, tissue oedema and hepatocyte swelling, 
all of which are likely to affect LSM, there was no histological confirmation of these features in 
these studies, as liver biopsy was not clinically indicated (Cobbold and Taylor-Robinson, 2008). 
1.7.3.6 Hepatic fat 
Hepatic fat may be assessed using a number of imaging modalities including ultrasound, CT and 
MR (Mehta et al., 2008). 
1.7.3.6.1 Ultrasound 
Ultrasound is widely used clinically to detect hepatic steatosis, based on the premise that 
steatosis causes increased echogenicity of the hepatic parenchyma, leading to a brighter image 
when compared to the cortex of the ipsilateral kidney. Other conditions, such as fibrosis may 
also lead to increased echogenicity, leading to potential confusion. A review of the non-invasive 
measurement of fat content found the sensitivity of ultrasound for the detection of steatosis to 
range from 60% to 94%, while the specificity ranged from 84 to 95% (Mehta et al., 2008). 
However, histologically-assessed mild steatosis resulted in a sensitivity of just 55% (Ryan et al., 
2002). In addition, obesity reduces the accuracy of ultrasound due to technical considerations 
and increased attenuation of signal caused by subcutaneous fat. Ultrasound performs more 
poorly for the quantification of hepatic lipid, although subjective grading systems, categorizing 
steatosis into mild, moderate and severe groups have been proposed (Fishbein et al., 2005). 
Liver stiffness is thought to be affected by hepatic fat. Substantial differences in cut-off values 
for cirrhosis have been observed between those with chronic hepatitis and those with alcohol-
related chronic liver disease and non-alcoholic fatty liver disease (NAFLD), perhaps 
representing modification of liver stiffness by coexisting fat (Ganne-Carrie et al., 2006; Yoneda 
et al., 2007). Liver stiffness was higher in a cohort of patients without evidence of liver disease 
who had metabolic syndrome, compared to healthy controls (Rowlot et al., 2008). Thus, there is 
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circumstantial evidence that steatosis affects liver stiffness. A recent presentation in which 
patients were stratified by histological steatosis suggested an increase in liver stiffness with 
increased steatosis, but these findings need to be corroborated (Lupsor et al., 2008). It appears 
that LSM is affected by steatosis, but the magnitude of the effect is likely to be smaller than that 
of other contributing factors, such as fibrosis, inflammation and portal hypertension. 
1.7.3.6.2 Computed Tomography 
CT enables the assessment of hepatic steatosis on the basis of radiographical density (Bydder et 
al., 1980), although the ability to quantify hepatic lipid is not clear (Park et al., 2006). Ionising 
radiation associated with CT-scanning confers a small excess risk to subjects, making it less 
suited for repeated measurements. 
1.7.3.6.3 Proton MRS 
As the 'H MR spectrum of the liver is dominated by lipid and water resonances, 'H MRS has 
been used for the assessment of hepatic fat. The percentage liver fat has been estimated from the 
number of protons in the lipid and water resonances by calibration with hepatic lipid extracts 
(Longo et al., 1995). Such measures have been used to assess racial differences in the 
prevalence of hepatic steatosis and the technique has also been applied in a population of over 
2000 participants (Browning et al., 2004; Szczepaniak et al., 2005). Simpler lipid to water 
resonance ratios have been used to compare hepatic steatosis between obese and lean 
individuals and have demonstrated a change in intrahepatic lipid in response to dietary 
intervention (Thomas et al., 2005; Thomas et al., 2006). However, more detailed information on 
lipid quantitation, composition and the relationship with chronic liver disease remain 
controversial (Chapters 4 & 5). 
1.7.4 Serum markers 
The development of serum markers is a popular approach for the non-invasive assessment of 
hepatic fibrosis. Blood tests are quick and acceptable to patients. The results are objective, 
although there is the possibility of the presence of confounding factors from extrahepatic 
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disease. These have been reviewed extensively elsewhere (Parkes et al., 2006b; Rockey and 
Bissell, 2006; Shaheen and Myers, 2007). Serum markers may broadly be divided into 
"indirect" and "direct" markers, single tests and panels. Indirect markers are markers of liver 
function, which reflect liver fibrosis, while direct markers include serum ECM components and 
intermediates of fibrogenesis (Manning and Afdhal, 2008). A selection of serum markers are 
described in Table 1-1. The APRI (aspartate aminotransferase (AST) to platelet ratio index) and 
the ELF ("Enhanced" Liver Fibrosis) score will be investigated further in Chapter 6. 
Table 1-1. Examples of serum markers for the assessment of hepatic fibrosis 
Name Consti tuents Reference 
Indirect markers 
APRI AST, platelets (Wai etal., 2003) 
Ferns platelets, cholesterol. yGT, age (Ferns et a!., 2002) 
FibroTest a2 macroglobulin, a2 and y globulin. (Imbert-Bismutetal., 2001) 
total bilirubin, apolipoprotein Ai, yGT 
Direct markers 
HA Hyaluronic acid (Guechet etal., 1996) 
ELF PIIINP, HA, TIMP-1, (age) (Rosenberg etal., 2004) 
FibroSpect HA, TIMP-1, a2 macroglobulin (Patel et al., 2004) 
Abbreviations: APRI, aspartate aminotransferase (AST) to platelet ratio index-, gGT, y-glutamyl 
transferase-, HA, hyaluronic acid, PIIINP, amino terminal of procollagenase IIP, TIMP-1, tissue inhibitor 
of matrix metalloproteinase 1. 
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1.8 Rationale for the project 
This introduction describes how chronic liver disease results in a major disease burden globally. 
Chronic liver disease arises from numerous aetiologies including viral hepatitides, which have a 
high prevalence worldwide, and NALFD, which is an increasing problem in westernised 
societies, associated with the metabolic syndrome of obesity, insulin resistance and 
dyslipidaemia. The pathogenesis of chronic liver disease has been reviewed in the context of 
viral hepatitis and hepatic steatosis. Fibrogenesis, the development of the prognostically key 
pathological lesion, fibrosis, is a complex, multi-step process involving multiple cellular and 
molecular pathways. Increasing numbers of potential targets for therapy are being uncovered, 
with the possibility of slowing the progression of disease and even the reversal and resolution of 
fibrosis. There is increasing recognition that hepatic steatosis is a pathologically-relevant 
cofactor in the development of a number of chronic liver diseases. In particular, hepatic steatosis 
is intimately related to the pathogenesis of chronic hepatitis C. Currently, however, assessment 
of hepatic fat by liver biopsy is limited, while imaging techniques can assess fat quantity and 
distribution, but not lipid types or composition. 
The current gold-standard for the assessment of chronic liver disease, liver biopsy, has 
limitations and engenders risk to patients. As such, the lack of suitable techniques for the safe, 
reliable and biologically-relevant assessment of chronic liver disease represents a major barrier 
to the development of novel therapies. Non-invasive techniques for the diagnosis and staging of 
chronic liver disease are required and approaches may be broadly divided into the development 
of serum markers and imaging techniques. Imaging techniques are able to assess a number of 
pathologically-relevant features of chronic liver disease and form the focus of this thesis. 
Proton magnetic resonance spectroscopy is a non-destructive, non-ionising technique, which 
provides information about the physico-chemical environment of protons within a sample or an 
anatomical region of interest. 'H MRS in vivo has been used to quantify hepatic lipid in a 
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number of studies, but, its potential to provide more detailed biological information has received 
little attention. 
For clarity in this thesis, in vivo studies on the clinical MR scanner will be denoted "MRS", to 
distinguish them from in vitro studies, to be denoted "NMR". 'H NMR spectroscopy of intact 
tissue at high field strength in vitro enables the generation of high-resolution MR spectra, which 
provide detailed information on tissue metabolism, in particular, lipid, carbohydrate and amino-
acid composition and relative concentrations. Application of this technique to liver tissue in 
examples of chronic liver disease may provide a framework to inform the interpretation of the 
lower resolution MRS, obtained in vivo at lower field strength. This application is available on 
most clinical MRI scanners, and MRS sequences may be added to other MR imaging protocols. 
As such, 'H MRS may provide biologically and clinically-relevant information related to 
chronic liver disease. 
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1.9 Hypotheses 
1. Characteristic metabolic perturbations in models of chronic liver disease are 
detectable using in vitro 'H NMR spectroscopy 
2. High resolution 'H NMR spectroscopy of intact human liver tissue informs in 
vivo 'H MRS studies 
3. In vivo 'H MRS findings complement other non-invasive techniques for the 
assessment of chronic liver disease 
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1,10 Aims 
The overall aim of this thesis is to apply and validate 'H MRS as a non-invasive technique for 
the assessment of chronic liver disease. 
In order to achieve this aim, there are a number of subsidiary aims; 
1. To optimise the experimental conditions for 'H NMR spectroscopy of intact 
liver tissue 
2. To examine the differences in the 'H NMR spectrum from murine models of 
NAFLD in vitro 
3. To investigate metabolic differences as assessed by 'H NMR spectroscopy with 
reference to histological features in murine models of NAFLD and human liver 
biopsy samples from patients with chronic hepatitis C 
4. To apply in vitro NMR spectroscopy findings to inform MR spectral analysis in 
vivo 
5. To compare the performance of imaging-based and serum markers of chronic 
liver disease (APRI, ELF, TE, HTT), head-to-head and in combination 
compared to histological assessment of liver biopsy in patients with CHC. 
6. To validate in vivo 'H MRS for the assessment of CHC in the context of other 
non-invasive markers of chronic liver disease. 
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1.11 Structure of the thesis 
The structure of the thesis is divided broadly into three parts: 
Development of 'H NMR spectrscopy of intact liver tissue; in Chapter 2 the parameters 
affecting acquisition of high-quality NMR spectrscopy data are considered and protocols are 
developed for robust and stable analysis of intact tissue. In Chapter 3, the technique is applied 
to murine models of NAFLD. Multivariate pattern-recognition tools are used to separate groups 
and to pinpoint metabolic differences. Disease-relevant MR indices are derived and tested. 
Translation of 'H NMR spectroscopy to the clinical setting: in Chapter 4, the techniques 
previously developed are employed for the analysis of human liver tissue from patients with 
chronic hepatitis C. In Chapter 5, disease-related MR indices, in particular, fatty acid 
functional group resonances, are applied to 'H MR spectra obtained at lower field strength, non-
invasively, in vivo. The indices developed in vitro are then validated in a separate cohort of 
patients with chronic hepatitis C in vivo. 
Evaluation of 'H MRS for the assessment of chronic liver disease: In Chapter 6, four 
currently-available non-invasive techniques for the assessment of chronic liver disease are 
compared, head-to-head and in combination, to liver biopsy in a cohort of patients with chronic 
hepatitis C to establish the most accurate and reliable markers for assessment of fibrosis stage 
and inflammatory grade. In Chapter 7, the 'H MRS indices developed during the course of this 
research are compared, quanititatively and qualitatively to the best performing markers as 
assessed in Chapter 6. In Chapter 8, work that would improve or validate the technique further 
is discussed. Finally, in Chapter 9, conclusions from this thesis are drawn and the potential 
place of 'H MRS in clinical and research protocols is considered. 
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2 TECHNIQUE OPTIMISATION STUDIES 
2.1 Abstract 
NMR spectroscopy provides information on tlie chemical composition of samples based on 
differences in the magnetic field experienced by nuclei within the sample. The resonances (or 
peaks) proportionately represent the nuclei contributing to particular chemical functional groups 
within the sample. The spectral resolution obtained from solid samples is improved by spinning 
the sample at 54.7° to the magnetic field. 
The aims of this chapter were to: 1) define the physical and technical variables that affect the 
quality of the NMR spectra and the information yielded; 2) optimise the experimental 
conditions for spectral acquisition; 3) discuss approaches to spectral analysis. 
NMR spectroscopy studies of intact liver tissue were carried out at 11.11. Snap-frozen murine 
liver tissue was examined. The effect of sealing cell size, acquisition temperature and 
experimental duration on spectral quality and the resultant metabolic profile were assessed. 
Using optimised techniques, high resolution 'H magic angle spinning NMR spectra were 
produced and the resonances assigned with reference to the literature. Larger sample sizes and 
smaller cells yielded a higher signal-to-noise ratio. Higher acquisition temperature led to an 
increased signal-to-noise ratio, but led to irreversible spectral changes with increasing 
experimental duration. 
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2.2 Principles of magnetic resonance spectroscopy (Gadian, 1995) 
NMR spectroscopy relies on the subtle differences in the magnetic field strength experienced by 
specific nuclei within different chemical environments or structures, to cause small differences 
in the nuclear energy levels. Excitation by radiofrequency energy at a frequency equalling that 
of the precessional frequency of the nucleus causes the nucleus to change energy level. Upon 
relaxation, energy at the precessional frequency is detected by the receiver coil. 
2.2.1 The NMR phenomenon 
The nuclei of some atoms may be considered to rotate around an axis; a phenomenon termed 
'spin'. Rotation provides angular momentum to the charged particle, producing a local magnetic 
field. These nuclei precess around an axis parallel to an externally applied magnetic field. The 
angular frequency or precession frequency (coo) is the rate of rotation in radions per second and 
is described by the Larmor equation 2-A: 
Equation 2-A 
(Do = yBo 
where y is the magnetogyric ratio, a property of a particular nucleus within a particular 
environment, and Bo is the applied magnetic field. 
Accordingly, the angular frequency is proportional to the applied magnetic field and equal to the 
resonant frequency of a nucleus. 
Nuclear dipoles may lie parallel or anti-parallel to Bo but the net alignment according to the 
Boltzman distribution determines the resultant magnetism (Figure 2-1). When a pulse of 
radiofrequency energy is applied at the resonant frequency, there is excitation of the nuclei from 
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equilibrium. The population difference between energy states is small, accounting for the low 
sensitivity of NMR and the requirement for application of high magnetic fields. 
Bfl 
Figure 2-1. Nuclear alignment in an applied magnetic field. 
The static applied magnetic field, Bg runs parallel to the z axis. The nuclei may align with the field (the 
low energy state) or against the fiield (the high energy state). 
The resonant frequency induces an electric signal in the receiver coil, which may be amplified 
and detected as a radiofrequency signal known as a free induction decay (FID). The amplitude 
of the signal decays with time as relaxation occurs towards the resting state. 
2.2.2 Nuclear relaxation 
On relaxation of nuclei following the application of an RF pulse, there is dephasing of nuclear 
orientations with transfer of energy between nuclear spins, leading to a reduction in the resultant 
signal. This relaxation is described by the transverse, or "spin-spin", relaxation time, T?. 
Longitudinal, or "spin-lattice" relaxation, T,, describes energy transfer between the nuclear 
spins and their molecular framework, the lattice. 
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A number of mechanisms exist to explain the relaxation phenomena. A dipole-dipole interaction 
refers to the moment that exists between two or more dipoles or charged particles. The dipole-
dipole interaction is strongly distance dependant and a dominant mechanism in molecules with a 
spin of 1/2. For nuclei with spin >1/2, transfer of energy to the orbiting electrons provides an 
efficient relaxation mechanism, the quadrupole interaction, which makes relaxation almost 
instantaneous and the resulting signal difficult to detect. The state of the immediate environment 
of a nucleus is an important contributor to the relaxation properties. Thermal motion in liquids 
and solutions contributes to relaxation by the transfer of thermal energy. Nuclei may be shielded 
from the applied magnetic field and the degree of shielding may be dependent on the orientation 
of a molecule (hence bonds) with respect to the applied magnetic field, termed chemical shift 
anisotropy. If the molecules are freely mobile, the fluctuation of orientation in a population 
results in cancellation of the chemical shift difference overall. However in solids, this will result 
in line broadening. 
2.2.3 Chemical shift 
The chemical and physical environment of a nucleus alters the magnetic field experienced 
locally by an individual nucleus. Movement of electrons around a nucleus and the spin of 
charged particles create small local magnetic fields proportional to, but opposing, the applied 
field. This has the effect of shielding or screening the nucleus from the full applied magnetic 
field. Different atoms (or protons in the case of 'H MR spectroscopy) within a molecule, 
different types of molecule and their chemical environment may therefore be distinguished. As 
the magnetic fields produced by electrons are very small compared to the Bo, high applied 
magnetic fields are required to separate specific entities, hi addition to the effects of electrons, 
local magnetic field inhomogeneities will also influence the locally-experienced magnetic field. 
The resonant frequency of a particular nucleus is thus altered for a given applied magnetic field. 
This leads to alteration of the frequency of the induced signal, so information regarding the 
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interaction between radiofrequency energy and matter is conveyed; the spectrum. The alteration 
in frequency of a given nucleus from a reference frequency is termed chemical shift. The 
chemical shift is compared to a reference that may be integral to (internal), or separate (external) 
from, the sample. The chemical shift is expressed in parts per million (ppm), a dimensionless 
unit, by dividing the frequency difference between the nucleus of interest and the reference by 
the frequency of the reference and multiplying by a million. 
2.2.3.1 Spin-spin (J) coupling 
The spectral pattern is complicated by the magnetic interaction between neighbouring nuclei 
within a molecule. This leads to a pattern of resonance-splitting that aids the identification of 
compounds within a studied sample. The separation of the split peaks is independent of the 
applied magnetic field. 
2.2.3.2 Signal generation 
If a pulse of energy is applied, the susceptible nuclei are aligned according to the applied field 
and their oscillations are 'in phase'. On cessation of the pulse, relaxation of the spin orientations 
towards the resting state occurs. However, on account of the slight differences in frequency 
between nuclei caused by the interactions described above, there is 'dephasing' of the signal 
with time. Dephasing leads to increasing destructive interference between emitted 
radiofrequency energy and therefore decay of the signal. The greater the difference in phase 
between spins, the faster the decay. The faster the decay of the signal, the shorter the T? and the 
broader the line width becomes. 
2.2.3.3 Quantification 
The raw signal produced when a sample relaxes completely following excitation is quantified 
by the area under the curve (or amplitude) of the resonances in the frequency domain, and is 
proportional to the number of nuclei contributing to the signal. A metabolite within a sample 
may be quantified relative to a reference compound of known concentration or relative to other 
metabolites within the sample. 
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2.3 Magic angle spinning nuclear magnetic resonance spectroscopy 
2.3.1 Rationale 
In section 2.2.2, mechanisms of NMR relaxation were described. Dipole-dipole interactions are 
spatially orientated with respect to the applied magnetic field. In a solution or liquid, free 
molecular motion causes those orientations to average out, but in solids and semi-solid samples, 
there are constraints to the orientation of molecular interactions, leading to differences in the 
relaxation of nuclei within the same chemical environment, and thus causing line-broadening. 
By spinning the sample at 54.7°, the magic angle, spatial differences in relaxation properties are 
averaged to zero (Andrew et al., 1959). There are magnetic field inhomogeneities at the 
molecular level caused by the influence of neighbouring nuclei on the electron shielding of a 
nucleus- chemical shift anisotropy, and macroscopically, magnetic field inhomogeneity may 
result from gross physical inhomogeneities in a sample, as might be observed in a tissue sample 
containing membranes, fluids and connective tissue. These spatially-related causes of 
differences in the magnetic field strength and thus precessional frequency, leading to line-
broadening, are averaged out by spinning the sample at the magic angle. 
2.3.2 Application to biological tissue samples 
The benefits of magic angle spinning (MAS) NMR make it a useful technique for the analysis of 
tissue samples. MAS NMR allows simultaneous analysis of lipid and aqueous compartments of 
intact solid tissue, resembling in vivo findings more closely than tissue extracts. In addition, 
MAS NMR spectroscopy requires a smaller mass of tissue for analysis compared to tissue 
extracts (Martinez-Granados et al., 2006) and enables histological evaluation of the sample 
following analysis (Dave et al., 2004). MAS NMR spectroscopy has been applied to metabolic 
profiling in liver and other tissues from animal models and from humans, demonstrating 
identification of numerous metabolites and provision of a snap-shot metabolic profile. 
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Since the first studies using 'H MAS NMR, applied to lymph node tissue (Cheng et al., 1996), 
the technique has been applied to the study of brain (Cheng et al., 1997), cardiac (Griffin et al., 
2001; Jones et al., 2005), prostate (Cheng et al., 2001), breast (Sitter et al., 2002), cervix 
(Mahon et al., 2004b), pancreas (Fang et al., 2007) and liver (Yang et al., 2007) tissue. 
Malignant tissue has been studied in a number of settings as the metabolic abnormalities are 
substantial. More recently, 'H MAS NMR has been used, together with other metabolic and 
genetic profiling techniques, in toxicology studies (Waters et al., 2006). 
2.3.3 Application to the study of liver disease in man 
Just three published studies have used 'H MAS NMR spectroscopy to examine intact liver tissue 
in man (Duarte et al., 2005; Martinez-Granados et al., 2006; Yang et al., 2007). Each has 
examined a small number of samples and sample provenance is varied, so disease-specific 
conclusions are unclear. 
Duarte and colleagues performed the first published study of 'H MAS NMR spectroscopy of 
intact liver tissue in man. The main purpose was to outline the metabolic profile of such tissue 
and to assign the resultant resonances. The clinical model was of donor liver tissue from six 
subjects for transplantation before retrieval, following storage and following transplantation into 
the recipient (a total of 18 samples). The main conclusions were a "proof-of-principle" of 'H 
MAS NMR spectroscopy as a potential screening tool for the assessment of the metabolic status 
of donor liver. Their biological conclusions were of identification of University of Wisconsin 
solution in biopsies during storage and of decreased glycerophosphocholine (GPC) levels 
throughout the transplant process, associated with presumed increased cell turnover (Duarte et 
4^,2005^ 
Martinez-Granados and colleagues applied 'H MAS NMR spectroscopy to intact liver biopsy 
samples from 16 patients with chronic liver diseases. 10 of these samples were of chronic 
hepatitis (aetiology, stage and grade unspecified), three were of cirrhotic liver (pathological 
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features and aetiology unspecified), two were from "non-pathological" liver adjacent to 
metastases (of unspecified origin) and one was from "non-pathological" liver, harvested from an 
elderly woman at autopsy, 24hr post-mortem. The stated aim of this study was the applicability 
to clinical studies of 'H MAS NMR biochemical profile determination in intact liver tissue by 
needle biopsy. Intensity ratios of resonances were used to derive indices separating "non-
pathological" tissue, "hepatitis" and "cirrhosis", including glucoseilipid, undefined fatty acid 
functional group ratios and alanine: lysine. As the disease classification was unclear, numbers 
were small, "non-pathological" tissue was unlikely to be metabolically normal and the stated 
ratios without known biological relevance, the conclusions of the study were again a statement 
of feasibility, rather than biologically plausible or clinically-useful information. Of importance, 
however, was their study of tissue degradation with time. They concluded that data acquisition 
at low-temperature led to negligible tissue degradation over a 4hr period (Martinez-Granados et 
al., 2006). 
Yang and colleagues applied the technique to biopsy samples from 17 patients with 
hepatocellular carcinoma (HCC), taking samples from 17 tumours and 14 adjacent areas of 
"non-involved" tissue. They aimed to assess applicability of the technique, to classify tumours 
according to metabolic differences and to assess the effect of co-existent cirrhosis on the 
metabolic profiles of HCC tissue. They applied principal components analysis to the 
multivariate data, separating tumour from adjacent tissue and "high-grade" from "low-grade" 
HCC. The metabolites thought to contribute to differences between tumour and adjacent tissue 
included increased bile acids, choline-related compounds, and a number of amino acids and 
decreased glucose, glycogen and lipids in tumour tissue. Moreover, they observed increased 
lactate and amino acids in high-grade compared to low-grade tumours. However, the authors did 
not specify how resonances were assigned. This study constituted application of 'H MAS NMR 
to a clinical problem, with biological plausibility of some of the results. However, metabolic 
changes in tumour tissue are likely to be gross, on account of tissue hypoxia, necrosis and 
cellular content (Yang et al., 2007). 
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These three studies demonstrate the potential applicability of 'H MAS NMR to the clinical 
setting. Challenges shared by these studies include the appropriate classification of tissue 
samples used, the choice of experimental conditions and the biological relevance of the 
metabolic perturbations observed. 
2.3.3.1 Extracts 
Prior to the application of 'H MAS NMR to the analysis of biological samples, lipid and 
aqueous extracts enabled tissues to be analysed in the solution state. By necessity, this is a 
destructive technique, but separation of the aqueous phase enables the analysis of water-soluble 
metabolites, without interference from larger co-resonant lipid peaks. Extract studies typically 
require >250mg of tissue and concentrations of metabolites may be affected by their solubility 
in the chosen solvent (Martinez-Granados et al., 2006; Maxwell et al., 1998). 
2.3.4 Technical considerations 
'H MAS NMR of intact tissue is a relatively new technology. The physical parameters and 
technical considerations vary between studies. The physical forces applied to the sample, spatial 
variation in radiofrequency (RF) energy and magnetic field across the sample all complicate the 
acquisition of high quality MR spectra of tissue, compared to biofluids. Optimal sequences and 
experimental conditions have not been established and depend on the hardware available and 
the information required from the study. Table 2-1 summarises some of the technical and 
physical variables from three studies, highlighting the lack of current consensus. 
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Table 2-1. Published methods for 'H MAS NMR of intact liver tissue 
Bol lard et al. 2000 Duarte et al. 2005 Mart inez-Granados et 
al. 2006 
System Bruker, 400MHz Bruker, 400IVIHz Bruker, 500MHz 
Tissue type Rat liver Human donor liver 
(pre-retrieval; post-
storage; post-
transplant) 
Liver needle-biopsy 
samples, CLD of 
varying aetiology. 
Sample size c. 8mg 19.5 ± 1.0mg 0.5mg - 12mg 
Sample prep Perfused with 0.9% 
NaCI witin D2O 
"Immediately" snap-
frozen in liquid N2 
"Cooled immediately" 
Sample storage Snap-frozen in liquid Stored at -70°C, then Stored at -80''C until 
N2, then stored at - washed with D2O use 
70°C saline (0.9%) 
Insert (sealing Not specified 4mm diameter zirconia 4mm diameter zirconia 
cell) type rotors with "top 
inserts", 15jil final 
volume 
rotors with spherical 
insert, topped up with 
D2O to 12^1 final volume 
Acquis i t ion 30°C 25°C 0°C, sample 
temperature temperature calculated 
as 4°C 
Spin speed 6200Hz 4000Hz 4000Hz 
Sequences Presat/N0ESYPR1D Presat Presat/ 1DN0ESY 
used CPiVlG CPMG CPMG 
TOCSY TOCSY TOCSY 
JRES JRES HSQC 
HiVlQC HMQC 
Number o f 128 for presat 128 for presat 400 - 1024 
scans 256 for CPMG 256 for CPMG 
(" t ransients") 
Echo t ime (for 80ms 120ms 36ms 
spin-echo 
sequences) 
Abbreviations: CLD, chronic liver disease; D^O, deuterated water, presat, fully-relaxed pulse and collect 
spectrum with water presaturation; NOESYPRlD, one-dimensional nuclear Overhauser effect 
spectroscopy with water presaturation-, CPMG, Carr-Purcell-Meiboom-Gill sequence (spin-echo); 
TOCSY, total correlation spectroscopy; JRES, J-resolved spectra; HMQC, heteronuclear multiple 
quantum correlation; HSQC, heteronuclear single quantum correlation. 
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2.4 Aims 
The experiments in this chapter were performed to optimise experimental conditions in order to 
obtain high quality, high resolution 'H MAS NMR spectra in vitro on the system to be used for 
subsequent experiments, by testing physical and NMR parameters. 
2.5 Hypotheses 
Using 'H m a s NMR of liver tissue, it was hypothesised that: 
a. Increased sample size increases the signal-to-noise ratio 
b. Decreased chamber size increases spectral resolution 
c. Increased temperature of acquisition increases spectral resolution but increases rate of sample 
degradation 
d. Longer duration of acquisition increases signal-to-noise, but also increase sample degradation 
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2.6 Methods 
A number of physical and NMR parameters affect the quality of data obtained by 'H MAS 
NMR spectroscopy. For experiments contributing to this thesis; parameters were defined on the 
basis of evidence from the literature. Where published evidence was lacking, experiments were 
performed to establish the optimum conditions for data acquisition. 
2.6.1 Equipment 
Proton MAS NMR experiments were carried out using a MAS probe (Doty Scientific Inc., 
Columbia, South Carolina, USA), interfaced with a JEOL Eclipse 500+ MR spectrometer 
(JEOL (UK) Ltd, Welwyn Garden City, UK) and a 11.7T superconducting magnet (Oxford 
Instruments, Oxford UK). Air temperature was detected by thermocouple and spin rate by an 
optical spin counter. A temperature control system was developed whereby water-depleted 
compressed nitrogen gas was passed through a heat exchange coil in liquid nitrogen prior to 
entering the probe and spinning the rotor. A heater and thermocouple were used to keep the 
temperature to the required settings. 
2.6.2 Sample provenance 
2.6.2.1 Sample acquisition 
Murine liver samples were obtained from mice culled by exsanguination under terminal 
anaesthesia, minimising residual blood in the sample. 
2.6.2.2 Sample storage 
All liver tissue samples were placed in a polypropylene tube and snap-frozen in liquid nitrogen 
immediately after acquisition and typically within 2 minutes of harvest in order to minimise 
sample degradation. Samples were transferred to a freezer at -80°C for longer term storage. 
75 
2.6.2.3 Sample preparation 
Samples were transferred to dry ice prior to preparation. Samples were thawed to the extent that 
they could be cut with a scalpel (typically up to 30s) and the remainder immediately placed back 
onto dry ice. The samples were inserted into pre-cooled, pre-weighed XC4 Kel-F sealing cells 
with Teflon plugs (Doty Scientific Inc., Columbia, South Carolina, USA) and the samples and 
cells weighed. The sample mass was determined by deduction. The prepared cells were then 
kept on dry ice prior to analysis. The filled cells were placed in pre-cooled silicon nitride rotor 
tubes with aurum finned caps (Doty Scientific Inc., Columbia, South Carolina, USA) prior to 
insertion into the probe. 
2.6.3 NMR parameters 
2.6.3.1 Choice of sequences 
The 'H MAS NMR spectrum of liver tissue is dominated by water and lipid resonances. 
Choline-related compounds, glucose and glycogen resonances are prominent, while a number of 
amino acid resonances are also detectable. NMR sequences were chosen to enable accurate 
assessment of all components. 
To assess the abundance of major lipid resonances compared to water content of samples, a 
fully-relaxed pulse and collect sequence was used (Figure 2-2). To compare the lipid 
components and choline-related compounds, assess measures of lipid saturation, and for used in 
multivariate analysis, a fully-relaxed pulse and collect spectrum with water presaturation (water 
suppression) was used (Figure 2-3). This sequence enabled simultaneous examination of lipid 
and other metabolite components without systematic suppression of either component. To 
investigate smaller metabolites, including the individual components of the choline region, a 
Carr-Purcell-Meiboom-Gill (CPMG) spin-echo pulse sequence with water presaturation was 
used (Figure 2-4). 
76 
Water Choline L2 L1 
' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I - ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' ' I ' ' ' • I ' • • ' 
8 7.5 7 6.5 6 5.5 5 4.5 4 3.5 3 2.5 2 1.5 1 0.5 0 
ppm 
Figure 2-2. Pulse and collect spectrum wi thout water suppression. 
A fully relaxed pidse and collect spectrum from normal murine liver shows a spectrum dominated by 
water. Magnification on the y-axis clearly shows the presence of the main spectral peaks, such as LI, 
methyl functional group and L2, methylene and the choline region. 
L2 
Ado Urd Tyr Ado Urd 
Choline 
region 
Glucose 
region 
L5 L4 L3 Glycerol 
3'5 8 7.5 1.5 
ppm 
Figure 2-3. Pulse and collect spectrum wi th water suppression. 
The lipid spectrum', a fidly relaxed water-presaturation spectrum demonstrates all the main lipid 
functional groups. The components of the choline and glucose/glycogen region may also be seen. On 
magnification of the region from 55.5-8.5ppm, a number of amino acid resonances are visible. The 
residual water peak has been removed and the L2 peak truncated. 
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Figure 2-4. Spin-echo pulse sequence with water suppression. 
A CPMG spectrum, TE 40ms, shows similar resonances to the lipid spectrum, but the broad components 
are removed. There is clear resolution of the choline region (see inset) including choline itself, 
phosphocholine (PC), glycerophosphocholine (GPC), phosphatidylcholine (PtC) with contibiitions from 
trimethylamine-N-oxide (TMAO) and betaine. The /^-glucose doublet, used for optimisation experiments 
is also enlarged (inset). 
2.6.3.1.1 Number of scans (acquisitions) 
MRS is a technique of inherently low sensitivity. In order to increase the signal-to-noise ratio, 
the number of data acquisitions (scans) is increased. As the number of scans {N) increases, the 
signal increases by a factor of # and the noise, being random, by accordingly, a doubling of 
scans leads to an increase in SNR of V2. Smaller samples or samples of low concentration 
provide less signal, so require more scans to derive a satisfactory SNR. Sequences that suppress 
components of the signal, such as spin-echo sequences, also require more scans. The number of 
scans performed is limited by the conflicting pressure of the time taken to perform the 
investigation and the degradation of the sample that might be expected to occur over that 
timescale. 
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2.6.3.1.2 Repetition time and acquisition time 
T| exceeds T? for a given moiety in a specified physico-chemical environment. Biological 
tissue, being chemically and physically complex, contains multiple T, and T; components. 
The repetition time (TR, in seconds) is the time from the start of one RF pulse to the start of the 
next RF pulse. TR consists of the acquisition time and the relaxation delay. If the TR is short 
relative to some or all of the T, components, there is insufficient time for the nuclei to relax 
between RF pulses, leading to incomplete signal generation; the signal is said to be "saturated". 
During the acquisition time, nuclei undergo T? relaxation, and the acquisition time needs to be 
selected to allow measurement of short and long T] components. It is defined by the spectral 
sweep width and the number of data points collected. 
In order to ensure that the spectra were fully relaxed with all components represented, a TR of 
10s was chosen for pulse and collect sequences without water suppression and 5s for pulse and 
collect sequences with water presaturation, and CPMG sequences. The longer TR was chosen 
for the spectra including water, as long water T, components had been observed (IJ Cox, 
personal communication). By using 32k datapoints and a spectral width of 15kHz, an 
acquisition time of 2.2s allowed complete detection of resonances with linewidths of less than 
IHz. 
2.6.3.1.3 Echo time 
Spin-echo sequences, such as CPMG, cause a refocussing of the transverse relaxation decay by 
reversing the dephasing of nuclei by application of a 180° inversion pulse after a time interval, 
the echo time (TE). By changing the TE, the signal from spectral components of a specified 
range of relaxation times may be selectively detected. 
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2.6.3.1.4 Pulse angle 
The pulse angle is the angle at which the RF pulse is applied, relative to Bo A pulse angle of 90° 
leads to maximal deviation of dipoles from Bo and, accordingly, to maximal signal production. 
Where samples are large or expected to generate a large signal, the signal may exceed the 
spectrometer capacity, leading to truncation of the signal. In this situation, the pulse angle may 
be reduced to reduce the absolute signal generated. Signal amplitude is proportional to sine of 
the pulse angle (sinG). 
2.6.3.1.5 Spectral width 
The spectral width (or sweep width) is the frequency range over which the signal is collected 
and was set at 15kHz to prevent the "spinning-sideband" artefact from overlapping with the 
metabolite peak of interest (Mahon et al., 2004a). The digital resolution of the spectrum is the 
spectral width divided by the number of datapoints. 
2.6.3.1.6 Rece iver gain 
The receiver gain magnifies the FID signal induced in the receiver coil. Therefore, absolute 
signal intensity may be modified by the pulse angle, the receiver gain, or both. 
2.6.3.2 Choice of parameters for in vitro NMR spectroscopy studies 
Initial murine studies were carried out using sequences developed for the analysis of human 
oesophageal and cervical tissue performed using the same hardware (Dave et al., 2004; Mahon 
et al., 2004b) and are shown in Table 2-2. The pulse angle was reduced in pulse and collect 
spectra with and without water suppression to prevent the signal exceeding the spectrometer 
capacity when large or lipid-rich samples were used. The time of acquisition and number of 
scans acquired were limited to minimise the effects of sample degradation. 
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Table 2-2. NMR parameters chosen for initial murine experiments 
Sequence Scans Receiver 
gain 
Pulse 
angle 
(°) 
Relaxation 
delay (s) 
Echo 
t ime 
(ms) 
X 
points 
(k) 
Spectral 
w id th 
(kHz) 
Time 
(min) 
Pulse and 
collect 
16 15 9 10 32 15 5 
Water 
presaturation 
64 15 45 5 32 15 8 
CPMG 64 15 90 5 40 32 15 9 
Abbreviations: X points, number of datapoints along the x axis', CPMG, Carr-Purcell-Meiboom-Gill 
2.6.4 Spectral processing functions 
Once MR data had been acquired, FIDs were imported from the JEOL Eclipse 500+ MR 
spectrometer to the processing software. 'H MAS NMR spectra were managed using the 
KnowItAll® Informatics System v7.8 (Bio-Rad, Philadelphia, USA). The following processes 
were applied: 
2.6.4.1 Exponential windows function (apodization) 
The exponential windows function adds a weighting to the FID, which amplifies the signal more 
than the noise, thus increasing SNR. 
2.6.4.2 Zero filling 
Zero filling increases digital resolution by adding null data to the end of the FID. The level of 
zero filling is selected automatically on the basis of the number of experimentally collected 
datapoints. Zero filling has the effect of smoothing data and increasing resolution. 
2.6.4.3 DC offset 
The NMR signal can be shifted from the baseline on account of instrumental errors. This 
artefact is corrected during processing. 
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2.6.4.4 Phasing 
The received NMR signal, the FID, takes the form of sine waves. The value of the waveform on 
the y axis at a given time may be positive, negative or anywhere in between. This depends on 
the phase of the wave, which depends on the time at which measurement starts and the direction 
from which the signal is measured. Following the delivery of an RF pulse, the receiver may be 
overloaded initially (the deadtime). Different components of the spectrum evolve during the 
deadtime, so may be out of phase when the receiver starts to detect the signal. If these 
components are out of phase, signal may be lost. Therefore, phase correction mathematically 
corrects the phase of the components at the start of data acquisition to ensure a symmetrical, 
positive lineshape upon Fourier transformation. 
All data processed in Knowitall® were subject to automatic GoodLook'^'^ phasing, 
systematically optimising the phase parameters to maximise the peak integral above the 
baseline. Manual phasing was performed if automatic phasing did not appear optimal. 
2.6.4.5 Baseline correction 
Baseline correction corrects severe baseline bias which causes a systematic error to the y-values 
of part of the spectrum. Using Knowitall®, an automatic spline algorithm is applied, which fits a 
number of polynomical curves to the spectral baseline, excluding spectral peaks. 
2.6.4.6 Referencing 
The chemical shift is defined as a difference in frequency between the peak of interest and the 
reference peak. A reference may be internal or external to the sample. An ideal reference is a 
well-defined peak, which is clearly identifiable in all spectra in a dataset, the position of which 
is independent of biochemical or physical changes, such as differences in pH and temperature. 
In plasma and serum, the lactate doublet at 51.32ppm is often used as a reference (Kirschenlohr 
et al, 2006), but this peak is often not visible in liver tissue samples, where it is often obscured 
by the large lipid resonance centered at 51.30ppm. In murine fatty liver experiments, where the 
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spectra were dominated by lipid resonances, the reference peak used was that of the methyl lipid 
proton at 50.9ppm. 
2.6.4.7 Peak assignment 
2.6.4.7.1 Analysis of samples of known composition 
The molecular structure of organic compounds may be inferred from the relative size and 
position of resonances, which correspond to the relative abundance of nuclei and the bonds or 
coupling between them. An external reference compound may be added, so that the chemical 
shift may be measured. Reference databases of spectral signatures have been established 
(Wishart et al., 2007). 
2.6.4.7.2 Correlation of resonances in complex biological samples 
In complex samples, NMR spectral signatures overlap and the relative concentrations of 
constituents may not be known. Resonances may be assigned by "spiking" the sample with 
substances of a known chemical shift pattern. Two-dimensional spectroscopy techniques, such 
as COSY (correlation spectroscopy) and HMQC (heteronuclear multiple quantum correlation) 
allow nuclear interactions to be studied. COSY combines spectra to illustrate coupling between 
proton pairs. Coupling may occur over a distance of two to three bonds, so complex structures 
may be assembled. HMQC plots spectra from different nuclei on each axis, allowing correlation 
between the assignments of resonances from spectra of one nucleus to the other. Combining this 
approach with information from pure sample databases allows the assignment of resonances in 
previously unstudied sample types. An early study of intact rat liver tissue by MAS NMR 
spectroscopy used total correlation spectroscopy (TOCSY) and HMQC to assign the resonances 
obtained (Bollard et ah, 2000). Subsequent studies by independent groups have examined 
human liver tissue using similar techniques to publish databases of metabolites to be found in 
intact liver tissue (Duarte et al., 2005; Martinez-Granados et al., 2006). 
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2.6.4.7.3 Assignment on the basis of the published literature 
The publication of databases of the relevant resonances for the tissue to be studied allows 
assignment of resonances in subsequent studies, although care should be taken not to extrapolate 
these databases beyond the sample type used. For the studies presented in this thesis, a database 
of the spectral assignments from three independent studies of intact liver tissue in rodent and 
humans was compiled for the assignment of resonances (Bollard et ah, 2000; Duarte et ah, 
2005; Martinez-Granados et al., 2006). The published chemical shifts were largely in agreement 
between studies, increasing confidence in the results. Where there was ambiguity or conflicting 
information, further references were sought as specified. 
2.6.5 Integration methods 
2.6.5.1 Signal to noise and linewidth measurement 
The signal to noise ratio (SNR) was calculated by dividing the height of the P-glucose peak at 
54.65ppm by the width of the noise band at 54.5ppm (peak to trough). The line width was 
defined as the breadth of the P-glucose doublet at half peak height. If two peaks were 
discernable at the P-glucose resonance, a doublet was considered to be visible. An optimal 
spectrum was considered to have a high SNR, a narrow line width, and to allow clear subjective 
assessment of a p-glucose doublet where present. The P-glucose resonance was chosen as it is 
easily identifiable, stands alone without interference or overlap from neighbouring peaks and 
consists of a doublet, which allows for a subjective interpretation of spectral resolution. 
2.6.5.2 Integration of pre-defined regions 
Quantification of metabolites was performed by integration of resonances, the area under the 
curve being proportional to the number of nuclei contributing to that resonance. Regions for 
integration were defined by placement "bins" or "buckets" defining the extent of the baseline 
subtending the region of interest. Such a technique is ideal for the integration of narrow, well-
defined and well-separated resonances, such as those obtained by solution-state work (Salek et 
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a/., 2007). In such spectra, there is little overlap between resonances and the nadir between 
peaks falls to baseline. 'H MAS NMR spectra from intact liver tissue approximate to that 
obtained from solution-state work (Rooney et al, 2003). However, the presence of cell 
membranes and connective tissue, which are absent in plasma, leads to broader resonances. The 
water presaturation sequences of liver tissue are also dominated by the lipid resonances. Smaller 
narrow resonances from metabolites, such as free amino acids, may be superimposed over the 
"shoulder" of the lipid resonance, with the nadir between peaks not reaching baseline. For most 
analyses, the peaks of interest were assumed to be sufficiently separated for integration of a bin 
subtended by the curve to be considered a close surrogate of the true peak integral. 
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2.7 Results of calibration experiments 
2.7.1 Physical parameters 
A number of physical parameters affect the tissue and the resultant NMR spectra. These have 
been examined in turn to determine the optimum experimental design for subsequent 'H MAS 
NMR studies. 
Theoretically, the signal amplitude received from a sample is proportional to the number of 
nuclei in the sample. Accordingly, a greater signal is expected from a sample of similar 
chemical constituents with a higher mass when all other parameters are kept constant. However, 
there is the potential for physical properties of biological tissue to interfere with quantification 
of spectral resonances. 
If a tissue sample is held in a strong magnetic field, a magnetic field gradient will vary over the 
sample according to the shape of the sample, tissue architecture and chemical constituents. 
Accordingly, nuclei in the same stereo-chemical environment can experience a different 
strength magnetic field, so will resonate at a different frequency and therefore at a different 
chemical shift. This leads to broadening of the peak in the frequency domain and reduction in 
spectral resolution. The process of shimming adjusts the applied magnetic field, reducing 
magnetic field strength gradients over the sample in order to minimise line broadening. 
In order to investigate the effect of sample mass, sealing cell volume and sealing cell shape on 
spectral quality, normal murine liver from 8 week-old cdla mice was analysed using differing 
sample masses, cell volumes and cell cavity shapes. Pulse and collect spectra with water 
presaturation were used with NMR parameters kept constant. Shimming was optimised manually by 
a single operator. 
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2.7.2 Sample mass 
To assess the effect of sample size on SNR and linewidth, NMR spectra from 11 samples of 
normal murine liver tissue of mass varying from 2-20mg, placed in 20pL sealing cells, were 
analysed retrospectively. On examination of the pulse and collect with water presaturation 
sequences, there was close correlation between sample mass and SNR, Spearman rho r=0.92, 
p<0.0001. The linewidth correlated more weakly with sample mass. Spearman rho r=0.63, 
p=0.04. The increase in linewidth seen in larger samples may have resulted from greater 
magnetic field inhomogeneity found in larger samples, but the effect of linewidth is accounted 
for in the calculation of SNR. These relationships are displayed in Figure 2-5. Accordingly, 
larger samples were considered preferable to smaller samples where sample size was not the 
limiting factor. 
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Figure 2-5. Sample mass plotted against signal to noise ratio and linewidth. 
A, signal-to-noise ratio (SNR) and B, linewidth. 
2.7.3 Sealing cell volume 
To assess the effect of chamber size on SNR, normal murine liver samples of matched mass and 
provenance were placed in 20^L cylindrical cells (n=3) and A\xL spherical cells (n=3). SNR and 
linewidth were calculated as described previously. The mean ± SEM sample mass was 3.3 ± 
0.8mg in the 20^L cells and 3.0 ± 0.06mg in the 4)j.L cells (unpaired t-test, p=0.73). The mean ± 
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SEM SNR was 17.1 ±3 .90 and 32.5 ±5 .61 respectively (p=0.13). The mean ± SEM linewidth 
was 0.031 ± O.OOlppm versus 0.032 ± 0.002ppm respectively, (p=0.46). In this small study, 
there was a suggestion that the SNR was greater for a given sample mass when analysed in the 
small 4fiL spherical cavity, although the linewidth was unchanged. 
The receiver coil was focused to the centre of the sealing cell. Accordingly, signal fi-om the 
centre was received maximally. Where a small sample was placed in a large cell, the sample 
was distributed evenly around the periphery of the cell, leaving little tissue in the centre. A 
similar sample in a small cell will remain centrally distributed, yielding a higher total signal. A 
centrally placed sample might also be expected to provide a narrower linewidth. This was not 
found in practice using tissue samples and fine resolution was, in fact, more difficult to achieve. 
This may be explained by the larger shearing forces experienced by a small sample in a large 
cell compared to a similar sample in cell with a small spherical chamber. Accordingly, such a 
sample will experience greater structural disruption, leading to enhanced molecular mobility 
and, therefore, decreased linewidth. 
As a result of these experiments, where sample mass was unlimited, large samples (>10mg) 
were inserted into 20|aL sealing cells. Where sample size was limited, the smallest cell able to 
contain the whole sample was used to reduce the shearing forces experienced, increase the 
magnetic field homogeneity and yield the maximal SNR. 
2.7.4 Temperature of data acquisition 
In order to assess how sample temperature affects the observed spectrum, three samples of 
normal murine liver tissue were analysed using pulse and collect sequences with water 
presaturation at the following temperatures: 0°C, 4°C, 25°C and 37°C before returning to 0°C. 
These temperatures were selected to represent temperatures used in previously published studies 
and mammalian body temperature (Bollard et al., 2000; Duarte et al., 2005; Martinez-Granados 
et al., 2006). The SNR and linewidth were calculated as described above. The sample 
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temperature also determines the chemical shift of water (ppm) according to Equation 2-B 
(Gottlieb et al., 1997): 
Equation 2-B 
5 = 5.051 - O.Olll(T) 
where 5 is the chemical shift in ppm and T is the sample temperature in °C. As a result, at 0°C, 
water is at 55.05 ppm and at 37°C, the water peak is at 54.64ppm. 
The SNR increased with successively increasing temperatures but did not increase further when 
the temperature returned to 0°C, with a decrease in SNR (non-significant). The linewidth 
decreased with successively increasing temperatures but did not decrease further when the 
temperature returned to 0°C, with a small increase in linewidth (non-significant) (Figure 2-6). 
This shows that, at higher temperatures, there was an increased SNR and a narrower linewidth. 
However, as the measurements at 0°C separated by time were not equal, an irreversible change 
may also have occurred, which may represent sample degradation. Although a higher 
acquisition temperature appeared to increase spectral quality (as assessed by improved SNR and 
linewidth), the effect of sample degradation with time must be considered. 
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Figure 2-6. Change in signal-to-noise ratio and linewidth with temperature. 
The mean ± SEM SNR and linewidth of the /3-ghicose resonance, n=3, plotted against temperature of 
acquisition and altered sequentially from left to right. 
2.7.5 Duration of acquisition 
It has been shown previously that sample spinning leads to spectral changes with time when 
compared to a matched sample kept motionless at the same temperature, particularly within the 
glucose and glycogen regions (Martinez-Granados et al., 2006). 
On the basis of these data, it was hypothesised that sample spinning leads to application of 
mechanical shearing forces to the sample, with disruption of tissue and cellular architecture. 
Such disruption decreases magnetic inhomogeneities and increases fluidity within the sample, 
causing an increase in T] relaxation times and consequent reduction in linewidth and increase in 
subjective spectral resolution. 
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The rate of change of the metabolic profile was examined by comparing the spectra from three 
samples spun at 4°C and three samples spun at 25°C, over a 4hr period. Acquisition 
temperatures were selected from previous studies (Table 2-1). The samples of histologically 
normal murine liver were placed in 20^L sealing cells as described above. The mean ± SEM 
weight was 15.4± 1.5mg for the samples at 4°C and 15.2 ± 0.7mg for the samples at 25°C. Fully 
relaxed 'H MAS NMR spectra with water presaturation were acquired every 20min for 4hr. 
The lipid -CH? and total choline resonances were integrated as representative of high molecular 
weight, lipid resonances and membrane metabolites. The alanine doublet at 51.48ppm and the 
[3-glucose doublet at 54.65ppm were integrated as representative of the low molecular weight 
metabolites. These resonances were chosen as they were well-defined and did not overlap 
substantially with other peaks. The SNR and line width were calculated as described above. 
The mean signal for the lipid -CH? resonance was significantly reduced by Ihr from baseline 
and remained so at 4hr at both 4°C and 25°C. The mean signal for alanine was significantly 
increased at 4hr at 25°C but not 4°C and in neither group at Ihr. The mean signal for P-glucose 
was significantly increased at both Ihr and 4hr at 25°C but not at 4°C (Table 2-3). 
The mean ± SEM signal intensity as a percentage of each of the measured resonances at 4°C and 
25°C with time is represented in Figure 2-7. There was a significantly greater change at 25°C 
compared to 4°C in both alanine and P-glucose resonances at 4hr. Quantitative comparison of 
signal intensity with time is displayed in Table 2-3. Significant changes in signal intensity over 
time are seen in the methylene lipid group at 4°C and in the methylene lipid, alanine and P-
glucose resonances at 25°C. 
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Table 2-3. Change in integrals of resonances with time at 4''C and 25''C. 
~ 4°C 25°C 
0 hr 1 hr 4 hr 0 hr 1 hr 4 hr 
Lipid CHz 10.64 9.99* 8.85* 8 .98(1 .76) 7.95** 6.70** 
(1.72) (1.92) (2.01) (1.85) (1.42) 
Alanine 0.48 0.46 0.51 0.42 (0.06) 0.52 0.81* 
(0.16) (0.15) (0.13) (0.07) (0.16) 
Choline 2.19 2.22 2.19 2.51 (0.38) 2,64 2.89 
(0.46) (0.42) (0.34) (0.34) (0.23) 
(3-glucose 0.57 0.60 0.64 0.59 (0.10) 0.71* 0.82** 
(0.08) (0.06) (0.06) (0.13) (0.12) 
Mean integrals for spectral peaks with standard deviation (s. d.) in arbitrary units showing change in 
values with time at 4°C and 25°C. Significant changes at the p<0.05 level, compared to baseline (start), 
are denoted by *, while changes significant at the p<0.01 level, compared to baseline are denoted by **. 
These data demonstrate that changes are observable in 'H MAS NMR spectra of normal liver 
samples over time. The changes are more marked and more extensive when the spectra are 
acquired at 25°C as opposed to at 4°C. Figure 2-7 shows that there is a linear relationship 
between these changes and time, so the effects of sample degradation must be considered when 
choosing the number of data acquisitions to use for a sequence. 
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2.7.6 Spin speed 
Spinning of the sample should be at a rate sufficient to remove the spinning sideband artefact 
from the region of interest (O-lOppm). The distance of the spinning sideband from the region of 
interest may be calculated by Equation 2-C: 
Equation 2-C. 
Distance of spinning sideband (ppm) = Spin speed (Hz) x 10^ / Operating frequency (MHz) 
The operating frequency is 500MHz, so spinning at 2000Hz gives sidebands at ± 4ppm and at 
4000Hz gives sidebands at ± 8ppm from the parent peak. The greatest sidebands are produced 
by water at 54.8ppm and lipid -CH] at 51.3ppm and the useful spectrum is found between 
50ppm and 58ppm. Therefore, in order that sidebands do not interfere with the spectrum 
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produced, they should be more than 8ppm from the parent peak, requiring a minimum spin 
speed of 3500Hz. 'H MAS NMR spectroscopy studies of intact liver tissue have used a spin 
speed of 4000Hz when the operating frequency is between 400 and 500MHz (Bollard et al., 
2000; Duarte et al., 2005; Martinez-Granados et ciL, 2006). 
High frequency spinning causes the generation of shearing forces within the sample, leading to 
disruption of tissue structure and acceleration of sample degradation. This factor was shown to 
be additional to degradation caused by the sample existing at a defined temperature (Martinez-
Granados et ah, 2006). 
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2.8 Discussion of N M R and physical parameters 
2.8.1 N M R parameters 
The choice of NMR parameters involves some compromise between competing phenomena. 
Thus, the aims of any studies should be considered when making these decisions. As the overall 
aims of the project were to assess the metabolic profiles of liver tissue in chronic liver disease 
and to use this information to inform the analysis and interpretation of MR spectra in vivo, the 
total spectral information was of interest. The use of fully-relaxed pulse and collect sequences, 
with and without water suppression, enabled the simultaneous assessment of aqueous and lipid 
components (Figure 2-2 and Figure 2-3). These sequences also enabled ratios of metabolites to 
be assessed without the introduction of spectral-editing-related bias, caused by the relative 
suppression of some metabolites over others. For full-relaxation and maximal signal production, 
long TRs were chosen (section 2.6.3.1.2), which increased acquisition time, but enabled spectra 
with good SNR to be obtained with fewer transients or averages, thus reducing the acquisition 
time. Reduction of the acquisition time is also important to limit sample degradation, hi contrast 
to previous studies, we have shown significant changes in resonances within Ihr at both 25°C 
and 4°C (Bollard et al., 2000; Martinez-Granados et al., 2006). The rate of degradation cannot 
be assumed to be equal from sample to sample or tissue to tissue, so, for the in vitro metabolic 
profiles to represent the metabolite ratios found in vivo, minimal degradation should be allowed 
to occur. This may, therefore, conflict with the need to obtain spectra with a maximal SNR. 
However, for the assessment of certain spectral regions, spin-echo (CPMG) sequences were 
used to suppress macro-molecular components over low molecular weight metabolites. This 
enabled the examination of smaller signals, which might be obscured by large lipid resonances. 
However, the spin-echo sequences reduce signal from all parts of the spectrum, so more 
transients were required to obtain high SNRs. This takes more time and so leads to potential 
degradation. By choosing a longer echo time, macromolecular signals were suppressed more, 
but more transients were required to obtain an appropriate SNR. 
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Maximal signal was obtained from a pulse angle of 90°, but in large samples there is a risk of 
signal saturation, which is mitigated by reducing the receiver gain. If the receiver gain is not 
specified, the signal amplitudes cannot be compared in absolute terms between samples. 
However, the studies in Chapter 3 were unaffected by saturation and spectral processing 
normalised the spectra to the total spectral integral, so absolute signal measurement was not 
required. For subsequent experiments (Chapter 4), 90° pulse angles were used. 
As a result of these considerations, the NMR parameters stated in Table 2-2, were revised for 
the studies of human tissue in Table 2-4. 
Table 2-4. NMR parameters optimised for subsequent experiments. 
Sequence Scans Receiver Pulse Relaxation Echo X Spectral Time 
gain angle delay t ime points w id th (min) 
n (ms) (k) (kHz) 
Pulse and 32 5 90 10 32 15 11 
collect 
Water 128 15 90 5 32 15 16 
presatu ration (10-18) 
CPMG 256 15 90 5 80 32 15 32 
(10-18) 
Abbreviations: X points, number of datapoints along the x axis; CPMG, Carr-Purcell-Meiboom-Gill 
sequence. 
2.8.2 Physical parameters 
A sample with a greater mass yields a higher signal-to-noise ratio for a given number of data 
acquisitions owing to the proportionately greater number of protons. However, differing 
amounts of a given metabolite in different samples will also affect the signal produced and 
therefore the SNR. The calibration experiments were carried out using normal 8 week old CD la 
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mouse liver, so metabolite differences between samples is likely to be small. A large sample 
therefore increases the SNR. 
A larger sample is likely to be more representative of the organ of interest, as demonstrated by 
studies of the diagnostic performance of human liver biopsies (Bedossa et al., 2003). However, 
occupation of a larger volume, either through a larger sample or a larger sample size, leads to 
greater magnetic field inhomogeneities throughout the chamber. This is demonstrated by an 
increased linewidth seen in the larger samples and potentially decreased spectral resolution as 
represented by the ability to determine the presence of a |3-glucose doublet subjectively. 
Therefore, a smaller chamber, which may necessitate a smaller sample, should yield a narrower 
linewidth. Accordingly, where tissue availability was not strictly limited, a sample size of 15-
18mg within a 20^L sealing cell was considered optimal. Where tissue availability was limited, 
as when analysing samples from human liver biopsies, the sample was placed in the smallest 
sealing cell that would contain the whole sample. 
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2.9 Discussion of spectral processing 
The choice of spectral processing functions, like that of NMR parameters, required compromise 
between functions, depending on the information required for a given analysis. Phasing and 
baseline correction should be consistent between samples, as differences in these functions may 
give rise to altered signal amplitudes, introducing further uncontrolled variables into the dataset. 
Therefore automatic functions were used where possible, with subjective assessment of each 
spectrum for quality control. 
Methods for the integration of spectral resonance may also affect the data obtained. Use of a 
inetabonomic approach to the analysis of 'H MAS NMR spectra involves the division of the 
spectrum into numerous bins, which are integrated, as described in section 2.6.5. This approach 
is ideal where the resonances are numerous (hundreds), narrow (~lHz linewidth) and well-
separated, as each peak may be fully contained within a single bucket, with the nadirs on either 
side falling to baseline. In these circumstances, the approach is accurate and reproducible. 
However, where lineshapes are broad and overlapping, buckets are unable to assess the 
contribution of each of overlapping peaks to the composite whole. This is of particular 
importance in vivo, where spectral resolution is poor (5-15Hz linewidth). In these situations, 
individual curve-fitting programs may be used, where the contributing resonances are modelled 
using prior knowledge (as described in section 5.5.2). However, this approach is currently only 
suitable for the analysis of a few peaks (<10) on account of the software processing limits and is 
labour-intensive, making it unsuitable for the analysis of many spectra. 
The spectra obtained by 'H MAS NMR consist largely of narrow resonances, but, as both 
aqueous and lipid fractions are present, including cell-membrane components, composite or co-
resonant peak are seen. Assumptions must therefore be made on the basis of the information 
required in the study. For example, where the lipid resonances are measured, as lipid peaks are 
dominant in the spectrum, the contribution from most co-resonant metabolites may be ignored. 
Where a smaller resonance is present on the shoulder of a larger peak, the contribution from the 
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larger peak must be assumed to be constant, or incorporated into the analysis as a ratio. Newer 
curve-fitting capabilities to metabonomic analysis software are in development (Dr C Peng, 
software engineer, BioRad, Philadelphia, USA, personal communication), but were unavailable 
for these studies. 
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2.10 Conclusions 
The rationale for the use of 'H MAS NMR spectroscopy to study intact liver tissue has been 
presented. NMR parameters and approaches to analysis have been discussed, where relevant to 
the experiments performed as part of this thesis. Previous studies using 'H MAS NMR 
spectroscopy for the study of liver tissue in chronic liver diseases have been reviewed and 
differences in the technical approach have been highlighted. Specific physical parameters 
including optimal sample size, sealing cell volume, acquisition temperature and experimental 
duration have been assessed experimentally; a large sample in the smallest available chamber 
yields the optimal SNR and resolution; acquisition temperature was set at 4°C to reduce sample 
degradation and the duration of experiments did not exceed Ihr. Finally, approaches to spectral 
analysis have been discussed. As a result of these studies and on the basis of the issues 
discussed in this chapter, experimental conditions have been defined for subsequent studies 
within the thesis. 
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3 PHENOTYPING MURINE MODELS OF NAFLD 
3.1 Abstract 
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, 
associated with the metabolic syndrome. Effective techniques are needed to investigate the 
potential of animal models of NAFLD. This study aimed to characterise murine models of 
NAFLD by metabolic profiling of intact liver tissue. 
Mice of three strains (BALB/c, C3H and the novel mutant, Gena/263) were fed either a control 
or high fat diet. Biometric, biochemical and histological analysis demonstrated a spectrum of 
NAFLD from normal liver to steatohepatitis. Metabolic profiling of intact liver tissue, 'H MAS 
NMR spectroscopy, showed an increase in total lipid-to-water ratio, a decrease in 
polyunsaturation indices and a decrease in total choline with increasing disease severity. 
Principal components analysis and partial least squares discriminant analysis showed separation 
of each model from its control and of each model from the total dataset. Class membership from 
the whole dataset was predicted with 100% accuracy in 6 of 8 models. Those models with 
steatosis discriminated from those with steatohepatitis with 100% accuracy. 
Conclusion: the separation of histologically-defined steatohepatitis from simple steatosis is 
clinically important. Indices derived from 'H MAS NMR spectroscopy studies may inform 
subsequent in vivo MR spectroscopy studies at lower field strengths. 
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3.2 Introduction 
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver disease encompassing 
steatosis (fatty change), non-alcoholic steatohepatitis (NASH) and cirrhosis in the absence of 
alcohol abuse (Anstee and Goldin, 2006). Population studies show that NAFLD is strongly 
associated with insulin resistance, type II diabetes mellitus, hypertension, obesity and 
dyslipidaemia (Marchesini et al., 1999; Powell et al., 1990; Sanyal, 2002). The pathogenic 
mechanisms remain poorly understood and are difficult to study in humans (Koteish and Mae, 
2002). While an estimated 10-24% of adults worldwide have a degree of hepatic steatosis 
(Angulo, 2002), only a small proportion of these go on to develop progressive disease, 
characterised histologically by steatohepatitis with fibrosis. In order to target therapy to the 
appropriate patients there is a need for accurate, well-validated, methods to analyse hepatic lipid 
content and metabolism. 
In vivo, MRS has been used to assess the prevalence of NAFLD (Szczepaniak et al., 2005); 
recently, more detailed information on lipid composition has been reported (Johnson et al., 
2008). In vitro, MRS has been applied to the study of liver tissue extracts in obese rats (Serkova 
et al., 2006) and urine and plasma from mice with features of NAFLD (Dumas et al., 2006; 
Fearnside et al., 2008). 
Much of the understanding of the pathogenesis of NALFD is based on research using animal 
models (Anstee and Goldin, 2006). No existing model exhibits the entire NAFLD phenotype. 
Many differ pathologically from human disease in all but superficial histological appearance. 
Thus, research is hampered by the lack of reliable models of progressive steatohepatitis that 
accurately reflect the human disease. Currently, the phenotyping of such models is reliant on 
physical observation, indirect biochemical assay and histopathology, all of which are time-
consuming. In addition, subtle changes in metabolism and hepatic disease severity may not be 
detected using conventional techniques. Liver histology may be used to document overt features 
of NAFLD, such as the presence of hepatocellular lipid droplets, inflammation and fibrosis. 
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Histological assessment is semi-quantitative and involves a degree of subjectivity in 
interpretation. There is a requirement for robust techniques to phenotype rapidly and categorise 
the output of programs that develop new models of NAFLD. In particular, there is a need to 
identify animals which exhibit the characteristics of more advanced disease, including 
steatohepatitis. 
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3.3 Aims 
The aims of this study were: 
a. To characterise murine models of NAFLD using H MAS NMR spectroscopy of intact liver 
tissue. 
b. To assess the predictive value of multivariate models to determine the strain and diet for each 
mouse on the basis of 'H MAS NMR spectroscopy differences. 
c. To compare NMR spectral differences between histologically characterised normal liver, 
steatosis and steatohepatitis. 
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3.4 Materials and methods 
3.4.1 Animals 
The study was approved by the local ethics committee and performed in accordance with the 
Animal (Scientific Procedures) Act 1986. Mice were housed under standard conditions (12hr 
light/dark cycle, temperature 21±2°C, humidity 55±10%) and provided with food and access to 
drinking water ad libitum. Two inbred strains of mice, known to differ in susceptibility to 
dietary induced NAFLD, C3H/HeH (sensitive) and BALB/cAnNCrl (resistant) were used in 
these studies (each group, n = 6) (Feamside et al., 2008). In addition, a recently described 
genetic model of NASH maintained on a C3H/HeH background, Gena/263 "Buttermouse", was 
studied (each group, n = 6-10). The Gena/263 model was identified using a phenotype-driven n-
ethyl-n-nitrosurea (ENU) mutagenesis screen for impaired glucose tolerance and 
histological/biochemical evidence of steatohepatitis (Matthews et al., 2007). Male animals were 
randomised at age 6 weeks to receive either control diet (CD) or a nutritionally replete high fat 
diet (HFD). Control diet (SDS, Witham, UK) contained 4% fat by mass (11.5% of kcal) and the 
HFD (Research Diets Inc., New Brunswick, USA) contained 24% fat by mass (45% of kcal). 
Detailed dietary constituents are published elsewhere (Cobbold et al., 2008a). 
The animals remained on the allocated diet for the remainder of the study. Body weight was 
measured at age 6 weeks, 20 weeks and where applicable, 36 weeks. Glucose tolerance assessed 
using an intraperitoneal glucose tolerance test (IPGTT) at age 12 weeks. Mice were culled by 
exsanguination under terminal anaesthesia at one of two time points, aged 20 or 36 weeks. 
The liver was excised and half was snap-frozen in liquid nitrogen prior to storage at -80°C, 
while the remainder was placed in 10% formalin. Formalin-fixed tissue was processed into 
paraffin wax and the sections were stained with haematoxylin & eosin, prior to histological 
examination by an experienced hepatopathologist, who was blinded to the phenotypic data. 
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using the well validated NASH Clinical Research Network semi-quantitative scoring system for 
cellular morphology, inflammation and fibrosis (Kleiner et al., 2005). 
3.4.2 N M R studies 
Two samples were analysed from each liver (mean sample mass 15.3mg, sd 2.9mg). Freshly 
thawed liver tissue was placed into XC4 Kel-F sealing cells (Doty Scientific Inc., Columbia, 
South Carolina, USA). 
3.4.2.1 'HNMR spectroscopy 
'H MAS NMR spectroscopy experiments were carried out using the equipment and methods 
described in section 2.6, and the parameters documented in Table 2-2. The pulse and collect 
sequence was used to derive a fully relaxed spectrum without suppression of the water 
resonance, the "total signal spectrum". A pulse and collect with a water presaturation sequence 
provided water suppression, producing a spectrum dominated by lipid. A Carr-Purcell-
Meiboom-Gill (CPMG) spin-echo pulse sequence with water presaturation was employed to 
suppress macromolecular signal (mainly lipid) and emphasize lower molecular weight 
metabolite signals. In particular, this enabled the resolution and quantification of the resonances 
within the total choline region. 32K data points were acquired for each spectrum with a spectral 
width of 15kHz (Mahon et al., 2004a). The overall time for data acquisition was 35 minutes. 
3.4.3 Data analysis and interpretation 
Spectra were processed using KnowItAll® Informatics System v7.8 (Bio-Rad, Philadelphia, 
USA). Free induction decays were zero-filled by a factor of 2 and multiplied by an exponential 
windows function with a IHz line-broadening function prior to Fourier transformation. Spectral 
resonances were assigned according to the published literature (Bollard et al., 2000; Duarte et 
al., 2005; Martinez-Granados et al., 2006; Rooney et al., 2003). Analysis was divided into 
hypothesis-generating multivariate analysis and biologically relevant conventional analysis of 
specific metabolites. 
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The spectral range of 50-10.0ppm was analysed, including the water region for the pulse and 
collect sequences and excluding the region containing the residual water resonance (84.8-
5.2ppm) in the sequences with water-presaturation. Spectra were scaled to the sum of the total 
spectral integral (water included for sequences without water suppression and excluded for those 
with water presaturation) to enable relative quantitative analysis of metabolites between 
samples. 
3.4.4 Multivariate data analysis 
Multivariate data-reduction techniques were applied in order to use information from the whole 
spectrum, and to determine which peaks contributed to the metabolic variation between 
individual samples and between groups of samples. NMR spectra acquired using the pulse and 
collect sequence with water presaturation were divided into small regions ("buckets") of 
0.04±0.02ppm, representing specific metabolite functional groups, placed using an "intelligent 
bucketing" algorithm in the Knowitall® software. The integral of each bucket was then 
quantified and expressed as a proportion of the total spectral integral, as discussed in detail in 
section 2.6.5. 
Unsupervised multivariate factor analysis was performed using principal components analysis 
(PCA) to assess clustering and the presence of outliers. PCA is an unbiased technique, which is 
independent of any classifying information (such as strain) and the output summarises the 
metabolite variation within the dataset as a whole. Each principal component represents a 
combination of peaks, representing metabolites, expressed as a vector. The principal 
components are combined orthogonally, avoiding duplication or redundancy of information. 
Scores plots show the position of the samples in the newly-defined multidimensional space, 
where the axes represent each orthogonal principal component. Examination of the loadings 
plots allows identification of those metabolites which predominantly account for variability 
within the dataset. 
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Supervised analysis was performed using partial least squares discriminant analysis (PLS-DA) 
to investigate factors associated with class membership, with the Pirouette v4.0 software 
package (Infometrics, Washington, USA). Here, the classifying information is included in the 
analysis, so the output summarises the MR spectral (metabolic) differences between the groups. 
Orthogonal signal correction (OSC) is a filtering technique applied to PLS-DA analyses to 
remove variation in the spectra, which is unrelated to the defined conditions (Gavaghan et al., 
2002). To determine the predictive power of the model, cross-validation was performed by 
leaving out each sample in turn (a leave-one-out algorithm), and a model was constructed from 
the remaining samples to predict the class membership of the excluded sample. Such an 
algorithm makes best use of a small dataset, where a separate validation dataset is not possible. 
The Q" value indicates the validity of the discrimination, with values >0.05 considered 
significant (Jones et al., 2005; Westerhuis et al., 2008). 
3.4.5 Examination of spectral resonances 
In order to examine the specific differences between metabolite ratios of prior interest and those 
identified in the loadings plots, peak integrals (proportional to the total quantity of the 
metabolite in the sample) were measured. The lipid:water ratio was derived from the pulse and 
collect spectra without water suppression, both as the sum of the integrals of all the fatty acid 
proton resonances and as the methylene proton:water peak expressed as a percentage. The 
polyunsaturated to monounsaturated fatty acid ratio index (PUFA:MUFA index) was derived 
from the pulse and collect spectra with water suppression, and comprised the resonance at 
82.80ppm (defined as the diallylic bond protons found in polyunsaturated fatty acids and 
denoted as "PUFA") divided by the resonance at 85.33ppm (-CH=CH-, or M-ene functional 
group, found in mono- and poly-unsaturated fatty acids, denoted here as "MUFA"). The 
polyunsaturation index (PUI) was defined as the diallylic resonance divided by the sum of the 
allylic, diallylic, methyl and methylene resonances, expressed as a percentage (Johnson et al., 
2008). Total choline (tCho) was derived from the pulse and collect spectra with water 
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suppression and comprised the summed integral of the choline region resonances from 53.18-
53.28ppm, expressed as a percentage of the total spectral integral. The tCho region was further 
analysed using the CPMG data. Specifically, the resonance at 53.26ppm, assigned as 
phosphatidylcholine (PtC) including contributions from betaine and trimethylamine-jV-oxide 
(TMAO) and denoted as "PtC", was compared to the tCho levels. The correct assignment of 
lipid and choline resonances was verified by comparison of spectra from lean and steatotic 
murine liver to an oil sample of known composition (Figure 3-1). 
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Figure 3-1. Al ignment of M R spectral lipid resonances from oil and intact liver tissue. 
High resolution 'H MAS MR pulse and collect spectra with water suppression from lean and steatotic 
murine liver are aligned with a spectrum from a sample of borage oil acquired using the same 
parameters and referenced to the methylene (-CH2) resonance at SJ.Sppm. Vertical red lines highlight the 
position of diallylic "PUFA " resonance at S2.7-2.9ppm and the choline resonances (total choline, tCho) 
found at 53.2-3.35ppm relative to the methylene resonance. 
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3.4.6 Convent iona l statistics 
Significant differences in piienotypic data were sought by ANOVA testing with post-hoc 
Bonferroni analysis. Significant differences in MR spectral data were identified by the Kruskal-
Wallis test (more than two groups) or the Mann-Whitney U test (pairwise comparisons) as 
appropriate (SPSS vl4.0, SPSS Inc. Chicago, USA). Statistical advice was obtained from a 
biomedical statistician (Dr Bernard North, Statistical Advisory Service, Imperial College 
London). 
I l l 
3.5 Results 
3.5.1 Phenotyp ic data 
3.5.1.1 Body weight 
At baseline there was no significant difference in body mass between the inbred strains. 
However, as shown in Table 3-1, by 20 weeks there were significant differences in body mass 
both between the inbred strains and the dietary groups (ANOVA, p<0.001). Control diet (CD)-
fed C3H mice gained weight more rapidly than CD-fed BALB/c animals (35.32±2.57g versus 
26.49±0.87g; t-test, p=0.006) and HFD-fed C3H animals gained the greatest weight, being 
significantly heavier than either CD-fed littermates (44.72±0.34g versus 35.3±2.57g; p=0.003) 
or HFD fed BALB/c mice (27.52±0.70g; p<0.001). Indeed HFD-fed BALB/c gained little 
weight and were not significantly heavier than CD-fed BALB/c mice. These differences 
increased during the course of the study with HFD-fed C3H animals being significantly heavier 
than all other groups at culling (55.24±0.80g versus C3H-CD 43.31±2.58g; p=0.001; BALB/c-
HFD 35.29±l . l lg ; p<0.001). Whilst HFD-fed BALB/c mice began to increase in weight 
compared with control this did not reach statistical significance. Throughout the study, the 
weight of mutant Gena/263 mice was not significantly different to wild-type C3H mice fed the 
equivalent diet. 
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Table 3-1. Phenotype of mice and effects of the high fat diet. 
Strain Diet Mean Body Weight/g (SEM)t Mean IPGTT at 12 Weeks Median NAS Hist 
/mmol/L (SEM) Score* 
6 Weeks 20 36 T=0 T=60 T=120 St. Fib. Inf. Ball. 
Weeks Weeks 
C3H Control 25.38 35.32 43.31 6^3 15.38 10.07 0 0 0 0 
(0.59) C2.58) (2.58) (0.22) (1.94) (0.41) 
HFD 25.24 44.72 55.24 10.42 21.26 11.86 2 0 1 1 
(0.23) (0.34) (0.80) (0.53) (1.17) (0.96) 
BALB/c Control 24.29 26.49 31.40 4.47 16.13 7.66 0 0 0 0 
(0.83) (0.87) ( 1 5 ^ (0.99) (2.48) (1.52) 
HFD 23.25 27.52 35.29 3.58 11.34 7.30 0 0 0 0 
(0.89) (0.70) (1.11) (0.20) (2.87) (1.80 
6 Weeks 20 Weeks 36 Weeks Mean IPGTT at 12 Weeks Median NAS Hist 
/mmol/L (SEM) Score* 
T=0 T=60 T=120 St. Fib. Inf. Ball. 
Gena/263 Control 24.56 41.60 
-
10.84 2666 22.43 1 0 0 2 
(1.2)* #.06) (1.81) P 1 3 ) (1.27) 
HFD 2538 45.50 
-
9.31 28.65 20.68 3 0 0 1 
(0.46) (0.64) (0.95) (1.42) (0.53) 
Non-Mut Control 27.89 42.40 
-
5.22 11.67 8.15 0 0 0 0 
(0.5)*- (2.57) (1.93) (0.29) (1.14) 
HFD 26.58 44.76 
-
8.42 23.43 13.30 2 0 0 1 
(0.33) (0.79) (0.65) (0.86) (0.36) 
Phenotype of mice and effects of the high fat diet (HFD) on body mass, glucose tolerance and histological 
scoring are tabulated. ' Weight recorded at start of experiment (age 6 weeks), mid-experiment and at cull 
point. BALB/c and C3H were culled at 36 weeks, Gena/263 mice (and non-mutant, C3H controls) were 
culled at 20 weeks. ^ 6 week control diet data from separate cohort of animals to those used in MRS 
study, shown for illustrative purposes. * NAS Score: St, Steatosis (0-3); Fib, Fibrosis (0-4); Inf 
Inflammation (0-3); Ball, Ballooning hepatocyte degeneration (0-2). 
3.5.1.2 Glucose tolerance 
ANOVA analysis identified significant differences in blood glucose levels at all IPGTT time 
points (Table 3-1). HFD-fed C3H mice had significantly higher mean t=120 minute blood 
glucose concentrations than BALB/c mice fed HFD (1].86±0.96 versus 7.30±1.80 mmol/l, t-
test, p<0.001). A trend towards impaired glucose tolerance was observed between HFD and 
CD-fed C3H animals but this did not reach statistical significance (11.86±0.96 versus 
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10.07±0.41 mmol/l). HFD fed Gena/263 mutant animals had significantly higher t=120 blood 
sugar levels than all other groups (p<0.001) including HFD-C3H mice (20.68±0.53 versus 
11.86±0.96 mmol/l). 
3.5.1.3 Histology 
In keeping with the blunted weight gain and preservation of glucose tolerance in response to 
high fat diet, BALB/c mice were highly resistant to dietary induction of steatosis showing no 
histological evidence of steatosis in either CD or HFD groups at 36 weeks post-randomisation. 
In contrast, HFD fed C3H animals consistently exhibited a florid macro and micro-vesicular 
steatosis (median steatosis score 2/3) associated with ballooning hepatocyte degeneration (score 
1/2) and a mild necroinflammatory infiltrate (score 1/3) (Table 3-1). Gena/263 mice exhibited 
mild spontaneous steatosis and a more moderate steatosis with some ballooning degeneration 
when fed HFD. A small but significant increase in serum ALT was observed between C3H 
dietary groups (HFD 47.60±4.41 versus CD 30.20±2.54 lU/L, p=0.009) and between HFD-fed 
C3H and BALB/c mice (47.60±4.41 versus 17.00±1.78 lU/L, p=0.001). 
3.5.2 M R character isat ion 
A representative water-suppressed 'H MAS NMR spectrum is shown in Figure 3-2 and 
illustrates the specific, quantifiable lipid resonances, including the fatty acid functional groups. 
The choline region (53.18-53.28ppm) contains four clearly identifiable peaks representing 
choline (63.20ppm), phosphocholine (PC) (53.22ppm), glycerophosphocholine (GPC) 
(53.23ppm) and PtC with contributions from TMAO and betaine at 53.26ppm. Glucose and 
glycogen resonances were also prominent. A number of amino acid resonances were also 
visible. 
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Figure 3-2, Water-suppressed H MAS NMR spectrum from murine liver tissue. 
Fully-relaxed pulse and collect 'H MAS NMR spectrum, with water suppression from intact liver from a 
C3H mouse on control diet. The residual water resonance at 84.8-5.2 was removed as indicated. Key: 
LI, lipid CH3CH2 (methyl)-, L2 lipid (CH2)„ (methylene)-, L3 lipid CH2CH2CO (methylene to 15)-, L4 lipid 
CH=CHCH2CH2 (allylic)-, L5 lipid CH2CH2CO (a-methylene to carboxyl)-, L6 lipid CH=CHCH2CH=CH 
(diallylic- "PUFA")', 17 lipid CH=CH (n-ene group- MUFA)-, Ala, alanine-, Cho, choline-, PC, 
phosphocholine-, GPC, glycerophosphocholine-, PtC, phosphatidylcholine-, TMAO, trimethylamine-N-
oxide; Glc, glucose', Glyc, glycogen-, Urd, uridine-, Tyr, tyrosine. 
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The sum of the integrals for all lipid peaks was compared to the integral of the methylene lipid 
peak in all samples, demonstrating strong correlation between measures (Spearman rho 
correlation, r=0.998, p<0.0005). Accordingly, the integral of the methylene proton resonance 
was considered a surrogate for total lipid when describing lipid quantities relative to water. 
Principal components analysis scores plots demonstrated clustering and separation of each 
mouse model from its control (Figure 3-3). This included the separation of models on the basis 
of diet (CD or HFD), strain (BALB/c and C3H, both on CD and HFD) and also presence of the 
Gena263 mutation from the wildtype controls, both on CD and HFD (data not shown). 
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Figure 3-3. Principal components analysis of murine models and their controls. 
Panels A, C, E and G denote scores plots, which place each sample in multidimensional space: axes 
labelled "factors 1-3 " represent principal components 1-3. B, D, F, and H denote loadings plots, which 
show the spectral regions or "buckets", labelled "variables", corresponding to chemical shift of 
resonances from the spectra for each sample, and which contribute to the variation between datapoints 
on the scores plots. Loadings plots are shown from the first principal component only. Panels A and B 
compare BALB/c on HFD (green) to B.ALB/c on CD (black)', C and D compare C3H on HFD (green) to 
C3H on CD (black)', panels E and F compare C3H on CD (black) to BALB/c on CD (green)', panels G 
and H compare C3H on HFD (black) to BALB/c on HFD (green). 
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Supervised PLS-DA models were then constructed. Correct class prediction was achieved with 
100% accuracy for 6 of 7 comparisons of differing diet, strain and presence of the 263 mutation 
(Table 3-2). 
Table 3-2. PLS-DA of each model compared to Its control. 
Model Control Components Correct Correct Incorrect No match Q' 
prediction prediction prediction 
of model of control of model 
(false 
positive) 
BALB/c HFD BALB/c CD 1 6/6 6/6 
-
0.998 
C3H HFD C3H CD 1 6/6 6/6 
-
0.898 
Gena/263 HFD Gena/263 CD 2 8/8 6/6 
-
0.877 
C3H CD BALB/c CD 1 6/6 6/6 
-
0.996 
C3H HFD BALB/c HFD 1 6/6 6/6 
-
0.917 
Gena/263 CD Non-mut CD 1 6/6 6/6 
-
0.982 
Gena/263 HFD Non-mut HFD 1 8/8 8/10 1 1 0.460 
Metabolites contributing to the spectral regions correlating strongly (positively or negatively) 
with each model compared to its control are documented in Table 3-3. Lipid moieties, choline-
related compounds, glucose, glycogen and a number of amino acid resonances (including 
glutamine, leucine, lysine and alanine) were found to contribute to class separation. In 
particular, PtC (with contributions from betaine and TMAO) was found to be a major 
contributor to the PLS-DA models. Accordingly, PtC was integrated using the CPMG spectra 
and divided by the tCho region for comparison with histological class. The use of tCho as a 
denominator allowed relative quantification of PtC without the potentially confounding 
dilutional effect of large changes in total lipid. 
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Table 3-3. Metabolites contributing to the discrimination of different murine models. 
Model Control Primary discriminator Major discriminators (order of 
decreasing influence on model) 
BALB/c HFD BALB/c CD Lipid CHz PtC, (3-glucose, amino acids 
C3H HFD C3H CD Lipid CHz Lipid CH=CH, PtC, lipid CH2CH2CO 
Gena/263 HFD Gena/263 CD Lipid CH=CH Lipid CH3, p-glucose, PtC 
C3H CD BALB/c CD Lipid CHz PtC. a and p glucose, amino acids 
C3H HFD BALB/c HFD a and (3 glucose Lipid CH2, PtC, amino acids lipid CH3 
Gena/263 CD Non-mut CD PtC Lipid CH2, a glucose, amino acids. 
glucose, PC, lipid CH=CH 
Gena/263 HFD Non-mut HFD lipid CH=CH lipid CH3, a and p glucose, amino acids 
Amino acid cluster includes resonances including leucine, alanine, lysine and glutamine. 
In addition to the separation of each model from its control, PLS-DA models were constructed 
to enable the classification of a single sample from the total dataset. 54 samples were included 
in the total dataset and class membership established with 100% accuracy in all but two models 
(Table 3-4). 
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Table 3-4. Comparison of each group against all mice in the dataset. 
Model Diet Components Correct 
prediction 
of model 
Correct 
prediction 
of non-fit 
Incorrect 
prediction 
of model 
No 
match 
Q ' 
BALB/c CD 2 4/6 48/48 - 2 0.994 
HFD 5 6/6 48/48 - - 0.996 
C3H CD 5 6/6 48/48 - - 0.761 
HFD 3 6/6 48/48 
- -
0.998 
Non-mut CD 3 5/6 48/48 
- 1 0.996 
HFD 3 10/10 44/44 - - 0.996 
Gena/263 CD 2 6/6 48/48 - - 0.994 
HFD 2 8/8 46/46 
- -
0.977 
Each PLS-DA model (from which 2 orthogonal factors had been removed, OSC) was constructed to 
separate the MR spectra obtained from a given mouse model from all other samples of all models in the 
total dataset. 
3.5.3 Comparison between NMR spectroscopy and histological assessment 
The distinction between simple steatosis and steatohepatitis is of importance for the 
development of models that reflect progressive disease in humans. Therefore PCA was 
performed on spectra from mice of all strains fed HFD and stratified by histological assessment 
of NAFLD. The samples were divided into histologically normal, steatotic and steatohepatitic 
groups on the basis of histological assessment of an adjacent slice of tissue. Steatohepatitis was 
defined in this study as the presence of hepatocyte ballooning +/- the presence of 
necroinflammatory infiltrate. The relationship between MR spectra and histological 
characteristics is shown in Figure 3-4. As disease severity increases, the lipid peaks increase in 
amplitude, compared to the water peak, while the glucose and glycogen resonances are reduced 
as steatosis worsens. All samples in the steatohepatitis group had evidence of hepatocyte 
ballooning. PCA demonstrated clustering of the groups, so PLS-DA was performed to assess the 
factors associated with category membership. Category membership (between histologically 
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normal, steatotic and steatohepatit ic samples) using the leave-one-out algori thm was predicted 
with very high accuracy, as shown in Table 3-5. 
Table 3-5. Compar i son of histologically normal , steatotic and steatohepatit ic samples . 
Histological Components Correct Correct Incorrect No match 
category prediction prediction prediction 
of model of non-fit of model 
Normal 3 
Steatosis 3 
Steatohepatitis 3 
5/6 
6/6 
18/18 
24/24 
24/24 
12/12 
1 0.997 
0.996 
0.999 
All samples from the HFD dataset The PLS-DA model with OSC was constructed to separate the MR 
spectra obtained from a given category from all other samples of the other categories in the dataset. 
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Figure 3-4. Representative H MAS NMR spectra witli paired histology. 
NMR spectra are fully-relaxed pulse and collect sequences without and with water presaturation. 
Histology shows liver sections stained with haematoxylin and eosin at an original magnification of x200. 
Samples shown with normal architecture (A, A ' and B), steatosis (C, C and D) and steatohepatitis (E, E' 
and F). The "total signal" MR spectra (A, C, E) illustrate the ratio of water to other metabolites. The 
"lipid signal" MR spectra (A', C, E') amplify other major metabolite groups. The lipid consituents 
increase, while the tCho decreases with increasing disease severity. Characteristic histological features 
of steatosis (lipid droplets) and steatohepatitis (hepatocyte ballooning) from the corresponding tissue 
sample are shown in D and F. 
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The intrahepatic lipid level (median, interquartile range) differed significantly between samples 
histologically categorised as normal (1.96%, 1.02), steatosis (8.09%, 3.71) and steatohepatitis 
(10.56%, 6.08) (Figure 3-5A). There was a significant decrease in the PUFA:MUFA index 
between the normal (0.68, 0.09) and either steatotic (0.37, 0.12) or steatohepatitic (0.32, 0.09) 
samples. The PUFA:MUFA index did not differentiate between the steatotic and steatohepatitic 
groups (Figure 3-5B). The PUI was decreased in steatotic (3.40%, 0.95) and steatohepatitic 
mice (2.95%, 1.13) compared to normal mice (6.29%, 1.25) (Mann-Whitney U test, p<0.001). 
Therefore, the increase in PUFAiMUFA index can be interpreted as consequent to a systematic 
decrease in PUFA with increasing disease severity. The resonances at 83.26ppm (PtC with 
TMAO and betaine) and 53.22-3.23ppm (PC and GPC) were found consistently to contribute to 
the difference between mouse classes on multivariate statistical modelling. tCho was 
significantly decreased in steatohepatitis (0.31%, 0.19) compared to steatosis (0.49%, 0.28) 
(p=0.01) and in both compared to the histologically normal samples (1.61%, 0.69) (p<0.005) 
(Figure 3-5C). Furthermore, PtC/tCho was significantly lower in the steatotic (33.7%, 16.8) and 
steatohepatitic animals (27.6%, 3.68) compared to normal animals (45.5%, 6.14) (Figure 3-5D). 
These findings are consistent with reports of low plasma PtC and high urinary choline oxidation 
products seen in 129S6 mice fed HFD (Dumas et al., 2006). 
123 
p <0.0005 p<0.000o 
p=0.023 p=0.004 
p=0.004 0=0.29 
"5. 10.0 < 0.40 
Steatosis Steatohepabti ("jofmal bteatoss bteatohepabti Norma 
p <0.0005 p=0.00f 
p=0.004 p=0.02o 
p=0.0f4 p=0.093 
Noimal Steaosis StWohepatiti Skatosis Steatohepatitis 
Figure 3-5. Differences in metabolite ratios (normal, steatotic and steatohepatitic liver). 
Sample groups are histologically-defined. A shows the lipid:water ratio, consisting of the methylene 
functional group resonance expressed as a percentage of water. B shows the PUFA:MUFA ratio index. C 
shows the tCho level, D shows the PtCitCho. p-valiies for the Mann-Witney U test are stated (in bold for 
significance at the 95% level). 
3.5.4 Relationship between intrahepatic lipid and obesity in murine models 
Mouse mass plotted against the % Upid:water (Figure 3-6A) demonstrated that intrahepatic 
lipid increased exponentially with increasing mouse mass at time of culling (R"= 0.80, 
p<0.0005). The % lipid:water was also compared to the histolological assessment of steatosis 
and demonstrated a close relationship between steatosis score and % lipid:water (Figure 3-6B). 
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Figure 3-6. MR lipid content compared to mouse mass and histological steatosis score. 
Scatter graphs showing the lipid:water ratio plotted against A, the mass of mouse in grams and B, the 
histological steatosis score. 
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3.6 Discussion 
These data demonstrate that metabolic profiling of intact liver tissue using 'H MAS NMR 
spectroscopy combined with PLS-DA is a powerful technique for the discrimination of NAFLD 
in animal models, differentiating by genetic (strain and the Gena/263 mutation), environmental 
(dietary) and histological factors. In particular, the first evidence is presented of accurate 
discrimination of histologicaliy-defmed steatosis and steatohepatitis using NMR of intact tissue. 
'H MAS NMR spectroscopy with PLS-DA also enables the separation and classification of 
different mouse strains on differing diets, despite normal histological appearances. 
Furthermore, it has been established that an exponential relationship exists between hepatic 
steatosis and obesity in these murine models. 
In liver tissue, the "total signal" NMR spectra are dominated by water and lipid resonances. 
Such spectra allow the quantification of lipid, either in absolute terms, or as a proportion of the 
total signal in the spectrum. This marker of hepatic steatosis is a quantitative objective linear 
variable which compares favourably with the semi-quantitative subjective histological 
assessment of steatosis (Figure 3-6) (Szczepaniak et al., 2005). This is an important observation 
as steatosis is prerequisite for the development of steatohepatitis and consequent fibrotic liver 
disease. In HFD-fed animals, there was a progressive significant increase in the % lipid;water 
from normal through steatotic to steatohepatitic samples. This may represent increased uptake 
of fatty acids by the liver, decreased export or decreased catabolism (Anstee and Goldin, 2006). 
Additionally, defective peripheral fatty acid uptake shunts more fatty acids to the liver 
(Goldberg and Ginsberg, 2006). Intrahepatic lipid increased exponentially with animal mass, 
suggesting that fatty acid uptake peripherally was maximised in these mice at a weight 
approaching 40g. Thereafter, intrahepatic lipid accumulated in preference to peripheral uptake 
of fatty acids and deposition of triacylglycerol (TAG). Accumulated free fatty acids may be 
disposed of by esterification to triglycerides and by fatty acid oxidation producing oxidative 
stress and initiating inflammation (Yamaguchi et al., 2007). While the traditional two-hit 
hypothesis proposed that the development of steatosis is followed by a second hit initiating 
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inflammation (Day and James, 1998), recent work by Yamaguchi and colleagues suggests that 
this model is now too simple, and that visible lipid deposition is less pathogenically relevant 
(Yamaguchi et al., 2007). Differential fatty acid partitioning between esterification, leading to 
the accumulation of visible fat and oxidation of the invisible FFA, is more relevant to the 
pathogenesis. The use of NMR spectroscopy techniques in this study enables the determination 
of total lipid composition, which includes the assessment of the invisible hepatic FFA 
component. 
The relative decrease in PUFA seen with increasing disease severity supports previous evidence 
that a decrease in PUFAs has been observed in in the liver and blood of obese Zucker rats 
(Serkova et al., 2006) and in the serum of human subjects with hepatic steatosis and 
steatohepatitis (Elizondo et al., 2007; Puri et ah, 2007). A reduced PUFA:MUFA ratio has been 
considered to represent a surrogate marker of lipid peroxidation, associated with oxidative stress 
(Serkova et al., 2006). Depletion of long chain PUFA (LC-PUFA) within the liver is thought to 
increase FA and TAG synthesis by upregulation of lipogenic genes via reduced downregulation 
of sterol regulatory binding protein (SREBP-1), and to decrease FA oxidation, including by a 
reduction of PPAR-a activation (Videla et al., 2004). 
PtC is an essential phospholipid (Li and Vance, 2008), existing as a membrane-bound 
macromolecule giving rise to a broad resonance (Millis et al., 1999) within which the -N(CH3)3 
functional group of trimethylamine-N-oxide (TMAO) and betaine (oxidation products of 
choline metabolism) are co-resonant (Rooney et al., 2003). Measurement of choline levels 
demonstrates a decrease in choline-containing products in the obese models, and in those 
animals with steatosis and steatohepatitis, compared to histologically non'nal controls. 
Importantly, the tCho is significantly lower in steatohepatitis compared to simple steatosis. This 
is consistent with the observation that mice fed a choline-deficient diet develop hepatic steatosis 
and steatohepatitis (Walkey et al., 1998). However, increasing lipid, which dominates the water-
suppressed NMR spectrum, may also contribute to the reduction in tCho observed, by means of 
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a dilution effect. Therefore, the PtC resonance (also containing betaine and TMAO) was 
integrated in isolation and expressed as a ratio of the total choline region. PtC biosynthesis from 
choline and methionine is required for normal hepatic secretion of VLDL (Yao and Vance, 
1988), and decreased PtC leads to accumulation of intracellular triglyceride (Noga et al., 2002). 
Indeed, when comparing the PtC resonance to the total choline region, PtC is reduced compared 
to other choline-containing products in mice with hepatic steatosis and steatohepatitis compared 
to histologically normal livers. This is consistent with work on aqueous liver tissue extract in 
obese Zucker rats: a reduction in betaine at 83.26, compared to lean controls (Serkova et al., 
2006), has been shown to protect against alcoholic hepatic steatosis in experimental animals 
(Kharbanda et al., 2007). 
3.6.1 Use of multivariate pattern recognition statistics 
'H m a s NMR spectra contain a large number of resonances, both discrete and overlapping, the 
area of each of which is a continuous variable. One approach to data analysis is the integration 
of particular pre-defined resonances and comparison of such quantities between groups. This is 
an appropriate approach for deductive studies in which candidate markers of known processes 
have been identified. For inductive studies or top-down studies where at the outset differences 
are unknown, such pattern recognition statistical techniques include known variables (such as 
strain) and unknown variables (such as NMR spectral lineshape), which contribute to the model. 
In order to characterise samples of mouse liver in models of N AFLD rapidly, as in this study, 
such techniques powerfully discriminate between groups on the basis of NMR spectral changes 
correlating with each state. 
In this study, PLS-DA has enabled the separation of different murine models of NAFLD from 
their control, and from each other. The discriminatory power of such classification has been 
assessed by cross-validation, by leaving out each sample in turn and constructing a model to 
determine the class membership of the excluded sample. This approach has enabled the correct 
prediction of the class membership of the spectrum from a given sample to be predicted both 
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from its control (100% accuracy in six of seven models) and from the whole dataset (100% 
accuracy in six of eight models). Accurate prediction of class membership suggests that this 
technique might be applied successfully to the screening of murine models to identify features 
ofNAFLD. 
3.6.2 Limitations and potential solutions 
While 'H MAS NMR spectroscopy allows the quantification of protons within functional 
groups of metabolites, it is not possible to quantify directly specific fatty acids, as this requires 
accurate measurement of fatty acid chain length and the position and number of functional 
groups within the chain. Nevertheless, the extent of saturation or (poly)unsaturation is of 
biological and clinical relevance. 
The overlap of certain resonances (particularly small resonances near the larger lipid peaks) 
may reduce the accuracy of integration of those peaks. However, by dividing the spectra into 
small regions or "buckets", quantification is objective and consistent. Curve-fitting software is 
used in the in vivo setting and enables quantification of small numbers of overlapping peaks. 
Newer approaches, such as "targeted profiling" may improve quantification of the multiple 
peaks found in complex tissue and biofluid samples in vitro (Weljie et al., 2006). 
The demonstration of accurate classification using PCA and PLS-DA, and the significant 
differences in metabolites concentrations as assessed by 'H MAS NMR spectroscopy between 
histological groups demonstrate the power of the technique. However, validation in this study 
was by using a "leave-one-out" algorithm. If more samples had been available, the use of a 
separate validation set, not previously studied, would increase confidence in results further and 
would demonstrate the effectiveness of the technique for phenotyping models in practice. 
Moreover, the murine models used in this study covered the mild end of the spectrum of 
NAFLD severity: severe inflammation and fibrosis were not well represented. Murine models of 
more severe disease, such as a combined db/db (leptin resistant) methionine-choline deficient 
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diet model, would enable more effective stratification of histological disease severity over a 
wider range. One might expect even more florid NMR spectral differences to occur in such 
models, although the aetiological and pathological relevance of such extreme models to human 
disease is debatable (Anstee and Goldin, 2006). 
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3.7 Conclusions 
In conclusion, this study has demonstrated the utility of 'H MAS NMR spectroscopy of intact 
liver tissue in conjunction with multivariate modelling techniques for the investigation and 
classification of murine models of NAFLD on the basis of environmental, genetic and 
histopathological features. Class membership may be predicted with high accuracy and it is 
possible to distinguish reliably between samples, even where histological appearances are 
indistinguishable. PLS-DA enables the identification of biologically-relevant metabolites 
contributing to the differences between models. Future studies may employ these techniques to 
screen the output of programs generating murine models of NAFLD and other liver diseases. 
Greater subject numbers will facilitate the use of separate large training and test sets. 
This study has demonstrated that a small number of resonances contribute reliably to the 
differentiation of the cohorts studied. Despite low field strength and the presence of motion 
artefact, tCho and a number of lipid resonances may be resolved in human liver in vivo 
(Fischbach and Bruhn, 2008), raising the possibility that 'FI MRS could provide discriminatory 
information in the context of NAFLD in vivo. 
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4 METABOLIC ANALYSIS OF HUMAN LIVER TISSUE IN 
HEPATITIS C IN VITRO 
4.1 Abstract 
Histological assessment of chronic hepatitis C-related liver disease provides a semi-quantitative 
morphological assessment of liver tissue. 'H NMR spectroscopy enables metabolic profiling of 
liver tissue in vitro, which may provide insights into pathogenesis, with potential for translation 
into the in vivo setting. 
The aim of this chapter was to investigate the metabolic profile of liver tissue in patients with 
chronic hepatitis C using 'H NMR spectroscopy with multivariate factor analysis. Liver tissue 
from 47 patients with chronic hepatitis C was divided into two portions, one snap-frozen and 
analysed by 'H MAS NMR spectroscopy at 11.7T, the other analysed using conventional 
histological techniques. Patients were stratified by fibrosis stage and HCV-genotype. 
'H MAS NMR spectroscopy was successfully performed using as little as 1.7mg of tissue. The 
resultant spectra were dominated by water and lipid peaks. Multivariate pattern-recognition 
analysis demonstrated characteristic NMR spectral differences by fibrosis stage and genotype, 
particularly from lipid and choline resonances. Total lipid was significantly increased in 
genotype 3 compared to genotype 1 and with increased fibrosis. Indices of lipid 
polyunsaturation, investigated previously in murine liver tissue, decreased with with increasing 
fibrosis stage and, independently, with increasing steatosis. 
Conclusion: characteristic differences in the metabolic profile of liver tissue in patients with 
chronic hepatitis C were discovered using high-resolution 'H MAS NMR spectroscopy. Robust 
MR indices of lipid and choline composition were derived, which have the potential to be 
translated into the in vivo setting. 
132 
4.2 Introduction and aims 
'H NMR spectroscopy enables a snapshot metabolic profile to be obtained from a sample of 
interest and has been applied to intact tissue (section 2.3). Small-scale proof-of-principle studies 
have used this technique to assess metabolic perturbations in liver samples from patients with 
chronic liver disease (Duarte et al., 2005; Martinez-Granados et al., 2006). However, such 
studies were too small, or the patient groups too heterogenous to ascertain characteristic 
differences attributable to chronic liver disease. 
Having optimised the parameters for 'H MAS NMR spectroscopy of intact liver tissue in 
Chapter 2 and applied the technique, in conjunction with multivariate pattern recognition 
analysis, to the characterisation of liver tissue in murine models of NAFLD in Chapter 3, the 
purpose of this study was to apply these techniques to tissue from liver biopsy from patients 
with chronic hepatitis C, in order to investigate characteristic metabolic differences that may 
complement histological assessment of liver biopsy or be translated into the in vivo setting. 
Accordingly, the aims of this chapter were: 
1. To apply high-resolution 'H MAS NMR spectroscopy to investigate the 
metabolic profiles of liver tissue from patients with chronic hepatitis C. 
2. To compare NMR spectral differences to histological assessment. 
3. To derive simple and robust indices to stratify disease by fibrosis severity. 
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4.3 Materials and methods 
4.3.1 Recruitment 
47 patients with chronic hepatitis C were prospectively recruited from Imperial College 
Healthcare Trust from April 2006 to August 2007. Ethical approval for the study was obtained 
from the regional ethics committee in accordance with the 1975 Declaration of Helsinki. 
Patients were included if they were aged 18-65, had evidence of replicating hepatitis C-virus 
infection on HCV RNA testing, and had been referred for percutaneous liver biopsy for clinical 
indications. 
Patients were excluded if they consumed >20g of alcohol per day, if they were obese (with a 
BMI >30kg/m~) or diabetic. Patients were also excluded if they were taking antiviral therapy; 
were co-infected with HIV or hepatitis B; were currently taking intravenous drugs, 
antihypertensive or lipid-lowering medications; had ongoing illness or had evidence of hepatic 
decompensation, defined by any of the following; jaundice, ascites, or hepatic encephalopathy. 
4.3.2 Sample preparation 
All patients underwent percutaneous liver biopsy by an experienced hepatologist using a 16-
guage Menghini needle. A portion (2-11 mm) was immediately snap-frozen in liquid nitrogen 
(within 3 minutes), then stored at -80°C and the remainder sent for routine clinical histological 
assessment. Biopsy samples for histology were fixed in formalin and embedded in paraffin wax, 
prior to staining with haematoxylin and eosin. All samples were scored according to the Ishak 
modified histological activity index (Ishak et al., 1995) and by NASH Clinical Research 
Network semi-quantitative scoring system for cellular morphology, inflammation and fibrosis 
by an experienced hepatopathologist (Kleiner et al., 2005). The patients were divided into three 
groups on the basis of the Ishak fibrosis stages as follows: group 1, mild fibrosis, stages 1-2; 
group 2, moderate fibrosis, stages 3-4; group 3, cirrhosis, stages 5-6. Freshly thawed liver tissue 
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was blotted to remove excess free fluid and placed into pre-cooled XC4 Kel-F sealing cells 
(Doty Scientific Inc., Columbia, South Carolina, USA) prior to examination. 
4.3.3 'HMASNMR 
'H MAS NMR spectroscopy experiments were performed as described in Chapters 2 and 3 
(Cobbold et al., 2008a). Briefly, an MAS probe was interfaced with a JEOL Eclipse 500+ 
spectrometer and an 11.7T superconducting magnet (section 2.6.1). Samples were spun at 
4000Hz and kept at 4°C to minimise sample degradation during data acquisition (section 2.7). 
Sequences specific to this study included a pulse and collect sequence (pulse angle 90°, receiver 
gain 5, repetition time (TR) 10s, 32 data collects), to derive a fully-relaxed spectrum without 
suppression of the water resonance and a pulse and collect with water presaturation sequence 
(pulse angle 90°, receiver gain 10, TR 5s, 128 data collects) produced a spectrum dominated by 
lipid. 32K data points were acquired for each spectrum with a spectral width of 30ppm (Mahon 
et al., 2004a). The overall time for data acquisition was 28 minutes. 
4.3.4 Data analysis and interpretation 
Spectra were processed using KnowltAll® Informatics System v7.8 (Bio-Rad, Philadelphia, 
USA) as previously described in section 3.4.3 (Cobbold et al., 2008a). Specifically, MR spectra 
were referenced to the methylene lipid (-CH?) peak at 51.30ppm and resonances were assigned 
according to the published literature (Bollard et al., 2000; Duarte et al., 2005; Martinez-
Granados et al., 2006; Rooney et al., 2003). Analysis was divided into hypothesis-generating 
multivariate analysis and biologically-relevant conventional analysis of specific metabolites and 
regions. 
4.3.4.1 Multivariate data analysis 
Multivariate data-reduction techniques were applied in order to use information from the whole 
spectrum, and to determine which peaks contributed to the metabolic variation between 
individual samples and between groups of samples. 
135 
Unsupervised multivariate factor analysis was performed using principal components analysis 
(PCA) to assess clustering and the presence of outliers. Supervised analysis was then performed 
using partial least squares discriminant analysis (PLS-DA) to investigate factors associated with 
disease severity and genotype, with the Pirouette v4.0 software package (Infometrics, 
Washington, USA) as described in section 3.4.4 (Cobbold et al., 2008a). 
4.3.4.2 Conventional statistical methods 
SPSS v l6 (SPSS Inc. Chicago, USA) was used for analysis. Clinical and biological indices were 
expressed as median values with interquartile range (or range). MRS-derived indices were 
compared using the Mann-Whitney U test for pair-wise comparisons. Correlation was 
performed using the Spearman Rho test, with fibrosis stage (0-6) approximating a linear 
variable. For the regression of dependent variables, residual plots were inspected for evidence of 
non-normality or non-linearity of effect and the dependent and independent variables were 
transformed appropriately. 
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4.4 Results 
4.4.1 Patient Characteristics 
The demographic and clinical characteristics of the 47 patients are displayed in Table 4-1. 35 of 
47 patients (75%) were Europoid, 5 were South Asian (11%), 3 were of Middle-Eastern or of 
Arab East African origin (6%), 2 were black African (4%) and 2 were East Asian (4%). 51% of 
patients were infected with genotype 1, 6% with genotype 2, 32% with genotype 3 and 11% 
with genotype 4. The median length of biopsy samples analysed for histology was 30mm (IQR 
14mm), while an average of 6mg (3.6mg) of tissue per patient was analysed using 'H MAS 
NMR spectroscopy. 
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Table 4-1. Patient characteristics 
Total Fibrosis group 
1 2 3 
Genotype 
1 3 Other (2,4) 
Number 47 19 19 9 24 15 8 
Sex M/F 29/18 8/11 13/6 8/1 14/10 11/4 4/4 
Age (years) 46 (13) 41.5(19.5) 47(10) 47 (11) 45(14) 46(10) 48.5 (24) 
Genotype (no. 1/3) 24/9 12/4 7/8 5/3 N/A N/A N/A 
Bx length, mm (range) 30 32 27.5 24 30 21 33 
(10-49) (11-43) (10-49) (10-48) (10-48) (10-49) (25-45) 
Mass sample for NMR, mg 5.8 5.5 5.9 5.8 5.95 6.0 4.8 
(range) (1.7-11.4) (2.0-10.8) (1.7-11.4) (2.3-7.7) (1.7-8.6) (2.3-11.4) (2.0-7.3) 
BMI 24.0 (4.1) 24L2 (5.3) 23.5 (3.2) 25.8 (2.7) 24.0 (4.4) 24.2 (3.1) 23.8 (3.7) 
ALT, iu/L [0-40] 61.5 (66) 45.0 (32.0)* 75.5 (46.5)* 160.0 (133.0)* 59.0 (42.0)t 86.5 (131.0)t 60 (78.3) 
AST, iu/L [0-40] 44.5(61.3) 32.0 (17.0)* 46.5 (45.0)* 118.0 (105.0)* 43.5 (23.8)t 79.5 (98.8)t 46.0 (104.5) 
Platelets, x10®/L [130-450] 253.0 (73.5) 291.5 (132.8)* 252.5 (37.5)* 185.0 (81.5)* 253.0 (101.0) 253.0 (97.2) 253.0 (90.0) 
Total Cholesterol, 4.3 (1.19) 4.6(1.1) 4.1 (0.7) 4.8 (1.5) 4k6(1.3) 4.2 (0.3) 
mmol/L [<6.5] 
Triglycerides, 1.0 (0.40) 1.0(0.2) 1.1 (0.6) 0.9 (0.4) 1.0 (0.40) 0.95 (0.73) 
mmol/L [<2.5] 
Figures are median (interquartile range) unless otherwise specified. M, male', F, female', Bx, biopsy, BMI, 
aminotransferase. * significant at the p=0.05 level, using the Kruskall- Wallis Test, f , significant at the p=0. 
body mass index', ALT, alanine aminotransferase', AST, aspartate 
05 level using the Mann- Witney U test for pairwise comparisons. 
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4.4.2 MR Characterisation 
A representative water-suppressed 'H MAS NMR spectrum from intact human liver tissue is 
shown in Figure 4-1, illustrating a number of specific lipid resonances including fatty acid 
functional groups. The total choline region (53.18-53.28ppm) (tCho) contains peaks 
representing choline, phosphocholine, glycerophosphocholine and phosphatidylcholine, with 
contributions from trimethylamine-N-oxide (TMAO) and betaine. 
L2 
Cho, PC, GPC, PtC, 
TMAO, betaine 
Glc, glyc, amino 
acids 
L5 L4 
5.5 3.5 
' 1 ' ' 
3 
PPM 
0.5 4.5 2.5 1.5 
Figure 4-1. 'H MAS NMR spectrum from human liver biopsy tissue. 
Fidly-relcaed pulse and collect 'H MAS NMR spectrum with water suppression, of intact liver from a 
liver biopsy specimen from a patient with hepatitis C, genotype 3, moderate fibrosis. The residual water 
resonance at 54.8-5.2 was removed in the region indicated. Key: LI, lipid CH^CHi (methyl)', L2 lipid 
(CH2)I, (methylene)', L3 lipid CH2CH2CO (methylene to L5)', L4 lipid CH=CHCH2CH2 (allylic)', L5 lipid 
CH2CH2CO (a~methylene to carboxyl)', L6 lipid CH=CHCH2CH=CH (diallylic- "PUFA")', L7 lipid 
CH=CH (n-ene group)', Cho, choline', PC, phosphocholine', GPC, glycerophosphocholine', PtC, 
phosphatidylcholine', TMAO, trimethylamine-N-oxide', Glc, glucose', Glyc, glycogen.. 
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4.4.2.1 Multivariate pattern-recognition analysis 
There was clustering of data according to fibrosis stage and genotype on PCA following 
integration of "bins". The major metabolites contributing to the differences between mild and 
moderate to severe fibrosis and between genotypes 1 and 3 are shown in Table 4-2. Fatty acyl 
functional groups and choline-containing compounds were seen to contribute substantially to 
the PLS-DA models separating samples and formed the basis of indices derived for subsequent 
analysis. Applying the leave-one-out cross-validation algorithm to the in vitro cohort, fibrosis 
group and genotype were correctly predicted in 46/47 cases (Table 4-3). 
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Table 4-2. Metabolites contributing to differences between groups 
Metaboli te Chemical shift Rank/total bins Coeff icient 
Fibrosis: Mild from 
moderate and cirriiosis 
GPC, PC 3.21-3,25 1 -6.74 
Lipid -CH3 0,81-0.93 2 -6.55 
Lipid -CH2 1.19-1,39 3 5.48 
Glycogen 3.67-3.73 4 -3.43 
PtC, TMAO, Betaine 3.25-3.28 5 -3.25 
Lipid -CH2CH2CH=CH 1.95-2.10 6 -3.13 
Ala, Lys, Gin, GPC 3.75-3.81 7 -2.92 
Lipid -CH3 0.75-0.81 8 -2.86 
Glycogen, PC, Gly, Thr 3.59-3,65 9 -2.41 
Lipid -CH2CH2CO 1,65-1.70 10 -2.09 
Diallylic lipid 2,74-2.79 50 -0.82 
Genotype 1 from 3 
GPC/PC 3.21-3.25 1 -4.01 
Lipid CH3 0.81-0.93 2 -3.99 
Lipid CH2 1.22-1.40 3 3.89 
Lipid CH2 1.16-1.21 4 -2.42 
Glycogen 3.67-3.73 5 -2.08 
Lipid -CH2CH2CH=CH 1.95-2.10 6 -1.78 
Lipid CH3 0.76-0.81 7 -1.65 
Ala, Lys, Gin, GPC 3.75-3.81 8 -1.61 
PtC, TMAO, Betaine 3.25-3.28 9 -1.57 
Glycogen, PC, Gly, Thr 3.59-3.65 10 -1.45 
Diallylic lipid 2.74-2.79 83 -0.65 
Abbreviations: GPC, glycerophosphocholine\ PC, phosphocholine\ PtC, phosphatidylcholine', 
TMAO, trimethylamine-N-oxide, Ala, alanine', Lys, lysine'. Gin, glutamine', Gly, glycine', Thr, 
threonine. Diallylic lipid is -CH=CH-CH2-CH=CH- functional group, PUFA. 
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Table 4-3. Cross-validation of PLS-DA models for prediction of fibrosis and genotype 
Category Correct Correct Incorrect No Q 
prediction of prediction of prediction of match 
category non-fit category 
Fibrosis 
Mild (stage 0-2) 19/19 
Moderate (stage 3-4) 19/19 
Cirrhosis (stage 5-6) 8/9 
27/28 
27/28 
38/38 
0 
0 
0 
0.994 
0.996 
0.994 
Genotype 
1 
3 
24/24 
14/15 
14/15 
24/24 
0 
0 
0.998 
0.998 
Leave-one-out cross-validation of PLS-DA three-component models for the prediction offibrosis category 
and genotype. 
4.4.2.2 Analysis of lipid composition 
On the basis of multivariate analysis and from previous studies, indices were derived to assess 
specifically the percentage total lipid, the total choline to lipid ratio, the degree of fatty acid 
saturation (saturation index, SI) and the degree of polyunsaturation (polyunsaturation index, 
PUI) (Cobbold et ah, 2008a; Johnson et al., 2008). The indices are defined in Table 4-4. 
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Table 4-4. Derivation of indices 
Index Water Definition 
suppression 
Total lipid (%) No 100 * (methyl + methylene / water + methyl + methylene) 
tCho:Lipid (%) Yes 100 * (tCho/ methyl + methylene +allylic +diallylic) 
sic%) Yes 100 * 1- (allylic + diallylic/ allylic + diallylic + methyl + 
methylene) 
PUI (%) Yes 100 * diallylic/ diallylic + allylic + methyl + methylene 
Abbreviations: tCho, total choline-, SI, saturation index-, PUl, polyimsaturation index. 
Indices of lipid composition were stratified by severity of fibrosis and displayed in Figure 4-2. 
There was a positive correlation between total lipid and fibrosis stage, r=0.43, p=0.003. SI 
increased with fibrosis, r=0.58, p<0.0005, while the choline to lipid ratio decreased with 
increasing fibrosis, r=-0.51, p<0.0005, and the PUI was also negatively correlated, r=-0.55, 
p<0.0005. 
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F i g u r e 4-2 . In vitro 'H M A S N M R spectra l indices plotted aga ins t fibrosis s tage . 
Categories are mild fibrosis (Fl-2), moderate fibrosis (F3-4) and cirrhosis (F5-6). "Box and whisker" 
plots represent the median (horizontal line) and interquartile range (box) with the range of values up to 
1.5 times the IQR within the range of each of the bars. Outliers are plotted individually beyond the bars. 
Significant p-values from the Mann-Whitney U test are displayed in bold, non-significant differences in 
normal weighted text. A, percentage total lipid: median (IQR) increased from 2.18% (0.74) through 
2.85% (0.76) to 3.22%) (1.54) with increasing severity of fibrosis group. B, the total choline to lipid ratio: 
decreased from 15.97% (13.54) through 10.19% (14.01) to 7.66%> (3.28)\ C, the saturation index 
increased from 84.98% (2.15) through 86.55% (2.79) to 87.19%> (2.09. D, the polyunsaturation index 
Clear d i f f e r ences in lipid load and compos i t ion w e r e a lso notable be tween pat ients wi th 
hepat i t i s C geno type 1 and geno type 3 (F igure 4-3). T h e total lipid content and SI were higher 
in those wi th geno type 3, compared wi th geno type 1. T h e t C h o did not d i f fe r s igni f icant ly 
be tween g roups , but the PUI w a s lower in geno type 3 than geno type 1. F rom T a b l e 4-1, it can 
be seen that pa t ients wi th geno type 3 d isease had m o r e severe d isease than those with geno type 
1 4 4 
1 (as assessed by histological fibrosis stage and aminotransferase levels). In order to determine 
whether the differences in total lipid were dependent on genotype or severity, the total lipid and 
PUI were plotted by severity and stratified by genotypes I and 3 (Figure 4-4). This showed that, 
in genotype 1, total lipid increased with histological fibrosis stage (Spearman rho r=0.53, 
p=0.01), while in genotype 3, there was no association with fibrosis stage (r=-0.01, p=0.74). 
However, PUI correlated with severity for both genotype 1 (r=-0.42, p=0.04) and genotype 3 
(r=-0.54, p=0.04). 
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p=0.076 p =0.033 
p=0.059 p=0.028 
Genotype Genotype 
Figure 4-3. 'H MAS NMR spectroscopy-derived indices, plotted by genotype. 
"Box and whisker" plots represent the median (horizontal line) and interquartile range (box) with the 
range of values up to 1.5 times the IQR within the range of each of the bars. Outliers are plotted 
individually beyond the bars. Significant p-values from the Mann-Whitney U test are displayed in bold, 
non-significant differences in normal weighted text. A, median total lipid was significantly lower in 
genotype 1, 2.17% (1.36) compared to genotype 3, 3.07 (5.87); B, the median total choline to lipid ratio 
higher in genotype I, 11.60 (15.40) versus 3, 9.18 (6.31); C, the median saturation index vi'Oi lower in 
genotype 1, 85.7 (3.04) than 3, 86.9 (2.31); D, the polyunsaturation index was significantly higher in 
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Figure 4-4. Total lipid and P U I stratified by severity of fibrosis and genotype 
"Box and whisker" plots represent the median (horizontal line) and interquartile range (box) with the 
range of values up to 1.5 times the IQR within the range of each of the bars. Outliers are plotted 
individually beyond the bars. A, total lipid\ B, polyunsatiiration index. 
147 
Multiple linear regression was performed to assess the relative contribution of fibrosis, necro-
inflammation and lipid load (lipid droplets as a percentage of hepatocytes) as assessed 
histologically on the NMR-derived indices (Table 4-5). The ordinal histological scores 
approximated a linear variable. On univariate and multivariate analysis, both fibrosis score and 
steatosis score significantly influenced PUI, but necro-inflammatory score had no effect. The 
magnitude of the effect of fibrosis on PUI was greater than that of steatosis in this cohort of 
patients, although this cohort was not recruited or stratified primarily by steatosis. 
Table 4-5. Linear regression of histological features on the MRS-derived indices. 
Model Variable Coefficient R" Significance 
PUI 0.413 
Fibrosis stage (0-6) -0.472 <0.0005 
Steatosis (0-3) -0.285 0.028 
SI 0.428 
Fibrosis stage (0-6) -0.503 <0.0005 
Steatosis (0-3) -0.315 0.011 
CLR 0.420 
Fibrosis stage (0-6) -0.449 0.001 
Steatosis (0-3) -0.399 <0.0005 
Significant values are in bold type. Candidate variables were fibrosis stage, steatosis grade and necro-
inflammation. Necro-inflammatory score was not a significant contributor to any of the models. 
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4.5 Discussion 
High resolution 'H MAS NMR spectroscopy of liver biopsy samples from patients with chronic 
hepatitis C provided metabolic profiles showing clear differences according to disease severity 
and genotype. Cross-validation of the PLS-DA model showed that the fibrosis category or 
genotype could be predicted correctly in 46 out of 47 cases and that these differences were 
predominantly due to changes in lipid and choline resonances. Total lipid and the degree of fatty 
acid saturation increased with increasing disease severity, and in genotype 3 compared with 
genotype 1. The extent of fatty acid polyunsaturation decreased independently with increased 
fibrosis and with increasing steatosis. The total choline to lipid ratio also decreased with 
increasing disease severity. Differences in indices according to genotype (1 or 3) should be 
interpreted in the context of the distribution of genotypes according to histological severity 
(Table 4-1). In this cohort, patients with genotype 3 had more severe disease than those with 
genotype 1: patients with genotype 3 were more likely to have moderate or severe disease 
(assessed histologically) than those with genotype 1 and transaminases were also higher. This 
may partly explain why the table of metabolites contributing to differences in fibrosis severity is 
similar to that differentiating genotypes 1 and 3 (Table 4-2). There is no clear evidence that the 
genotype has a substantial effect on the rate of progression of disease, although some studies 
have suggested that genotype lb is associated with more aggressive, rapidly progressive disease 
(Zein, 2000). The explanation for increased disease severity in those with genotype 3 may lie in 
the duration of infection, although this information was unavailable for the current study. 
Certainly, (south) Asians with genotype 3 disease have been found to have a higher fibrosis 
stage at presentation than non-Asians and this has been linked to infection earlier in life among 
this group (Freshwater et al, 2008). 
The cohort of 47 biopsies from well-characterised patients with chronic hepatitis C, analysed 
using 'H m a s MRS with multivariate pattern recognition statistics has enabled the observation 
of characteristic metabolic differences with fibrosis stage and genotype. This represents the 
largest number of patients with chronic liver disease studied using this approach. Proof-of-
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principle in vitro studies have applied high resolution MRS to human liver tissue from six 
organs for transplantation pre-and post transplant (Duarte et al., 2005) and to 17 patients with 
chronic liver disease of differing aetiologies (Martinez-Granados et al, 2006). These initial 
studies demonstrated the range of metabolites observable in human liver tissue, but owing to 
their small size and the heterogenous patient groups, robust characteristic changes with disease 
state were not seen. 
4.5.1 Biological relevance of indices 
Total intrahepatic lipid was found to increase with increasing fibrosis stage. The presence of 
steatosis is associated with an increased rate of progression of fibrosis (Adinolfi et al., 2001), 
which may leading to a higher prevalence of steatosis with increasing fibrosis stage. Total lipid 
is also increased in those patients with genotype 3 compared with those patients with genotype 
1. Stratification of data by both histological fibrosis severity and genotype categories (Figure 
4-4) showed that, although total lipid was higher in genotype 3 than in genotype 1 overall, in 
genotype 1 there was a good correlation with fibrosis stage, while in genotype 3, there was no 
such correlation. This suggests that in patients with genotype 3, HCV-related "viral" steatosis is 
the dominant effect, rather than a constitutive, host-related process. Moreover, hepatic steatosis 
is strongly influenced by genotype, rather than simply being a correlate of disease severity. To 
substantiate these relationships, larger prospective longitudinal studies would need to be 
performed with acquisition of data including the duration of infection and consideration of race. 
Virological mechanisms for steatosis have been proposed, including inhibition of the 
microsomal triglyceride transfer protein by HCV core protein (Perlemuter et al., 2002), the 
activation by cleavage of sterol regulatory binding proteins (Waris et al., 2007), and the 
presence of genotype 3-specific core protein residues (Hourioux et al., 2007), as discussed in 
detail in section 1.5. Mechanisms of metabolically mediated steatosis in HCV include increased 
insulin resistance (Hui et al., 2003), which is associated with increased levels of TNFa in 
animal studies (Shintani et al., 2004). Fasting insulin assays were unavailable in this study, but 
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would have enabled more detailed analysis of the contributions of "viral" and "metabolic" 
aspects of HCV-associated hepatic steatosis. 
The hepatic total choline concentration decreased with increasing fibrosis. The dominant 
components of the choline region, GPC, PC and PtC, are prominent contributors to the PLS-DA 
models separating NMR spectra by fibrosis severity and by genotype. Total choline also 
decreases with increasing hepatic lipid, in keeping with decreased phosphocholine in NAFLD 
observed using chromatography-based lipidomic analysis (Puri et al., 2007). Studies have 
shown PtC to be required for normal hepatic secretion of VLDL (Yao and Vance, 1988) and 
decreased PtC leads to accumulation of intracellular triglycerides (Noga et al., 2002). In 
addition, mice fed a choline/methionine deficient diet are known to develop hepatic steatosis 
and steatohepatitis (Walkey et al., 1998). However, as studies are carried out on a fixed volume 
of tissue, increasing steatosis may contribute to decreased total choline measurement, owing to a 
dilutional effect of higher lipid levels. 
There was a decrease in PUFA indices and, conversely, an increase in saturation with increasing 
fibrosis stage (Figure 4-2). PUI correlated with fibrosis severity, both in those with genotype 1 
and in genotype 3, in contrast to total lipid measurement (Figure 4-4). This supports PUI being 
predominantly a marker of disease severity, rather than a marker of the steatotic effects of 
genotype. Regression of histological features demonstrated that reduced PUI was independently 
associated with increased fibrosis and steatosis, but not with necroinflammation (Table 4-5). 
PUFAs are important cell membrane constituents, incorporated into phospholipids and 
contributing to fluidity and cell membrane function (Cabre and Gassull, 1996). The degree of 
lipid polyunsaturation is of particular interest in chronic liver disease and has been seen to be 
reduced in animal studies using MRS in vitro (Cobbold et al., 2008a; Serkova et al., 2006), and 
in human studies of NAFLD using chromatography techniques (Puri et al., 2007). Moreover, 
studies of hepatic cell lines have shown that addition of PUFA inhibit HCV RNA replication 
(Kapadia and Chisari, 2005). The decrease in PUFA seen in our study may be a result of 
reduced dietary essential fatty acids and/or a reduction in desaturase activity consequent to liver 
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insufficiency per se (Cabre and Gassull, 1996; Pun et ah, 2007). However, as discussed in 
section 1.5.3, diseased liver is subject to oxidative stress, which in the case of CHC, is 
associated with the HCV viral load and inflammation (Okuda et al., 2002). PUFAs are 
consumed by oxidative and peroxidative processes in conditions of oxidative stress and 
consequent products, such as malondialdehyde (MDA) and 4-hydroxyl-2,3-nonenal (HNE) 
adducts, have been associated histologically with viral chronic liver disease, correlating with 
fibrosis score and disease activity (Paradis et al., 1997b). Proteomic profiling of liver biopsy 
samples suggested impairment of fatty acid oxidation and response to oxidative stress with 
severe fibrosis compared with mild fibrosis (Diamond et al., 2007). These studies suggest that 
the ability to monitor hepatic PUFA non-invasively may be of considerable biological 
importance for subsequent studies of disease progression and intervention. 
4.5.2 Limitations 
'H m a s NMR spectroscopy enables the quantification of total lipid, but also conveys 
information on lipid composition in addition to other metabolites. Indices of fatty acid saturation 
and polyunsaturation are robust and of clinical and biological importance, but the information is 
limited, as individual fatty acid species are not directly quantifiable. 
These experiments were performed on a small portion of clinical liver biopsy specimens (1.7-
11.4mg) likely resulting in sampling variability. However, the portion used for 'H MAS NMR 
spectroscopy was from the same core as that sent for histology, so was spatially related to the 
reference standard. 
As the water-suppressed NMR spectra are dominated by lipid resonances, quantification of any 
resonance as a proportion of the total spectra integral will be influenced by the lipid load, 
leading to a dilutional or "bulk" effect. Correction for sample mass may allow the derivation of 
molar quantities of metabolites, but does not correct for increased steatosis. Water unsuppressed 
MR spectra allow absolute quantititation, although the presence of a large water peak interferes 
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with neighbouring resonances. While CPMG sequences preferentially suppress signal from 
macromolecules including lipids, the effects on other metabolites are variable, so absolute 
quantification requires knowledge of T2 values. Novel approaches to spectral processing may 
allow the editing out of lipid resonances, so a proportion of the tissue excluding lipid might be 
assessed (Weljie et al., 2006). Pragmatically, however, where the mass or volume of tissue is 
constrained, MRS data is easily expressed as ratios of the metabolites of interest. However, 
interpretation of these ratios should include consideration of bulk effect. 
For the purposes of establishing the pathological significance of lipid composition indices, 
subgroup analysis by race and genotype was underpowered to make firm conclusions. In 
addition, fasting insulin measurements were not obtained prospectively, so the relationship 
between insulin resistance, genotype and hepatic steatosis could not be explored in this cohort. 
The effects of insulin resistance and race will, however, be investigated further in Chapter 5. 
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4.6 Conclusion 
This study has used high resolution 'H MAS NMR spectroscopy of liver biopsy samples to 
examine the metabolic profile in patients with chronic hepatitis C. Lipid quantity and 
composition accounted for much of the "NMR spectral differences between groups: an increase 
in total lipid and a decrease in lipid polyunsaturation was observed with increasing hepatic 
fibrosis, while increased intrahepatic lipid was also observed in patients with genotype 3. These 
robust NMR indices demonstrate potential to be translated to the in vivo setting. 
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5 NON-INVASIVE ASSESSMENT OF LIPID COMPOSITION IN 
PATIENTS WITH HEPATITIS C 
5.1 Abstract 
Hepatic steatosis is an important factor in the pathogenesis, progression and response to 
treatment in hepatitis C. Histological assessment of hepatic lipid is limited by sampling 
variability and the semi-quantitative nature of scoring systems. 'H MRS enables metabolic 
profiling of liver in vivo, providing a potentially non-invasive approach. 
The aim of this study was to investigate lipid composition in patients with chronic hepatitis C 
using 'H MRS. The spectral information derived from in vitro 'H MAS NMR studies was used 
to define the assignment and interpretation of 'H MRS in vivo. 
A cohort of 59 patients with biopsy-proven chronic hepatitis C was stratified by fibrosis stage 
and genotype. In vivo MR spectra were obtained using a Philips Achieva clinical MR system at 
1.5T. MR spectra were obtained with and without water-suppression. MR spectra were analysed 
using prior knowledge informed by high-resolution in vitro studies of liver tissue from Chapter 
4. Differences in lipid quantity and composition, according to fibrosis stage and genotype seen 
in vitro were validated in this separate in vivo cohort. 
Conclusion: Lipid composition in chronic hepatitis C was assessed non-invasively using 'H 
MRS, informed by high resolution NMR studies of intact tissue. Total lipid increased and 
polyunsaturation decreased with increasing fibrosis stage. This technique may provide insights 
into the pathogenesis of chronic liver diseases and could be added to other MR sequences in 
subsequent studies. 
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5.2 Introduction 
Hepatic lipid composition is an important factor in the aetiology and pathogenesis of chronic 
liver disease (section 1.5). In the context of hepatitis C infection, hepatic steatosis is associated 
with more severe fibrosis, with more rapid progression of disease (Adinolfi et al., 2001; Rubbia-
Brandt et al., 2004), while response to antiviral treatment has been associated with a decrease 
in steatosis in patients with genotype 3 (Reddy et al., 2008). Hepatic steatosis in hepatitis C is 
thought to evolve in a genotype-related manner. Virologically-mediated steatosis is associated 
more with genotype 3 (Rubbia-Brandt et al., 2000), mediated in part by viral inhibition of fatty 
acid export mechanisms (Hourioux et al., 2007) and steatosis associated with the presence of 
insulin resistance is commonly found in non-genotype 3 (particularly genotype 1) disease 
(Asselah et al., 2006; Camma et al., 2006; Hui et al., 2003; Moucari et al., 2008). 
The current gold-standard for the clinical assessment of hepatic lipid is liver biopsy, which 
provides a semi-quantitative assessment of hepatocellular lipid droplets, in addition to evidence 
of inflammation and fibrosis (Kleiner et al., 2005). A number of validated scoring systems are 
used for the assessment of the severity of hepatitis C-related chronic liver disease, including the 
modified histological activity index of Ishak and the METAVIR scoring systems (Bedossa and 
Poynard, 1996; Ishak et al., 1995; METAVIR, 1994). These systems assess liver disease 
severity in terms of fibrosis stage and inflammatory features. To this may be added an 
assessment of lipid load on the basis of the proportion of hepatocytes with visible lipid droplets. 
Recently, histological lesions associated with non-alcoholic steatohepatitis (NASH) were 
studied in patients with chronic hepatitis C in the context of clinico-biological correlates 
(Bedossa et al., 2007). However, histological assessment of hepatic lipid does not provide 
information on lipid composition. Non-invasive techniques for the assessment of hepatic lipid 
composition are required. 
Murine and human studies of intact liver tissue using high resolution 'H MAS NMR 
spectroscopy have shown the 'H MR spectrum to be dominated by water, lipid and choline 
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resonances (section 2.6.3.1, Figure 3-2, Figure 4-1). Moreover, characteristic metaboHc 
perturbations associated with disease severity in patients with hepatitis C have been noted, and 
MR indices derived, in Chapter 4. In this study, the aim was to translate and validate these 
findings in a cohort of patients with hepatitis C studied in vivo. 
5.2.1 Technical criticism of previous hepatic 'H MRS studies 
In vivo 'H MRS has been shown to be a quantitative tool for the non-invasive assessment of 
hepatic total lipid load (Browning et ah, 2004; Szczepaniak et ah, 2005; Thomas et al., 2005) 
and the techniques used have been discussed in section 1.7.3.6.3. Absolute quantification of 
intrahepatic lipid has been estimated by calibration of the number of MR-visible protons within 
the lipid resonances, with quantification of hepatic lipid extracts (Longo et al., 1995). The 
relative quantification of hepatic lipid has been derived as a simple ratio to the hepatic MR 
spectral water resonance, although this method of quantification is not directly comparable to 
absolute concentrations of intrahepatic lipid (Thomas et al., 2005). 
Studies have used 'H MRS to stratify chronic liver disease (Cho et al., 2001; Orlacchio et al., 
2008), but the assignment of metabolites in such studies is controversial, hi the study by Cho 
and colleagues, metabolites were likely to have been assigned to MR spectral noise (Lim et al., 
2003a). The study by Orlacchio and colleagues aimed to stratify patients with chronic hepatitis 
C according to disease severity. For the assignment of in vivo MR spectral resonances, they 
used a study of high resolution 'H NMR spectroscopy of aqueous extract of liver tissue (Bell et 
al., 1993), thus assigning an aqueous "glutamine-glutamate" complex to a large lipid resonance 
(Duarte et al., 2005). 
Recently, hepatic lipid content was assessed in subjects with differing degrees of hepatic 
steatosis, with a calculation of the degree of fatty acyl saturation, demonstrating the potential for 
'H MRS to assess lipid composition (Johnson et al., 2008). Models of oils of known 
composition were studied at 1.5T and indices of fatfy acid saturation derived. Patients with 
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differing degrees of hepatic steatosis were then studied using 'H MRS at 1.5T. Scrutiny of the 
published MR spectra from the oils showed the chemical shift difference between the methylene 
resonance and the diallylic resonance was 51.5ppm, consistent with results from in vitro MR 
studies of intact liver of 51.47ppm (Duarte et al., 2005) and 51.48ppm (Martinez-Granados et 
al., 2006). However, the relative chemical shift between the methylene resonance and the peak 
assigned as the "diallylic" resonance in humans was 51.9ppm, more consistent with the 
published chemical shift difference between methylene and tCho resonances of 81.90ppm 
(Duarte et al., 2005) and 51.88ppm (Martinez-Granados et al., 2006). This criticism is 
supported by Figure 3-1 in Chapter 3, showing high resolution 'H MAS NMR spectra from 
normal and steatotic liver from mice aligned with a 'H MAS MR spectrum from a sample of oil 
of known composition. Thus, in the paper by Johnson and colleagues, the significant differences 
were seen between groups should have been interpreted as being a result of a reduced tCho:lipid 
ratio, rather than a reduction in PUI (Cobbold et al., 2008b). 
These fundamental criticisms of previous work provide lessons for subsequent studies: the 
model or reference used for the assignment of resonances should be physiologically relevant to 
the samples being tested and the reference peak used to assign spectra should be present in both 
the model and the subject. 
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5.3 Hypotheses 
The hypotheses for this study were that: 
1. Information gained from high resolution 'H MAS NMR spectroscopy studies of 
intact liver tissue would inform the assignment and analysis of lower resolution 
'H MR spectra in vivo 
2. Indices of lipid composition observed in vitro can be reproduced in a separate 
cohort, in vivo 
5.4 Aims 
The aims of this study were: 
1. To define prior knowledge for the analysis of 'H MR spectra in vivo using high 
resolution 'H MAS NMR spectral data 
2. To validate the indices tested in Chaper 4 in a separate cohort of patients in vivo. 
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5.5 Materials and methods 
5.5.1 Recruitment 
59 patients with chronic hepatitis C were prospectively recruited from Imperial College 
Healthcare Trust from September 2006 to January 2008. Ethical approval for the study was 
obtained prospectively from the regional ethics committee in accordance with the 1975 
Declaration of Helsinki. Patients were included if they were aged 18-65, had evidence of 
replicating hepatitis C-virus infection on HCV RNA testing, and had been referred for 
percutaneous liver biopsy for clinical indications. 
Patients were excluded if they consumed >20g of alcohol per day, if they were obese (with a 
BMI >30kg/m^) or diabetic. Patients were also excluded if they were taking antiviral therapy; 
were co-infected with HIV or hepatitis B; were currently taking intravenous drugs, 
antihypertensive or lipid-lowering medications; had ongoing illness or had evidence of hepatic 
decompensation, defined by any of the following: jaundice, ascites, or hepatic encephalopathy. 
All patients underwent percutaneous liver biopsy by an experienced hepatologist using a 16-
guage Menghini needle, which was sent immediately for histology. Biopsy samples for 
histology were fixed in formalin and embedded in paraffin wax, prior to staining with 
haematoxylin and eosin. All samples were scored according to the Ishak modified histological 
activity index (Ishak et al, 1995) and by NASH Clinical Research Network semi-quantitative 
scoring system for cellular morphology, inflammation and fibrosis by an experienced 
hepatopathologist (Kleiner et al., 2005). The patients were divided into three groups on the basis 
of the Ishak fibrosis stages as follows; group 1, mild fibrosis, stages 1-2; group 2, moderate 
fibrosis, stages 3-4; group 3, cirrhosis, stages 5-6. 
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5.5.].] 'H MRS studies 
A Pliilips Achieva ] .5T whole-body system (Philips Medical Systems, Best, The Netherlands) 
with a 4-channel SENSE body coil and Q body coil was used. Routine T,-weighted survey 
images were used for voxel placement. An 8cm^ (2 x 2 x 2cm) voxel was placed in the right 
lobe of the liver, avoiding large blood vessels or biliary structures. A single voxel PRESS 
(point-resolved spectroscopy) sequence was used without water suppression for the assessment 
of total lipid content, and with water suppression for assessment of lipid composition (TR 2s, 
TE 40ms). 16 blocks, each of eight acquisitions per breath-hold, were acquired. Patients fasted 
for at least 6hr prior to scanning. 
5.5.2 /n vzvo MR spectral analysis 
Spectra were processed using MRUI software, v3.0 (www.mrui.uab.es/mrui) (Naressi et al., 
2001). Analysis was perfonned on spectra derived from a single block of eight acquisitions, as 
summation of blocks reduced the spectral resolution because of respiratory motion. Following 
Fourier transformation, DC correction was applied, followed by apodisation (line-broadening) 
of 5Hz. Manual phasing was performed and the reference peak (methylene fatty acyl functional 
group) set at 51.3ppm. Prior knowledge applying "soft"' constraints to the curve-fitting 
parameters in terms of chemical shift, phase and linewidth (derived from in vitro data as 
detailed in Table 5-1) was applied to integrate the spectral peaks using AMARES (Hamilton et 
ah, 2003; Vanhamme et ah, 1997). An example of curve-fitting using jMRUI and the newly 
applied prior knowledge is shown in Figure 5-1. The investigator (the author) was blinded to 
the clinical and biochemical details pertaining to each spectrum at the time of spectral analysis. 
In order to estimate the reliability of curve-fitting, all spectra were re-analysed separately by an 
additional blinded investigator (J. Patel, BSc student). 
' "Soft" constraints refer to a specified range of values for a parameter. The curve is fitted optimally, 
within the range of values supplied as "prior knowledge". 
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Table 5-1. Prior knowledge used for the analysis of in vivo H MRS 
Metabolite Functional Chemical Chemical Constraints Linewidth Phase 
group Shift in shift in vivo to chemical constraints constraints 
vitro starting shift in vivo (Hz) n 
(ppm) values 
(ppm) 
(ppm) 
NWS 
Methyl fatty -CHs 0.9 0.9 0.7-1.0 5-20 nil 
acyl group 
Methylene -CH2- 1.3 1.3 1.2-1.4 5-30 nil 
fatty acyl 
group 
Water H2O 4.7 4.5-4.9 5-40 nil 
WS 
Methyl -CH3 0.9 0.9 0.7-1.0 5-20 -20 to +20 
Methylene -CH2- 1.3 1.3 1.2-1.4 5-30 -20 to +20 
Methylene to -CH2-CH2- 1.6 1.6 1.5-1.7 5-20 -20 to +20 
a-methylene to c o o 
Carboxyl 
Allyllc -CH2-
CH=CH-
2.04 2.0 2.0-2.1 5-20 -20 to +20 
a-methylene to COO-CH2- 2 . 2 6 2.2 2.2-2.3 5-20 -20 to +20 
carboxyl CH2-
Diallylic —CH-CH2-
CH= 
2.80 2 . 8 2.7-2.9 5-20 -20 to +20 
Total Choline - N ( C H 3 ) 3 3.20-3.26 3.2 3.15-3.35 5-20 -20 to +20 
Water residual H2O 4.7 4.5-4.9 5-30 -5 to +5 
n-ene group -CH=CH- 5.33 5.3 5.2-5.4 5-20 -20 to +20 
Abbreviations: NWS, non water-suppressed', WS, water-suppressed 
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g eslirnate 
A ongjMl 
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Frequency (ppm) 
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0 
Figure 5-1. An example of the curve-fitting output using jMRUI . 
The panels have been expanded vertically to show the smaller spectral resonances, leading to truncation 
of the display of the residual water and lipid -CH2 peaks. Panel A shoM's the original water-suppressed 
spectrum, with major resonances labelled (tCho, total choline). Panel B shows the spectrum 
reconstructed from the curves specified by the prior knowledge supplied. Panel C shows the individual 
curves, as fitted. The numbers refer to the order that the curves were fitted. Panel D shows the residual, 
that is, the parts of the spectrum not fitted by the prior knowledge curve algorithm. A well-fitted spectrum 
should have little residual. 
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5.5.3 Statistical methods 
SPSS v l6 (SPSS Inc. Chicago, USA) was used for analysis of both cohorts with advice from a 
biomedical statistician. Clinical and biological indices were expressed as median values with 
interquartile range (or range). MRS-derived indices were compared using the Mann-Whitney U 
test for pair-wise comparisons. Correlation was performed using the Spearman rho test, with 
fibrosis stage (0-6) approximating a linear variable. Reliability assessment between 
investigators was assessed using the intraclass correlation coefficient (ICC). Correction for 
multiple comparisons was not performed as indices were correlated. 
164 
5.6 Results 
5.6.1 Patient characteristics 
The demographic and clinical characteristics of the 59 patients in this cohort are summarised in 
Table 5-2 and Table 5-3. 
Table 5-2. Numbers of patients stratified by race and genotype. 
Race 
Genotype 
2 3 Total 
Europoid (British) 
Europoid (non-British) 
South Asian 
Middle- Eastern 
Black African 
East Asian 
Total 
17 
11 
1 
0 
1 
0 
28 
3 
0 
0 
0 
1 
1 
5 
2 
3 
0 
0 
1 
14 
0 
3 
0 
4 
0 
0 
7 
28 
16 
4 
4 
2 
2 
56 
Patient numbers in the cohort of 59 patients studied using H MRS are tabulated by genotype and race. 
Genotyping was unavailable for three patients. The Middle-Eastern group included those of Arab East 
African origin. 
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Table 5-3. Patient characteristics 
Total Fibrosis group 
1 2 3 
Genotype 
1 3 Other (2,4) 
Number 59 27 21 11 30 14 1 2 # 
Sex M/F 3a%i 17/10 15/6 6/5 18/12 8/6 9/3 
Age (years) 5 0 ( 1 5 ) 50 (18) 48 (10) 48 (14) 4 9 . 5 ( 1 4 ) 46.5 (10) 54 (20) 
Genotype (no. 1/3) 30/14 15/4 9/7 6/3 N/A N/A N/A 
Bx length, mm (range) 25 27 21 25.5 2&5 30 25 
(10-49) (10-48) (11-49) (10-47) (10-48) (11-49) (10-38) 
BMI 24.5 (5.09) 23.0 (4.44) 25.3 (7.82) 26.4 (4.46) 23.8 (4.45) 23.0 (7.25) 26 .5 (5 .5 ) 
ALT, iu/L [0-40] 90 (95) 52(89) 98 (73) 137 (100) 90 (65) 140 (85) 7 9 ( 1 0 1 ) 
AST, iu/L [0-40] 60 (58) 39 (35) 79 (45) 106 (63) 59 (50) 90 (79) 58 (49) 
Platelets, x10®/L 209 (84) 214 (76) 186 (117) 181 (104) 213 (105) 197 (72) 202(35) 
[130-450] 
Total Cholesterol, 4 .30 (1 .36 ) 4.50 (1.17) 4 .68 (1.35) 3 .64(1 .12) 4.54 (1.12) 4.28(1.83) 4.18 (1.06) 
mmol/L [<6.5] 
Tr iglycer ides, 0.96 (0.55) 1.00 (0.67) 1.02 (0.48) 1.58 (0.51) 1.03 (0.52) 0.94 (0.62) 0.94 (0.56) 
mmol/L [<2.5] 
HOMA-IR 1.97 (2.02) 1.78 (1.94) 2 .16 (2 .24 ) 2.26 (1.95) 1.69 (0.96) 2.26(1.77) 3.09 (2.17) 
Figures are median (interquartile range) unless othem'ise specified. M, male-, F, female-, Bx, biopsy-, BMI, body inass index-, ALT, 
aminotransferase. # genotype data missing for 3 patients. Values in bold are significant differences at the p=0.05 level using the Kruskall-
alanine aminotransferase-, AST, aspartate 
Wall is test. 
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5.6.2 M R character isat ion 
Representative water-suppressed 'H MR spectra in vitro and in vivo are shown in Figure 5-2, 
illustrating a number of specific lipid resonances including fatty acid functional groups. The 
total choline region (53.18-53.28ppm) (tCho) contains peaks representing choline, 
phosphocholine, glycerophosphocholine and phosphatidylcholine, with contributions from 
trimethylamine-N-oxide (TMAO) and betaine. 
iL7 Glyceryl Glc, 
group glyc 
tCho iL5iL4 L3 iL2 iL1 
3 
ppm 
Figure 5-2. In vitro and in vivo MR spectra aligned by chemical shift. 
The residual water resonance at S4.8-5.2ppm was removed as indicated. Key: LI, lipid CH^CHi 
(methyl)-, L2 lipid (CH2)„ (methylene)', L3 lipid CH2CH2CO (methylene to L5)-, L4 lipid CH=CHCH2CH2 
(allylic); L5 lipid CH2CH2CO (a-methylene to carboxyl)\ L6 lipid CH='CHCH2CH=CH (diallylic-
"PUFA')i L7 lipid CH=CH (n-ene - "MUFA')\ tCho, total choline region with contributions from 
choline, phosphocholine, glycerophosphocholine, trimethyl amine oxide (TMAO) and betaine', glc, 
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5.6.3 Peak assignment and fitting 
Peak assignment in vivo was performed using higher resolution in vitro MR spectra, plotted 
along the same scale of chemical shift and both referenced to the dominant lipid peak, the 
methyl fatty acid resonance (Figure 5-2). By direct comparison to in vitro NMR spectra, only in 
vivo peaks corresponding to substantial peaks in vitro were assigned, reducing the chance of 
inappropriate peak assignment. 
The spectra shape, relative size and position of peaks identified in vitro enabled appropriate 
prior knowledge for the jMRUI AMARES curve-fitting algorithm. Peak chemical shift, phase, 
linewidth and lineshape were subject to soft constraints as detailed in Table 5-1. Application of 
this prior knowledge to all in vivo MR spectra and blinding of the analyst ensured consistent 
unbiased analysis throughout. 
The reliability of curve fitting, assessed independently by two blinded investigators, is displayed 
in Table 5-4. The MR spectra including water were fitted with high reliability. In the water-
suppressed spectra, the "«-ene" (-CH=CH-) lipid peak was fitted by both investigators in 95% 
of cases, while the diallylic lipid peak was fitted in 77% of cases with high reliability (0.86). 
Thus, PUI values were available for 45 of the 59 patients in this cohort. The other peaks were 
fitted in 100% of cases. 
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Table 5-4. Reliability of curve fitting 
Peak ICC 95% CI Fitted peaks (%) 
NWS 
Water 0.982 0.968-0.990 100 
Methylene 0.980 0.965-0.989 100 
Methyl 0.776 0.604-0.874 96 
yys 
"n-ene" 0.887 0.797-0.937 95 
tCho 0.873 0.782-0.926 100 
Diallyllc 0.862 0.714-0.934 77 
a-methylene to 0.848 0.739-0.911 100 
carboxyl 
Allylic 0.774 0.610-0.869 100 
Methylene 0.999 0.998-0.999 100 
Methyl 0.942 0.900-0.966 100 
Curve-fitting was performed by two independent observers. Abbreviations: NWS, non water-suppressed', 
WS, water-suppressed', tCho, total choline', ICC, intraclass correlation coefficient', CI, confidence 
interval. 
5.6.4 Analysis of lipid composition 
The MRS trends observed in vitro (Chapter 4) were confirmed in this separate in vivo cohort as 
shown in Figure 5-3: total lipid increased with increasing fibrosis (r=0.48, p<0.0005); SI 
correlated positively (r=0.39, p=0.003); the choline to lipid ratio was negatively correlated with 
fibrosis stage (r=-0.52, p<0.0005) and the PUI also decreased with increasing fibrosis (r=-0.55, 
p<0.0005). 
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Figure 5-3. Indices validated at 1.5T plotted against fibrosis stage. 
Categories are mild fibrosis (Fl~2), moderate fibrosis (F3-4) and cirrhosis (F5-6). "Box and whisker" 
plots represent the median (horizontal line) and interquartile range (box) with the range of values up to 
1.5 times the IQR within the range of each of the bars. Outliers are plotted individually beyond the bars. 
Significant p-values from the Mann-Whitney U test are displayed in bold, non-significant differences in 
normal weighted text. A, total lipid increased with severity of fibrosis, from 1.30% (1.49) through 4.30% 
(7.18) to 5.25% (2.93); B, the total choline to lipid ratio decreased from l4.43%o (13.66) through 4.57% 
(7.89) to 3.58% (3.32); C, the saturation index increased from 95.21%o (5.73) through 97.02% (1.64) to 
97.52% (1.85); D, the polyunsaturation index decreased from 0.75% (1.70) through 0.19% (0.39) to 
0.73% fO. 72/ 
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Figure 5-4. Indices validated at 1.5T plotted by genotypes 1 and 3. 
"Box and whisker" plots represent the median (horizontal line) and interquartile range (box) with the 
range of values up to 1.5 times the IQR within the range of each of the bars. Outliers are plotted 
individually beyond the bars. Significant p-values from the Mann-Whitney U test are displayed in bold, 
non-significant differences in normal weighted text. A, total lipid was lower in genotype 1, 7.26% (2.95) 
than genotype 3, 3.94% (5.46)\ C, the saturation index was 96.0% (3.83) for genotype 1 and 96.8% (1.33) 
for genotype J; D, the polyimsatiiration index was higher in genotype 1, 0.73% (1.22) than genotype 3, 
Differences in indices according to genotype are shown in Figure 5-4, and confirm those seen 
in vitro (Figure 4-3). However, while the absolute measures of total lipid were similar between 
groups, the absolute total choline and (poly)unsaturation indices were lower in the in vivo cohort 
compared to the in vitro cohort (Chapter 4). To confirm the observation in vitro that the total 
lipid measurement increased with increasing severity of disease in genotype 1, but not in 
genotype 3, total lipid was plotted against fibrosis severity and stratified by genotype (Figure 
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5-5). Indeed, in genotype 1, total lipid correlated with severity of fibrosis (r=0.46, p=0.016), but 
in genotype 3, there was no correlation with disease severity (r=-0.04, p=0.91). This 
discrepancy was most notable in those with mild disease. 
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Figure 5-5. Percentage total lipid signal plotted by fibrosis, stratified by genotype. 
"Box and whisker" plots represent the median (horizontal line) and interquartile range (box) with the 
range of values up to 1.5 times the IQR within the range of each of the bars. Outliers are plotted 
individually beyond the bars. 
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5.7 Discussion 
The interpretation of in vivo 'H MR spectra at 1.5T was aided by information obtained from the 
high resolution 'H MAS NMR spectra from liver biopsy tissue. Indices tested in Chapter 4 
were validated here in the separate in vivo cohort. The in vivo cohort was similar to the in vitro 
cohort in terms of distribution of patient characteristics, supporting the comparison of MR 
indices. Total lipid and the degree of fatty acid saturation increased with increasing disease 
severity, and in genotype 3 compared with genotype 1. The extent of fatty acid polyunsaturation 
decreased independently with increased fibrosis and with increasing steatosis. The biological 
significance of these indices and differences has been discussed in section 4.5.1. 
The importance of using relevant in vitro data to inforni interpretation of in vivo MR spectra is 
reinforced by the errors seen in other studies and described in section 5.2.1. When using low 
resolution MR spectra, where information is obtained at the limit of the sensitivity of the 
technique, such mistakes are understandable, but would have been avoided by using this 
approach. The use of oils as a model may be useful to calibrate equipment, but cannot be 
considered to be biologically representative. Therefore, the results presented here represent a 
proof-of-principle for the non-invasive analysis of lipid composition using 'H MRS. 
HOMA-IR scores were variable within histological groups, but correlated weakly with 
increasing fibrosis stage (r=0.29, p=0.03) and with total lipid (r=0.32, p=0.02), consistent with 
recent studies assessing the effect of insulin resistance, steatosis and fibrosis in hepatitis C, 
which showed that HOMA-IR was a significant predictor of fibrosis stage (Cua et al., 2008; Hui 
et al., 2003). In this cohort, the median HOMA-IR was higher in patients with genotype 3 than 
those with genotype 1 (although non-significantly), contrary to those larger studies. This current 
study was not designed to look at differences in insulin resistance and genotype, so is 
underpowered to make such conclusions. Race may be a confounding factor in such analyses as 
the prevalence of insulin resistance and high levels of visceral adipose tissue is known to vary 
accordingly. For example, there is a high prevalence of insulin resistance, central obesity, 
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diabetes and coronary heart disease in those of South Asian origin (Despres et al., 2000; Tillin 
et al., 2005), while there is also a relatively high prevalence of genotype 3 HCV in the Indian 
subcontinent (Fang et al., 1997). It might be hypothesized, then, that in a cohort of patients 
where a substantial number originate from South Asia, the background risk of T2DM and 
insulin resistance might confound the genotype-related effects on IR and intrahepatic lipid. Such 
an analysis was not possible with the relatively small number of patients studied in this cohort, 
particularly as obesity and diabetes were exclusion criteria for this study. Future studies aiming 
to assess intrahepatic lipid composition in patients with hepatitis C should control for race and, 
ideally, diet. 
Other in vivo 'H MRS studies have demonstrated non-invasive estimation of total hepatic lipid 
(Longo et al., 1995; Szczepaniak et al., 2005). Reproducibility analysis showed a coeffiecient of 
variation for the quantification of hepatic triglyceride of 8.5% (Szczepaniak et al., 2005), but 
these studies did not assess lipid composition or the presence of other metabolites. Studies of in 
vivo 'H MRS in chronic liver disease have demonstrated spectral differences between patients 
with disease of differing severity (Cho et ah, 2001; Orlacchio et al., 2008). Additionally, 
Orlacchio and colleagues demonstrated an increase in the dominant lipid resonances with 
increasing disease severity in 30 patients with chronic hepatitis C (Orlacchio et al., 2008). 
However, in the current study, the assignment of spectral resonances was informed by 
physiologically relevant models, ensuring appropriate assignment of resonances and preventing 
the assignment of metabolites to spectral noise (Lim et al., 2003a). 
5.7.1 Limitations and potential solutions 
Some limitations are inherent to the technique of 'H MRS. In particular, sensitivity is low and 
the output is the relative amount of MR-visible molecular functional groups, rather than a molar 
concentration of metabolites within a sample. Moreover, the length of fatty acid chains or the 
individual fatty acid species are not directly identifiable or quantifiable. 
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5.7.].] Sampling variability 
A voxel or region of interest was used to obtain MRS data in vivo. If patliology is not evenly 
distributed, there may be a degree of sampling variability. There is a trade-off between the use 
of a large or small voxels. When using a large voxel, there is less sampling variability, greater 
signal, but poorer resolution on account of magnetic field gradients and inhomogeneity artifact. 
When using a small voxel, less signal is produced, the risk of sampling variability is greater, but 
resolution is improved. On the basis of preceding work in our group, an 8cm^ voxel was 
considered to be the appropriate compromise for these studies (M. Wylezinska, physicist, 
personal communication). Using an 8cm^ voxel in vivo, the portion of liver tested is around 
lOOOx greater than that sampled by biopsy. Sampling variability of 'H MRS in vivo is therefore 
minimal compared to the reference standard, liver biopsy. However, in the future, placement of 
more than one voxel (for example within both the right and left lobes of the liver) would enable 
spatial variability of spectral differences to be assessed. 
5.7.1.2 Delay from biopsy to investigation 
There was a delay between liver biopsy and in vivo MRS studies of up to one year. In this study, 
biopsy was used as a classification tool rather than as a strict reference standard, as histological 
assessment of liver biopsy was not used to assess the lipid profile. As the fibrosis stage is 
unlikely to change within a year, the effect of such a delay on the classification is likely to be 
insignificant (Marcellin et al., 2002; Poynard et al., 1997). All other clinical and biochemical 
parameters were obtained on the day of MR investigation. 
5.7. ] .3 Limitations of spectral quality and analysis 
The resolution and SNR of the in vivo spectra at 1.5T limited the peaks that could be reliably 
estimated. The intraclass correlation of main resonances showed that the larger lipid peaks were 
fitted with excellent reliability between raters, but that the PUFA peak was fitted by both 
analysers in 77% of cases, although when fitted, the reliability was good. The values of the 
smaller resonances, such as the allylic and diallylic peaks in vivo were lower than those assessed 
in vitro. The lower SNR in vivo, together with the broader linewidths, is likely to have led to 
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underestimation of these resonances in vivo compared to the integrals observed in vitro. 
Accordingly, while estimation of total lipid may be quantified using MRS (Szczepaniak et al., 
2005), assessment of lipid composition may currently be considered quantitative only relative to 
other subjects studied on the same system or longitudinally. A direct, within-patient correlation 
from NMR of the biopsy sample in vitro to hepatic MRS in vivo would be useful to quantify the 
relationship between the resonances found in each setting in order to try to identify a conversion 
constant. Such an analysis was not performed as insufficient numbers of subjects for whom 
biopsy tissue had been taken for analysis were recruited for in vivo MR scanning. 
Suppression of the water resonance in vivo was variable, in part due to variable patient motion. 
As the "n-ene" -CH=CH- functional group resonance at 55.3ppm lies close to the residual water 
peak, there was a risk of variable constructive interference between the peaks. Accordingly, this 
resonance was excluded from incorporation into lipid indices (Johnson et al., 2008). 
MRS performed on systems at higher field strength (such as 3T) and better control of motion 
artifact will enhance spectral resolution and the SNR, and enable more reliable fitting of further 
resonances (Fischbach and Bruhn, 2008), but the need for physiologically-relevant assignment 
of peaks remains important. In this study, the investigation of resonances in intact tissue in vitro 
will provide a reference for future in vivo MRS studies. There is considerable interest in the 
relaxation properties (such as T?) of metabolites in different tissues and differing disease states 
(Fischbach and Bruhn, 2008). Such effects should be studied directly in future studies. By 
collecting data at two or more echo times, any systematic difference in To according to disease 
seventy would be detected by a difference in the signal reduction in a resonance with increasing 
echo time between samples of differing disease severity. A direct calculation of the T?* 
(measured T2) could be calculated by using a STEAM (stimulated echo acquisition mode) 
sequence of multiple echo times in health and disease. Although T? times may lead to MR 
spectral differences in vivo, the in vitro pulse and collect fully-relaxed NMR spectra were 
independent of T?. As the trends were similar in both cohorts, it may be surmised that the effect 
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of T2 on the in vivo MR spectral integrals is likely to be small compared to the effect of disease 
severity per se. 
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5.8 Conclusions 
To conclude, lipid composition in patients with chronic hepatitis C has been assessed non-
invasively at 1.5T. An increase in total lipid and a decrease in lipid polyunsaturation have been 
observed with increasing hepatic fibrosis, while increased intrahepatic lipid was observed non-
invasive ly in patients with genotype 3. The non-invasive assessment of lipid composition in 
chronic liver diseases using MRS adds a biologically and clinically relevant dimension to 
current disease assessment and the technique has potential to provide signs of efficacy in 
longitudinal studies in response to therapies which modulate hepatic lipid. 
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6 NON-INVASIVE ASSESSMENT OF HEPATITIS C-RELATED 
CHRONIC LIVER DISEASE 
6.1 Abstract 
The development of effective non-invasive biomarkers to assess the severity of chronic liver 
disease is of importance both in clinical practice and for the development of novel antifibrotic 
therapies. Combinations of markers may improve the ability to discriminate disease severity. 
The aim of this study was to compare four validated serum and ultrasound-based non-invasive 
markers of hepatic disease severity head-to-head: AST to platelet ratio index (APRI); Enhanced 
Liver Fibrosis (ELF) panel; transient elastography (TE) and ultrasound microbubble hepatic 
transit times (HTT). It was hypothesised that combining the markers in steps according to 
increasing cost and complexity would enable the relative contributions of each marker to be 
assessed. Regression analysis was performed to predict fibrosis stage and necro-inflammatory 
score in three-stage models and to establish the contribution of each marker. 
Sixty seven patients with biopsy-proven chronic hepatitis C were recruited prospectively into 
the study. ELF and TE predicted cirrhosis with a diagnostic accuracy of 91% and 90%, 
respectively, and mild from more severe disease with a diagnostic accuracy of 82% each. APRI 
predicted cirrhosis and mild disease with a diagnostic accuracy of 86% and 83% respectively, 
while HTT performed least well. Either ELF or TE combined with APRI significantly enhanced 
the prediction of fibrosis stage, but all three combined did not improve the model further. 
Conclusion: a combination of APRI with either ELF or TE effectively predicted fibrosis stage 
using a three-group model of fibrosis, but combinations of three or more tests led to redundancy 
of information. HTT did not enhance the combinations of other markers for the prediction of 
fibrosis. Large-scale cost-benefit analyses are required to evaluate further the additional benefit 
of marker combinations. 
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6.2 Introduction 
The development of effective biomarkers of the severity of chronic liver disease is of 
importance, both in clinical practice and for the development of novel antifibrotic therapies. The 
currently accepted reference standard, histological examination of liver biopsy, is hampered by 
sampling variability, the semi-quantitative nature of scoring systems, inter-observer variability 
and, importantly, the risk of discomfort, significant morbidity and a small but significant risk of 
death to the patient, as detailed in section 1.6.4. Patients with CHC are an appropriate cohort for 
the investigation of markers of chronic disease severity (section 1.4). 
The field of biomarker development for the assessment of disease severity and fibrosis in 
chronic liver disease is burgeoning and broadly comprises the development of serum markers, 
singly or in combination as serum panel markers and imaging-based technologies, including 
ultrasound and magnetic resonance techniques (section 1.7). 
Although fibrosis itself is a continuous process and histological scoring systems divide fibrosis 
into five or seven stages, statistical analysis of disease severity has relied on two (histological) 
class ("binary") analysis in many studies (such as cirrhosis or absence of cirrhosis, significant 
fibrosis or insignificant fibrosis), based on the commonly-expressed receiver operating 
characteristic (ROC) curve. Such analyses are expressed in readily understandable forms, such 
as sensitivity, specificity, positive predictive values and negative predictive values. These 
figures depend on the prevalence of the disease state in the population studied and, 
correspondingly, may be skewed by selection bias (Poynard et al, 2007). It is often important to 
distinguish between more than two histological groups to determine where an individual exists 
within a range of disease severity. 
Markers of varying cost and complexity are being developed with evidence of accuracy in a 
number of studies. However, for such markers to be adopted clinically, they should be cost-
effective, relatively easy to perform and acceptable to the patient. Combinations of serum 
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markers, including APRI, FibroTest and Forns Index (Leroy et al., 2007; Sebastiani et al., 2006) 
and serum markers (APRI and FibroTest) with transient elastography have been studied 
(Castera et ah, 2005). A combination of imaging-based and serum markers may provide the best 
assessment of liver disease severity, as the differing modalities assess different parameters, 
which in combination may reduce redundancy between tests. 
The APRI score is a simple derivative of routine blood markers: AST and the platelet count, 
validated in a number of chronic liver disease settings (Wai et al., 2003; Wai et al., 2006). It is 
easily calculated at the bedside and available globally. The Enhanced Liver Fibrosis (ELF) 
panel is a proprietary algorithm of extracellular matrix components (tissue inhibitor of matrix 
metal loproteinase 1 (TIMP-1), hyaluronic acid (HA) and the aminoterminal peptide of 
procollagenase 3 (PIIFNP)), which estimates fibrosis on the basis of intermediates of 
fibrogenesis (Rosenberg et al., 2004). Transient elastography (TE) is a marker of liver stiffness, 
which correlates with chronic liver disease severity, in terms of fibrosis stage (Castera et al., 
2005; Sandrin et al., 2003; Ziol et al., 2005), portal pressures (Kazemi et al., 2006; Vizzutti et 
al., 2007) and inflammation (Coco et al., 2007) in a number of disease settings (Corpechot et 
al., 2006; Ganne-Carrie et al., 2006) (section 1.7.3.4), Dynamic contrast-enhanced ultrasound to 
derive HTT has been shown to stratify chronic liver disease in patients with hepatitis C (Lim et 
al., 2005b; Lim et al., 2006; Ridolfi et ah, 2007) and in comparison to Child-Pugh score 
(Blomley et ah, 2003). The estimated costs for the use of these markers are tabulated in Table 
6-1, with a summary of the resources required to provide the service. 
Neither the ELF panel nor HTT has been compared head-to-head to other non-invasive markers 
in the setting of chronic hepatitis C. The difference in diagnostic performance of markers has 
not been clearly demarcated, with many markers performing similarly within and between 
studies. Accordingly, a pragmatic step-wise approach to employing such markers is to start with 
the cheaper, more widely-available, easy-to-perform tests, which are least inconvenient to the 
patient, then to add in further markers according to additional benefit, availability, cost and 
patient acceptability, as outlined in Table 6-1. 
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Table 6-1. Comparison of marker costs and complexity. 
Marker Cost / Capital Personel Notes 
event outlay 
APRI <£1 No Phlebotomy Routine laboratory tests 
Globally available 
ELF c. £180' No Phlebotomy and 1 UK-based laboratory, cost 
transport subject to contract 
TE c. £200° Yes Single operator, simple Real-time results. 
£54 000= training Time taken: c. 5min 
increasing availability globally 
HTT c. £60' Yes Two operators Real-time results. 
c. £100 000* required. Time taken: c. 20min 
- £200 000 One sonographer with May be performed as part of a 
specialist training routine abdominal ultrasound 
One assistant, for procedure 
cannulation and contrast Performed in a few specialist 
injection centres (UK, France, Australia, 
Japan) 
Costs are not directly comparable and do not include economies of scale. These figures are produced to 
support the combinations of markers used in this study and cannot be used as the basis for service or 
research costings. 
" ELF cost on "per sample" basis inclusive of VAT (September 2008). Costs may differ according to 
number of samples and potential discounts to the NHS andfor academic studies. 
''TE using FibroScan' quoted by the Liver Unit at St Mary's Hospital, Imperial College Healthcare Trust 
for a single procedure, inclusive of staffing time and overheads. 
'^Purchase cost for FibroScan'^ in the UK, from Artemis Medical Ltd, quoted September 2008 at an 
exchange rate of £1 to €L2, exclusive of VAT, inclusive of staff training, warranty and I year service 
contract. 
'^Cost of 1 vial of Sonovue to the Department of Radiology,Hammersmith Hospital, Imperial College 
Healthcare Trust, September 2008. Excludes staff and room time, hardware and interpretation of results. 
'^Estimated cost of Toshiba Aplio ultrasound machine from October 2005. The cost of ultrasound 
equipment varies widely. HTT requires "vascular recognition imaging" or similar software to be 
supported on the system used. 
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6.3 Aims 
The aims of this study were: 
a. To evaluate the diagnostic performance and reliability of APRI, ELF, TE and HTT 
head-to-head, compared to liver biopsy. 
b. To employ a statistical model of three histological groups for the assessment of 
accuracy. 
c. To assess the performance of these markers combined in a stepwise manner, based on 
cost and practicality of tests, and their individual contribution to each model. 
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6.4 Methods 
Ethical approval for the study was obtained from the regional ethics committee and the study 
was conducted in accordance with the Declaration of Helsinki. 67 patients with chronic hepatitis 
C were recruited prospectively from the Liver Unit at Imperial College Healthcare Trust from 
March 2006 to January 2008. All gave written, informed consent to participation in the study. 
Patients were included if they were aged 18-65 years, had undergone liver biopsy within one 
year of investigation and if they had evidence of ongoing viral replication on hepatitis C RNA 
testing. Patients were excluded if they consumed >20g of alcohol per day on average, if they 
were taking antiviral therapy, if they were co-infected with HIV or hepatitis B, or if they were 
currently taking intravenous drugs or antihypertensive medications. Patients were also excluded 
if they had renal impairment, evidence of ischaemic heart disease, congestive heart failure, 
malignancy, autoimmune, inflammatory or infectious illness including, but not limited to, 
rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis, diabetes mellitus, 
hyperthyroidism and tuberculosis. Patients were excluded if they had evidence of hepatic 
decompensation, defined by any of the following: jaundice, ascites, hepatic encephalopathy, or 
evidence of oesophageal or gastric varices on endoscopic examination. 
To assess the reliability of the markers, 26 patients attended for investigation on a second 
occasion, 7 days after the first investigation point. All 26 patients underwent all tests 
successfully on both occasions. 
6.4.1 Histology 
Percutaneous liver biopsy was obtained from all participants in the clinical setting and all 
samples were reassessed by a single, blinded hepatic histopathologist according to the modified 
histological activity index (Ishak et al., 1995). In this scoring system, fibrosis was assessed on a 
seven-point scale (0-6), with stages 5 and 6 considered to have cirrhosis. Disease activity or 
184 
necro-inflammation (inflammation) was assessed on a 19-point scale (0-18). Patients were 
excluded if their biopsy was shorter than 10mm. 
All patients underwent haematological, biochemical and virological investigations on the day of 
their participation in the study. An abdominal ultrasound scan was performed on all subjects to 
exclude biliary obstruction, presence of space-occupying lesions and to confirm normal 
hepatobiliary anatomy. 
6.4.2 Non-invasive markers 
All blood samples and imaging tests were obtained on the same visit and within 2hr of each 
other. Patients fasted overnight or for a minimum of 6hr prior to the investigations to reduce 
variation in hepatic and splanchnic flow, which could be attributed to digestion. 
6.4.2.1 APRI 
The APRI, as defined in Equation 6-A, was derived from routine clinical blood tests obtained 
at venepuncture (Wai et al., 2003). Each part of the index is divided by the upper limit of 
normal (ULN) for the measure in a particular laboratory. 
Equation 6-A 
APRI = 100 (AST/AST lULNl) 
Platelet count (xlO®) 
6.4.2.2 ELF 
Serum samples were obtained on the same occasion as other blood tests at venepuncture. 
Samples were collected in serum separator tubes and centrifuged at 3000rpm for 10 minutes, 
then stored at -80°C according to company instructions prior to processing by IQur Ltd (IQur, 
Southampton, UK). The output consisted of a numerical continuous variable for each sample. 
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6.4.2.3 Liver stiffness measurement 
Liver stiffness measurement was obtained by TE using FibroScan® (EchoSens, Paris, France) as 
previously described (Ziol et al., 2005). The operators were formally trained by the 
manufacturers and had performed at least 50 examinations by the start of the study. TE was 
considered valid if 10 measurements were obtained with a success rate of >60% and an 
interquartile range of values <30% of the median value. Patients with invalid scores were 
excluded from the head-to-head analysis. 
6.4.2.4 Hepatic transit times 
HTTs were performed using the microbubble contrast agent, SonoVue® (Bracco, Milan, Italy), 
based on the methods of previous studies (Lim et al., 2006; Searle et al., 2008). Briefly, a region 
of interest was selected containing hepatic artery and either the right or middle hepatic vein. A 
scanner-specific contrast agent software, vascular recognition imaging (Toshiba Medical 
Systems Europe, Zoetermeer, Netherlands) using ultralow acoustic power (mechanical index of 
0.6) was used. A 21-gauge cannula with a three-way tap was inserted into an antecubital fossa 
vein. The microbubble contrast agent was reconstituted in accordance with the manufacturer's 
instructions. A ImL rapid bolus of Sonovue®, followed by a 8mL normal saline flush were 
administered, as described previously (Lim et al., 2006). A timer was started at the beginning of 
the Sonovue® injection. The time of arrival of the contrast agent (defined as the first appearance 
of a definite increase in signal) in the hepatic artery (the hepatic artery arrival time) and then the 
hepatic vein (the hepatic vein arrival time) was recorded in real time by the operators, blinded to 
the patient details. The HTT was calculated as the hepatic artery arrival time subtracted from the 
hepafic vein arrival time. Clearance of the contrast agent from the circulation took 
approximately 5 minutes, after which the process was repeated. The recorded HTT was the 
mean of the two measures, in seconds. 
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6.4.3 Statistics 
SPSS v l6 (SPSS Inc. Chicago, USA.) was used for statistical modelling in collaboration with an 
experienced biomedical statistician (Dr Peter Colman, Pfizer UK Ltd., Sandwich, UK). Binary 
analysis was performed using receiver operator characteristic (ROC) curves, separating patients 
into two groups based on histological features (fibrosis stage or necro-inflammatory grade). The 
diagnostic accuracy was the area under the ROC (AUROC), expressed as a percentage. Cut-off 
values for each marker (or test) in the cohort were established where the sensitivity and 
specificity were maximal and corresponding positive and negative predictive values were 
calculated. 
Reliability was assessed using the intraclass correlation coefficient (ICC). The ICC was used to 
indicate how much variation in the dataset was found between the patients (random) compared 
to the variation between the visits (fixed). An ICC of >0.8 indicates that variation is 
predominantly between patients, with good agreement between visits, indicating a reliable test. 
An ICC of <0.4 indicates that the variation is predominantly inherent in the test. 
For the three-group analysis, a non-orthogonal, ordinal regression analysis was performed to 
identify the goodness-of-fit for each marker compared to the reference standard, histological 
assessment of liver biopsy (Norusis, 2008). This process was carried out to model marker 
performance against fibrosis stage and (necro)-inflammation. The fibrosis stage was divided 
into three groups: mild fibrosis (stages 0-2), moderate to severe fibrosis (stages 3-4) and 
cirrhosis (stages 5-6). Similarly, the necroinflammatory score was divided into mild (0-3), 
moderate (4-6) and severe inflammation (7+). The goodness-of-fit of the model was described 
by the deviance (chi-square) divided by the degrees of freedom, with a lower deviance denoting 
better fit for a given number of degrees of freedom. The accuracy of the models was denoted by 
the proportion of patients whose grouping was predicted correctly, and expressed as a 
percentage. The significance of the contribution of a marker to the model (combination) was 
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denoted by a p value and confidence intervals, with a p-value of <0.05 and confidence intervals 
not spanning zero denoting a significant contribution of that marker to the model. 
Combinations of markers were constructed as shown in Table 6-2 according to increasing cost 
and complexity as detailed in Table 6-1. The diagnostic accuracy and the significance of the 
relative contribution of each marker to the model were also assessed using the three-group 
ordinal regression analysis. The model was structured in a step-wise manner to determine the 
contributions of the markers assessed by limited forward selection and backwards elimination. 
Table 6-2. Marker combinations 
Model Tests included 
A 
Bi 
Bii 
C 
D 
APRI 
APRI + ELF 
APRI + I E 
APRI + ELF + TE 
APRI + ELF + TE + HTT 
Abbreviations: APRI, aspartate transaminase to platelet ratio index', ELF, the enhanced liver fibrosis 
panel, TE, transient elastography; HTT, hepatic transit time. 
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6.5 Results 
Initially, 80 subjects were recruited into the study. Antecubitai vein cannulation was not 
possible in five subjects (all of whom had a histoiy of intravenous drug use or self-harm), 
satisfactory liver stiffness measurement was not possible in five subjects (of whom two were 
obese and two were South Asian females with narrow intercostal spaces), three subjects had 
insufficient liver biopsy length (<10mm), leading to the exclusion of a total of 13 patients. The 
characteristics of the 67 patients included in the analysis are displayed in Table 6-3. The median 
length of time from liver biopsy to investigation was 4 months, and this did not vary 
significantly between groups (Kruskal-Wallis test, p=0.41). 
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Table 6-3. Pat ient characterist ics 
Total Mild f ibros i s Moderate f ibros i s Cirrhosis 
( s t a g e 0-2) ( s t a g e 3-4) ( s t a g e 5-6) 
Number 67 30 23 14 
M/F 44/23 18/12 17/6 9/5 
Age, years (range) 50 (19-65) 49.5 (19-63) 49.0 (27-65) 52.5 (38-65) 
BMI, kg/m^ 23.8 (5.2) 23.2 (4.9) 25.2 (6.9) 26.1 (4.3) 
Time, Bx to Ix, 4 ( 5 ) 5 ( 6 ) 4 ( 4 ) 4.5 (4.25) 
months 
Length Bx, mm 24 (17) 25(15.5) 23 (16.5) 25 (18.5) 
ALT, iu/L [0-40] 87.5 (93.5) 52.5 (79.5) 87.0 (82.0) 107(106) 
AST, iu/L [0-40] 58.0 (57.0) 37 .0 (31 .3 ) 67.0 (47.0) 103 (81.5) 
Platelets, x10®/L 214 (96.0) 242 (77.8) 206 (119) 177 (95.0) 
[130-450] 
Albumin, g/L [35-50] 4 2 ( 5 ) 42.5 (3) 4 1 ( 5 ) 39 (5.5) 
Total Bilirubin, 1 1 ( 8 ) 11 (9.25) 1 1 ( 6 ) 1 5 ( 7 ) 
pmol/L [0-20] 
Viral load, iu/L x10® 2.95(12.5) 3.00(12.1) 4.22 (13.1) 0.65(11.9) 
Values expressed as median (interquartile range) unless stated otherwise. Reference ranges of values are 
included in square brackets. Abbreviations: M, male-, F, female\ ALT, alanine aminotransferase', AST, 
aspartate aminotransferase', BMI, body mass index', Bx, biopsy, Ix, investigation. 
The output of each marker was compared to f ibrosis stage (in three groups) (Figure 6-1). There 
was a monotonic increase of median APRI , ELF and liver s t i f fness measurement with 
increasing f ibrosis stage, whi le there was a negative correlation between H T T and increasing 
f ibrosis stage. 
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Fibrosis staqe Fibrosis stage 
W 30.0 
W.12.0 
Fibrosis stage Fibrosis stage 
F i g u r e 6-1 . M a r k e r scores plotted by fibrosis s tage . 
Categories are mild fibrosis (Fl-2), moderate fibrosis (F3-4) and cirrhosis (F5-6). "Box and whisker" 
plots represent the median (horizontal line) and interquartile range (box) with the range of values up to 
1.5 times the IQR within the range of each of the bars for the four markers with increasing fibrosis stage. 
Outliers (* & °) are plotted individually beyond the bars. A: APRl', B: ELF\ C: TE\ D: HTT. 
Abbreviations: APRI, aspartate aminotransferase to platelet ratio index\ ELF, Enhanced Liver Fibrosis 
panel, TE, transient elastography, HTT, hepatic transit time. 
R O C curves fo r each test fo r the d iagnos is o f c i r rhosis and modera t e to severe f ibros is 
demons t r a t e s imilar d iagnos t ic p e r f o r m a n c e fo r E L F and T E fo r the d iagnos is o f c i r rhosis and of 
A P R I , E L F and T E fo r the predict ion of modera t e and more severe f ibrosis , compared to mild 
d i sease (F igure 6-2). 
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Figure 6-2. ROC curves show the diagnostic accuracy of each marker. 
Panel A represents the diagnosis of cirrhosis (stage 5-6) and B, the diagnosis of fibrosis stage >2 
(moderate to severe fibrosis). Corresponding AUCs and confidence intervals are displayed in Table 6-4. 
Abbreviations: APRI, aspartate aminotransferase to platelet ratio index', ELF, Enhanced Liver Fibrosis 
panel, TE, transient elastography, HTT, hepatic transit time. Diagonal lines represent ties. 
The diagnostic accuracy, derived from the AUROC, with 95% confidence intervals, sensitivity, 
specificity, positive predictive value and negative predictive value for the markers in this cohort 
are displayed in Table 6-4. ELF and TE both demonstrated high diagnostic accuracy for the 
prediction of cirrhosis. When using the optimal cut-off for each test, ELF demonstrated higher 
sensitivity and TE, higher specificity. Using these cut-off points, the negative predictive value 
was high; from 92% for HTT to 98% for ELF. However, the relatively small number of patients 
with cirrhosis contributed to relatively low positive predictive values (ranging from 50-67%). 
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Table 6-4. Diagnostic accuracy of tests. 
Total n=67 APRI ELF TE HTT 
Cirrhosis 
(stage >4), n=14 
AUC 0.86 0.91 0.90 0.83 
95% CI 0.75-0.97 0.82-1.00 0.81-0.99 0.69-0.97 
Cut-off 0.92 9.4 10.0 8.0 
Se(%^ 86 93 79 71 
Sp(%0 77 79 87 91 
PPV (%) 50 54 61 67 
NPV (%) 95 98 94 92 
Moderate-
severe 
(stage >2), n=37 
AUC 0.83 0.82 0.82 0.71 
95% CI 0.73-0.93 0.73-0.92 0.71-0.92 0.59-0.84 
Cut-off 0.66 8.75 8.0 10.25 
Se(%^ 83 84 90 53 
Sp(%4 78 70 65 73 
PPV (%) 76 78 68 62 
NPV (%) 85 78 89 66 
Cirrhosis is defined as Ishak fibrosis stage 5-6 compared to stage <J, with positive state being cirrhosis. 
Moderate to severe fibrosis is defined as Ishak fibrosis stage >2 compared to stage 1-2, where the 
positive state is stage >2. Cut-off values were derived from the ROC curves, where the sum of the 
sensitivity and specificity was maximal. Abbreviations: AUC, area under (the receiver operating 
characteristic) curve', APRI, aspartate aminotransferase to platelet ratio index', ELF, the enhanced liver 
fibrosis panel', TE, transient elastography, HTT, hepatic transit time', F, fibrosis stage', A UC, area under 
the curve', CI, confidence interval', Se, sensitivity, Sp, specificity, PPV, positive predictive value', NPV, 
negative predictive value. 
Reliability was assessed using the intraclass correlation coefficient on 26 patients, who were 
assessed on two occasions, separated (Table 6-5). This showed that ELF and TE were the most 
reliable tests with an ICC of 0.94 apiece, demonstrating that the variability in the dataset was 
much greater between patients than between visits. HTT was least reliable; ICC, 0.80. 
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Table 6-5. Reliability of markers 
ICC 95% CI 
APRI 0.91 0.81-0.96 
ELF 0.94 0.88-0.97 
TE 0.94 0.87-0.97 
HIT 0.80 0.61-0.91 
Abbreviations: APRI, aspartate aminotransferase to platelet ratio index', ELF, the enhanced liver fibrosis 
panel, TE, transient elastography; HTT, hepatic transit time. 
Each marker was applied to three-group models of disease severity; the goodness of fit, 
accuracy and significance are displayed in Table 6-6. This demonstrated that each test was a 
highly significant predictor of fibrosis and that while ELF demonstrated the highest goodness-
of-fit, TE showed the highest diagnostic accuracy for the prediction of fibrosis. ELF was the 
strongest predictor of necro-inflammation, while TE did not significantly predict necro-
inflammation. The accuracy of all marker combinations for assessment of necro-inflammation 
was substantially lower than those of fibrosis. 
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Table 6-6. Individual marker performance assessed using a three-group analysis 
Marker Goodness-
of-fit 
Accuracy % Estimate 95% CI Significance 
(P=) 
Fibrosis 
APRI 0.84 64.2 2.45 1.30-3.60 <0.0005 
ELF 0,77 65.7 133 0.81-1.85 <0.0005 
TE 0.80 68.7 0.28 0.14-0.41 <0.0005 
HTT 0.90 522 -0.50 -0.75- -0.25 <0.0005 
Inflammation 
APRI 1.04 49 3 0.68 0.14-1.22 0.014 
ELF 1.02 53.7 0.53 0.19-0.88 0.003 
TE 1.04 35 8 0.05 -0.005-0.11 0.075 
HTT 1.30 4&3 -0.24 -0.44- -0.036 0.021 
Goodness of fit was calculated as the deviance divided by the number of degrees of freedom. Accuracy is 
the predicted class divided by the actual class, expressed as a percentage. Abbreviations: APRl, aspartate 
aminotransferase to platelet ratio index; ELF, the enhanced liver fibrosis panel; TE, transient 
elastography; HTT, hepatic transit time. 
The results of the step-wise ordinal regression analysis are displayed in Table 6-7. Both ELF 
and TE contributed significantly to two-test combinations (Bi and Bii), which included the 
APRI score, with an accuracy of 70% for the prediction of fibrosis stage within a three-stage 
scale. A three-test combination (C) increased the goodness-of-fit and accuracy, although the 
individual tests were not independently significant contributors to the model. For the prediction 
of necro-inflammation, ELF was a significant contributor to combinations C and D, with the 
optimal accuracy 61% for model C. 
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Table 6-7. P e r f o r m a n c e of marker combinat ions assessed using a three-group analysis 
Model Goodness- Accuracy APRI ELF T E HTT 
of-fit (%) p= p= p= p= 
Fibrosis 
A 0.84 64.2 <0 .0005 
Bi 0.75 70.1 0.045 0.002 
Bii 0.76 70.1 0.018 0.006 
C 0.74 73.1 0.079 0.095 0.203 
D 0.74 74.6 0.089 0.151 0.251 0.456 
Necro-
inflammation 
A 1.04 49.3 0 .014 
Bi 1.02 53.7 0.509 0.058 
Bii 1.05 49.3 0.071 0.932 
C 1.00 61.2 0.196 0.010 0.081 
D 1.00 53.7 0.179 0.026 0.065 0.356 
Marker performance tabulated according to goodness-offit and accuracy of marker combinations in 
predicting three-group models of fibrosis and necro-inflammation. Figures in bold type are statistically 
significant. Abbreviations: APRI, aspartate aminotransferase to platelet ratio index, ELF, the enhanced 
liver fibrosis panel, TE, transient elastography; HTT, hepatic transit time. 
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6,6 Discussion 
6.6.1 Novel findings 
This is the first study to compare the diagnostic performance of ELF and HTT with other 
markers of the severity of chronic liver disease and with each other. For the diagnosis of 
cirrhosis, ELF performed as well as TE, and better than APRI. ELF performed as well as both 
TE and APRI for the diagnosis of moderate to severe fibrosis. The diagnostic accuracy for HTT 
was substantially lower than that of the other three markers. In addition, HTT did not contribute 
significantly to the marker combinations for either fibrosis or inflammation, despite the modest 
increase in accuracy. HTT was also the least reliable test, with an ICC of 0.8 (compared to 
reliability in excess of 90% for the other markers). 
This is also the first study to combine markers explicitly on the basis of cost and practicality. As 
increasing numbers of biomarkers have been shown to predict liver disease severity, such 
considerations will help to determine which markers enter clinical practice or are employed in 
clinical trials. 
The novel three-group ordinal regression analysis enabled the interactions between markers to 
be investigated in combinations on the basis of increasing cost and complexity. A single cheap 
test, the APRI score, correctly predicted 92% of those correctly predicted by a two-test model 
including either ELF or TE and 88% of those correctly predicted by a three-test model including 
both TE and ELF. 
Scrutiny of the multi-marker models allowed an assessment of the interplay between tests when 
predicting the histological stage. When a component of the combination was significant, its 
removal from the model significantly altered the goodness-of-fit of that particular model; those 
tests were considered complementary. If there was no significant change on removal of a test, it 
was considered redundant. For example, both ELF and TE significantly enhanced a two-test 
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model of fibrosis containing the APRI score, while neither ELF nor TE contributed significantly 
to the three-test model provided by the other two tests (Table 6-7). This does not imply that 
either test is not a predictor of fibrosis, but that its inclusion in that model did not provide 
additional information to the other tests; that is, there was a degree of redundancy. 
As this was a head-to-head analysis without missing data, systematic bias between tests was 
minimised. The tight exclusion criteria and well-matched patient groups minimise potentially 
confounding factors. The analysis approach enables the contribution of each test to the 
accumulated combinations to be quantified. 
6.6.2 Results in context of previous studies 
The diagnostic accuracy achieved by the tests, derived from ROC curves for the diagnosis of 
cirrhosis from less severe fibrosis, was comparable to that found previous studies using TE 
and/or APRI. The diagnostic accuracy for the separation of mild from more severe fibrosis 
exceeded 80% for APRI score, ELF panel and TE, but only just exceeded 70% for HTT 
(Castera et al., 2005; Parkes et al., 2006a; Parkes et al, 2006b; Shaheen and Myers, 2007). 
Demonstration of similarity in results, using conventional analysis of markers that have been 
studied previously, validates the cohort used in this study and suggests that the novel findings 
would be reproducible if extended to other cohorts. The use of conventional analysis also 
provides a context for the assessment of marker combinations using ordinal regression. 
Previous publications have proposed algorithms where agreement or concordance between tests 
of similar diagnostic accuracy lent confidence to the interpretation of a binary result and 
proposed the avoidance of diagnostic liver biopsy. Where results were discordant, biopsy was 
proposed (Castera et al., 2005). By contrast, this current study provides evidence on whether 
tests are complementary or redundant. This may enhance the building of optimal combinations 
of tests. Furthermore, if tests are complementary, agreement will reflect the disease state. If tests 
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are redundant, agreement may simply reflect that the tests are measuring a similar parameter, 
which may or may not be closely related to the disease state or reference standard. 
The performance of HTT should be discussed in the context of previous studies using the 
technique. An earlier study using microbubble ultrasound on a cohort of patients with chronic 
hepatitis C demonstrated apparently excellent separation of histologically-classified disease 
severity groups (Lim et al, 2005b). However, there were a number of differences between that 
study and the current study. Firstly, the previous studies compared groups stratified by a 
combination of fibrosis stage and necroinfiammatory score. The inflammatory component 
increased the separation of groups. Therefore, this was not strictly a study to predict liver 
fibrosis and the results were not readily comparable to analyses of other markers, as both 
classification and statistical methods differed from those used by other groups. Secondly, the 
previous study used an older-generation microbubble contrast agent, Levovist, which had a 
slower transit time than Sonovue®, used in the current study (Lim et al., 2006). Mechanisms for 
the differences in transit times between agents have not been established, but microbubble size, 
homogeneity, durability and potential microbubble surfactant-to-endothelial interaction 
("stickiness") all differ between agents. These factors may influence the pharmacokinetics of 
the agent, leading to differences in microbubble tropism (Lim et al., 2004). Thirdly, the newer 
ultrasound hardware and vascular recognition software have resulted in increased image 
sensitivity. Fourthly, the HTT calculation used in the current study (section 6.4.2.4) differs from 
the H F I T , used historically in the publications by Lim and colleagues, in which the time from 
microbubble injection to appearance in the hepatic vein was used. The current calculation, used 
at Imperial College London and elsewhere, has evolved with the changes listed above (Searle et 
al., 2008). 
6.6.3 Validity of the patient cohort 
Biopsy criteria in many centres lead to the under-representation of patients with mild disease, 
where histology is the reference standard compared to the patient population as a whole. 
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Moreover, a significant minority of patients with normal transaminase tests, who are less likely 
to undergo biopsy, are found to have a substantial degree of fibrosis (Sebastiani et al, 2008). 
Patients with clinically overt or decompenated cirrhosis of known aetiology do not usually 
require biopsy for clinical purposes, so the full spectrum of diseases is unlikely to have been 
fully represented. This selection bias may be present in the current study population, potentially 
affecting ROC curves and values of sensitivity, specificity, positive predictive value and 
negative predictive value (Poynard et al., 2007). However, the ordinal regression model 
presented is robust to such effects, since strict cut-off values are not used and assumptions about 
disease state prevalence are not used. Moreover, as pointed out in section 6.6.2, the results for 
individual markers are similar to previous publications. This raises the possibility that other 
studies may be similarly biased. 
6.6.4 The contribution of inf lammation to markers of fibrosis 
It has been shown previously that inflammation increases liver stiffness (section 1.7.3.5). 
Furthermore, APRI is likely to be affected by inflammation on account of the hepatitic AST 
component. Indeed, the ordinal regression analysis for each individual marker demonstrates that 
ELF is the most significant predictor of inflammation, with APRI and HTT also proving to be 
significant predictors. The predictive ability of TE for the assessment of inflammation was not 
significant in this cohort, although a number of studies have shown that inflammation 
profoundly affects liver stiffness in cohorts of patients where inflammation is the predominant 
pathology (Arena et al., 2008; Coco et al., 2007; Sagir et al., 2008). Although there was a 
significant correlation between fibrosis score and NI score in this cohort of patients (Spearman; 
r=0.3, p=0.018), these findings suggest that all markers of fibrosis are likely to be influenced by 
inflammation. Thus, the presence of co-existent inflammation must always be considered when 
predicting fibrosis stage from biomarker scores. 
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6.6.5 Practicality of markers 
Practical differences between markers, including cost, staffing and technique availability are 
highlighted in Table 6-1. Where the diagnostic performance of markers is equivalent, such 
considerations may influence their future use clinically and in the research setting. APRI is 
clearly cheap, simple and would not require further samples in addition to those used for routine 
clinical purposes. TE is quick, simple, effective and provides real-time information, requiring a 
single operator. It is easily applied if the relatively expensive hardware is in place. ELF is easy 
to acquire, but expensive on a sample-by-sample basis. HTT involves ongoing costs for 
consumables (microbubbles) and requires the availability of high specification ultrasound 
hardware, specialist software and two operators. However, HTT may be performed at the time 
of abdominal ultrasound examination, which is a part of routine assessment of patients with 
chronic liver disease, thus reducing the additional costs. Examination of the dynamic 
enhancement of the hepatic parenchyma increases the detection of hepatocellular carcinoma 
(Leen et al, 2006; Quaia et al., 2004), which is a major complication in patients with cirrhosis, 
but is also seen in pre-cirrhotic disease, particularly in patients with chronic hepatitis B virus 
infection. Such a technique may, therefore, be an appropriate addition to APRI in those without 
access to TE or ELF markers, and in cohorts of patients where imaging of the liver is required, 
particularly where there is an increased risk of hepatic malignancy. 
6.6.6 Limitations and solutions 
The most prominent limitation of this study was the use of liver biopsy with inherent sampling 
variability (Regev et al., 2002), itself a surrogate marker of disease, as a reference standard. 
Sampling variability was minimised by the exclusion of samples <10mm in length. Inter-
observer variability was minimised by the review of all biopsy specimens by an experienced 
hepatic histopathologist. There was a delay from biopsy to investigation of 4 months in this 
cohort. However, there was no difference in delay between groups. In addition, studies have 
demonstrated that in chronic hepatitis C, it is unlikely for a significant change in fibrosis stage 
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to be observed within 3-5 years (Marcellin et al., 2002; Poynard et al., 1997; Wright et al., 
2003). The necroinflammatory score may indeed change over a number of months, but as there 
was no difference in delay between groups, such changes apply to all the tests evaluated. 
However, such short term inflammatory changes may result in an underestimation of marker 
performance for the prediction of inflammation in this study. In ideal circumstances, however, 
only biopsies in excess of 20mm, with 11 or more complete portal tracts would be used, and 
biopsies would be perfonned on the day of investigation. However, given current clinical 
circumstances, such a recruitment strategy would have resulted in smaller numbers of subjects 
included in the study. Analysis of histology might also be performed by two blinded 
histopathologists independently, but these resources were unavailable for the purposes of this 
study. 
This study was limited by a relatively small number of patients included in the analysis. Patients 
with decompensated cirrhosis were excluded from the study and patients with established 
cirrhosis of known aetiology may not require liver biopsy, as the diagnosis may be made 
clinically. Accordingly, the pool of patients with cirrhosis who were eligible for inclusion in the 
study may not represent the full spectrum of disease. Of those with mild disease, there may be 
patients without deranged liver function tests in whom hepatitis C is either not diagnosed or in 
whom a liver biopsy is not considered a clinical priority. Therefore, care should be taken when 
extrapolating the results of this study to the wider population. In addition, for these reasons, the 
creation of clinical algorithms was not considered appropriate. 
6.6.7 Future studies 
This study has examined marker performance in a cohort of patients with chronic hepatitis C. 
For these results to be generalisable to chronic liver disease as a whole, their performance 
should be assessed for the prediction of disease severity in other disease cohorts, including 
chronic HBV infection, alcoholic liver disease and NAFLD. While this study provides novel 
information about the relative diagnostic performance of four markers, singly and in 
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combination, a formal cost-benefit analysis would allow further appraisal of these tests for 
widespread incorporation into clinical usage. Cost-benefit analysis would require estimation of 
clinical events saved by the use of non-invasive tests and should incorporate economies of scale. 
Such data were unavailable for this study. Consideration should also be made of potential access 
to hardware, appropriately-trained personnel or external laboratory services. Attempts to predict 
clinically-important endpoints prospectively using marker combinations are warranted. A 
longitudinal study assessing the change in these markers in response to antiviral treatment with 
pegylated interferon and ribavirin in a cohort of patients with chronic hepatitis C is underway 
and results are awaited. 
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6.7 Conclusions 
To conclude, this impartial head-to-head analysis of the diagnostic performance of two serum 
and two imaging-based markers of fibrosis shows that ELF and TE have a high diagnostic 
accuracy for the prediction of fibrosis, and that HTT performs less well than the other tests. A 
combination of APRI with either ELF or TE effectively predicts fibrosis stage using a three-
group model of fibrosis, but that, in combinations of three or more tests leads to redundancy of 
information. This study may provide a basis for future clinically-based cost-benefit analyses to 
assess optimal combinations of markers. 
Finally, the work presented in this chapter has defined analysis techniques, which will enable 
the effectiveness of candidate markers (such as those conveyed by 'H MRS) to be assessed by 
comparison with the most effective biomarkers of liver disease severity in CHC in the next 
chapter. 
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7 H MRS IN THE CONTEXT OF OTHER NON-INVASIVE 
TECHNIQUES 
7.1 Abstract 
In preceding chapters, 'H MRS for the assessment of chronic liver disease has been developed 
in vitro and applied to patients with CHC in vivo. MR indices of lipid composition and choline 
have been shown to correlate with disease severity. In Chapter 6, two imaging-based markers 
and two serum markers were assessed head-to-head and in combination to determine their 
relative performance and the interactions between them. The purpose of this chapter was to 
evaluate the performance of MR indices derived and validated in preceding chapters for the 
assessment of disease severity in CHC, compared to established biomarkers validated in this 
thesis and elsewhere. 
38 patients with biopsy-proven chronic hepatitis C were recruited into the study. All patients 
had 'H MRS, TE and APRI. The MR indices used were the polyunsaturation index (PUI) and 
the total choline to lipid ratio (CLR). In binary analyses, PUI and CLR predicted cirrhosis with a 
diagnostic accuracy of 83% and 76% and mild from more severe disease with a diagnostic 
accuracy of 77% and 79% respectively. The accuracy for the prediction of cirrhosis was less 
than that of TE but similar to that of APRI. For the separation of mild from more severe disease, 
the accuracy was less than that of either APRI or TE. Using ordinal regression, either PUI or 
CLR significantly contributed to the prediction of fibrosis stage when combined with APRI. 
When combined with both APRI and TE, PUI or CLR significantly contributed to the model, 
where TE did not make a significant contribution. 
Conclusion: the MR indices predicted fibrosis with less accuracy in this study than leading 
markers currently available. Combination of these indices with APRI improved the model, but 
combination with APRI and TE led to redundancy of information from TE. 
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7.2 Introduction 
In preceding chapters, 'H MRS for the assessment of chronic liver disease has been developed 
in vitro and applied to patients with chronic hepatitis C in vivo. MR indices have been derived 
on the basis of pattern-recognition analysis of MR spectra of intact liver tissue and from the 
literature (sections 4.4.2.1 and 4.5.1). These indices have been shown to correlate with disease 
severity in patients with chronic hepatitis C. In Chapter 6, two imaging-based markers (HTT 
and TE) and two serum markers (APRI and ELF) were assessed head-to-head, and in 
combination, to determine their relative performance and the interactions between them. 
Individually, TE or ELF performed best for the prediction of histological fibrosis stage, while 
combination with APRI improved the performance of each. The aim of this chapter was to 
evaluate the performance of these MR indices for the assessment of disease severity in chronic 
hepatitis C, compared to APRI and TE. 
Two 'H MRS indices were selected. The PUI is an MR-detectable measure of fatty acid 
polyunsaturation within the region of interest. As discussed in section 4,5.1, reduced 
polyunsaturation is associated with increasing severity of fibrosis and increased hepatic 
steatosis. Polyunsaturated fatty acids are protective against oxidative stress and are consumed 
by lipid peroxidation. Tissue environments subject to oxidative stress are associated with 
cellular damage, inflammation and scarring or fibrosis (section 1.5.3). As such, PUI might be 
considered a surrogate marker of disease severity, providing an insight into pathogenically-
relevant processes not assessed by current non-invasive markers. The choline to lipid ratio 
(CLR) was established from the regression vector of the partial least squares discriminant 
analysis (PLS-DA) of in vitro MRS resonances, which were most associated with increased 
severity of fibrosis (section 4.4.2.1, Table 4-2). Biologically, the total choline resonance 
consists of the functional group comprising a number of choline-related compounds, including 
choline, phosphocholine, glycerophosphocholine, phosphatidylcholine, TMAO and betaine. The 
resolution of 'H MRS in vivo is insufficient to observe each constituent, but the choline region 
itself is likely to be related to membrane metabolism and cell-turnover (Katz-Brull et al., 2002; 
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Ruiz-Cabello and Cohen, 1992; Taylor-Robinson et al., 1995). Like liver stiffness measurement, 
such a marker is a blunt correlate of disease, of which the contributing factors are not clearly 
delineated. Although PUI has been observed in the context of hepatic steatosis, neither PUI nor 
CLR has previously been applied to chronic fibrotic liver disease, or compared to other markers 
of disease severity. 
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7.3 Materials and methods 
7.3.1 Patients 
Ethical approval for the study was obtained from the regional ethics committee and the study 
was conducted in accordance with the Declaration of Helsinki. A total of 85 patients with 
chronic hepatitis C were recruited prospectively from the Liver Unit at Imperial College 
Healthcare Trust from March 2006 to January 2008. The patient cohorts for the analyses 
described in Chapters 5-7 were all taken from this total. All gave written, informed consent to 
participation in the study. The inclusion and exclusion criteria are specified in sections 5.5.1 
and 6.4. 'H MRS was performed on a subset of these patients (n=59). In order to maximise the 
number of patients eligible for inclusion in the study and to include a range of modalities, APRI 
and TE were chosen for comparison to the MR indices. Of these patients, 38 had satisfactory 
PUI, CLR, APRI and TE measurements, so were included in this analysis. 
7.3.2 Histology 
Percutaneous liver biopsy was obtained from all participants in the clinical setting and all 
samples were reassessed by a single, blinded hepatic histopathologist according to the modified 
histological activity index (Ishak et al., 1995), as described in section 1.6.3.1. Patients were 
excluded if their biopsy was shorter than 10mm. All patients underwent venesection on the day 
of 'H MRS examination. 
7.3.3 Non-invasive markers 
All blood samples and imaging tests were obtained on the same visit and within 2hr of each 
other. Patients fasted overnight or for a minimum of 6hr prior to the investigations. 
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7.3.3.] .dLPJ&r 
The APRI was defined as described previously and derived from routine clinical blood tests 
(section 6.4.2.1). 
7.3.3.2 Liver stiffness measurement 
Liver stiffness measurement was obtained by TE as previously described (Ziol et al., 2005). 
Criteria for satisfactory measurements are described in section 6.4.2.3. 
7.3.4 Statistics 
SPSS vI6 (SPSS Inc. Chicago, USA.) was used for statistical modelling. The statistical 
techniques used were described in section 6.4.3. As both the PUI and CLR included the total 
MR-visible lipid resonances as the denominator, they were not analysed in combination. All 
other combinations of the markers tested were considered. Correction for multiple comparisons 
was not performed as the markers used in this chapter have been shown to be correlated to each 
other in Chapters 5 and 6. 
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7.4 Results 
The patient characteristics of the cohort are displayed in Table 7-1. The distribution of patients 
according to fibrosis stage is skewed towards mild disease. The median biopsy length was 
26mm, ranging from 12mm to 49mm, representing adequate sample size. The ALT and AST 
increase with severity of disease, and platelets and cholesterol are lower in the cirrhosis than the 
mild category, which is consistent with clinical experience. 
Table 7-1. Patient characteristics 
Total Mild f ibrosis 
(stages 1-2) 
Moderate f ibros is 
(stages 3-4) 
Cir rhosis 
(stages 5-6) 
Number 38 19 13 6 
Sex M/F 21/17 11/8 8/5 2/4 
Age, years 49 (19-65) 50 (19-63) 48 (27-60) 52 (39-65) 
(range) 
Bx length, mm 26.0 29.0 21.5 28.0 
(range) (12.0-49.0) (13.0-48.0) (12.0-49.0) (15.0-38.0) 
BMI, kg/m^ 23.0 (4.7) 22.5 (4.44) 24.9 (8.22) 25.1 (4.49) 
ALT, iu/L [0-40] 73.0 (106.0) 50.0 (58.0) 101.0 (92.5) 160.0 (197.5) 
AST, iu/L [0-40] 58.5 (60.5) 36.0 (29.0) 80.0 (48.5) 114.5 (143.0) 
Platelets, x10®/L 208.0 (98.0) 210.0 (76.0) 170.0 (117.5) 172.0(93.5) 
[130-450] 
tChol , mmol /L 4.33 (1.26) 4.50 (1.08) 4.68 (1.56) 3.55(1.21) 
TG, mmol /L 0.95 (0.61) 0.91 (0.64) 0.96 (0.63) 1.00 (0.20) 
Values expressed as median (interquartile range) unless stated otherwise. Reference ranges of values are 
included in square brackets. Abbreviations: M, male', F, female', ALT, alanine aminotransferase', AST, 
aspartate aminotransferase', BMI, body mass index', Bx, biopsy, Ix, investigation', tChol, total cholesterol', 
TGs, triglycerides 
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The indices were plotted by severity of fibrosis in Figure 7-1, demonstrating that the trends of 
APRI and TE to increase with disease severity in this subset were similar to that of the larger, 
overlapping cohort in Chapter 6 (Figure 6-1). PUI and CLR both decreased with increasing 
disease severity, as described for the "parent" cohort in Chapter 5 (Figure 5-3). 
(A 30.0 
£V 3.00 
o: 3)0 
Fibrosis stage 
3^  
Fibrosis stage 
Figure 7-1. Marker scores plotted against fibrosis stage. 
"Box and whisker" plots represent the median (horizontal line) and interquartile range (box) with the 
range of values up to 1.5 times the IQR within the range of each of the bars, for the four markers with 
increasing fibrosis stage. Outliers are plotted individually beyond the ba?-s. A: APRI; B: TE\ C: PUl\ D: 
CLR. Abbreviations: APRI, aspartate aminotransferase to platelet ratio index; TE, transient 
elastography; PUI, polyunsaturation index; CLR, total choline to lipid ratio. 
The ROC curves in Figure 7-2 show graphically that, for the diagnosis of cirrhosis, TE 
outperformed the other markers, which performed similarly to each other in this cohort. For the 
diagnosis of moderate to severe disease, both APRI and TE had a higher AUROC than the MR 
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indices. Using cut-off values derived f rom the R O C curves, optimal sensitivity, specificity, PPV 
and N P V are displayed for this cohort in Table 7-2. As the number of patients in the cirrhosis 
group was small in this cohort , the PPV for cirrhosis was low for all tests. 
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Figure 7-2. R O C curves show the diagnostic accuracy of each marker . 
Panel A shows ROC curves for the diagnosis of cirrhosis (stage 5-6) and B) the diagnosis of fibrosis 
stage >2 (moderate to severe fibrosis). Corresponding AUCs and confidence intervals are displayed in 
Table 7-2. Abbreviations: APRI, aspartate aminotransferase to platelet ratio index', TE, transient 
elastography, PUI, polyunsaturation index', CLR, total choline to lipid ratio. Diagonal lines represent 
ties. 
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Table 7-2. Diagnostic accuracy of tests 
Total n=38 APRl TE PUI CLR 
Cirrhosis (stage >4), 
n=6 
AUC 0.82 0.94 0.83 0.76 
95% CI 0.63-1.00 0.87-1.00 0.68-0.98 0.60-0.92 
Cut-off 0.92 9.0 0.19 5.1 
Se(%^ 83 100 83 83 
Sp(%0 72 84 72 69 
PPV (%) 36 55 36 33 
NPV (%) 96 100 96 96 
Moderate-severe 
(stage >2), n=19 
AUC 0.88 0.86 0.77 0.79 
95% CI 0.77-1.00 0.73-0.98 0.62-0.92 0.64-0.94 
Cut-off 0.65 6.2 0.24 7.0 
Se(%^ 84 84 74 74 
Sp(%0 84 84 68 68 
PPV (%) 84 84 70 70 
NPV (%) 84 84 72 72 
Abbreviations: APRl, aspartate aminotransferase to platelet ratio', TE, transient elastography, PUI, 
polyunsaturation index', CLR, total choline to lipid ratio', AUC, area under the curve', CI, confidence 
interval', Se, sensitivity, Sp, specificity, PPV, positive predictive value', NPV, negative predictive value. 
The ordinal regression showed the correct prediction of one of three fibrosis severity categories, 
using the markers singly and in combination. When looking at all three cateogories, the APRI 
performed best in terms of the lowest figure for goodness-of-fit, and the highest number of 
patients with the fibrosis category correctly predicted (Table 7-3). These figures are comparable 
to those displayed in Table 6-6, demonstrating that this cohort is representative of the larger 
patient cohort in Chapter 6. 
In combination, it can be seen that, although the goodness-of-fit improved with the addition of 
successive markers, the diagnostic accuracy was optimal with a combination of APRl and TE or 
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PUl. PUI and CLR contributed significantly to the marker models, suggesting that in these 
cases, the markers were complementary. The addition of TE to combinations which included 
APRl and one of the MR indices did not significantly enhance the model, so this information 
may be considered redundant. 
Table 7-3. Ordinal regression of Individual markers for the prediction of fibrosis 
Marker Goodness of Accuracy Regression 95% CI Signi f icance 
f i t % Estimate (p= ) 
APRl 0.79 71.1 2.00 0.77-3.23 0.002 
TE 0,85 63.2 0.24 0.08-0.39 0.003 
PUI 0.87 55.3 -2.18 -4.00--0.36 0.019 
CLR 0.87 63.2 -0.19 -0.31--0.06 0.004 
The model is based on three fibrosis categories: mild (stages 0-2), moderate (stages 3-4) and cirrhosis (5-
6). Abbreviations: CI, confidence interval, APRl, apsartate aminotransferase to platelet ratio index", TE, 
transient elastography; PUl, polyunsaturation index', CLR, total choline to lipid ratio 
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Table 7-4. Diagnost ic per formance of combinat ions of markers 
Model Goodness- Accuracy APRl TE PUI CLR 
of-fit (%) p values p values p values p values 
APRl 0.79 71.1 0.002 
APRI+TE 0.72 73.7 0.022 0.040 
APRI+PUl 0.68 7 3 7 0 .003 0 .043 
APRI+CLR 0.68 71.1 0.005 0.011 
TE+PUl 0.70 68.4 0.010 0.094 
TE+CLR 0.69 71.1 0.008 0 .015 
APRI+TE+PUl 0.59 73 7 0 .012 0.052 0.023 
APRI+TE+CLR 0.64 73.7 0.045 0.071 0.018 
Ordinal regression of combinations of markers for the prediction of fibrosis severity. Fibrosis categories 
are mild (stages 0-2), moderate (stages 3-4) and cirrhosis (5-6). Abbreviations: CI, confidence interval', 
APRl, aspartate aminotransferase to platelet ratio index', TE, transient elastography; PUI, 
polyunsaturation index', CLR, total choline to lipid ratio. 
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7.5 Discussion 
When considered as surrogate markers of fibrosis, both PUI and CLR have been shown to 
predict fibrosis category with moderate accuracy in this cohort. Moreover, in combination with 
a simple blood test, APRI, they enhanced the diagnostic accuracy further. Individually, 
however, they performed less well than either APRI or TE. However, it must be stressed that 
fibrosis is a pathologically-defined lesion, indicative of chronic liver injury and prognostically-
related to risk of end-stage liver disease. Fibrosis, despite being undeniably relevant to chronic 
liver disease cannot be considered to define chronic liver disease entirely, as it is in itself a 
surrogate marker of liver disease. Aetiology, host-factors and other pathological lesions are all 
relevant to the natural history of liver disease and to the probability of response to treatment. 
Alternative biologically-relevant indices are required to provide a global assessment. The non-
invasive assessment of hepatic lipid composition is one such aspect. Of the 'H MRS indices 
assessed in this chapter, the PUI was selected as lipid polyunsaturation was hypothesised to be 
an important biological factor in chronic liver disease. CLR was selected as, on multivariate 
pattern recognition using PLS-DA, the choline and lipid resonances were found to be prominent 
predictors of disease severity in liver biopsy samples (Chapter 4). 
The utility of new technologies in clinical practice depends not only on diagnostic performance, 
but also on cost effectiveness and practicality. These issues have been addressed for the 
ultrasound and serum markers in Table 6-1 and section 6.6.5. For comparison, 'H MRS is more 
expensive and time-consuming than either of APRI or TE; MR scans for academic research at 
the Robert Steiner MR Unit, Hammersmith Hospital Campus, London, UK were charged at 
£450 per patient study (2005-2008). On the evidence from this cohort, neither PUI nor CLR can 
be recommended as markers of fibrosis for routine clinical purposes. CLR in particular, is 
strongly influenced by total hepatic lipid, so would be confounded by major alterations in lipid 
levels. However, when considering markers of disease more broadly, it can be argued that 
steatosis is integral to the aetiology and progression of many chronic liver diseases (Chapter 1). 
Moreover, it has been discussed in Chapters 3 and 4 how lipid composition and, in particular, 
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measures of lipid polyunsaturation are relevant to both NAFLD and chronic hepatitis C. That 
lipid composition differs with disease severity is an argument for its importance in chronic liver 
disease, rather than a suggestion that such an index is a direct marker of hepatic fibrosis. Table 
7-4 has demonstrated that PUI and CLR are complementary to APRI and TE for the prediction 
of fibrosis stage. More broadly, the non-invasive assessment of lipid composition may 
complement the assessment of other aspects of liver disease, in combination with other non-
invasive techniques. 
7.5.1 Limitations and solutions 
7.5.1.1 General limitations 
This study is limited by relatively small numbers of patients included in the analysis. In 
particular, there were only six patients in the cirrhosis group. Accordingly, as discussed in 
section 6.6.6, it is not appropriate to make firm conclusions about the relative performance of 
markers for the prediction of cirrhosis from this small number of patients. It is assumed that 
these patients are representative of patients with cirrhosis, which may not be the case. Patients 
with decompensated cirrhosis have been excluded from the study and patients with established 
cirrhosis of known aetiology may not require liver biopsy, as the diagnosis may be made 
clinically. Accordingly, the pool of patients with cirrhosis who were eligible for inclusion in the 
study does not represent the full spectrum of disease. The mild group contained 19 patients, 
making a comparison of techniques for the discrimination of mild from more severe disease 
more valid. Nevertheless, within the mild group, there may be those without deranged liver 
function tests in whom hepatitis C is either not diagnosed or in whom a liver biopsy is not 
considered a clinical priority. Therefore, care should be taken when extrapolating the results of 
such a small study to the wider population. 
7.5.1.2 Specific limitations 
Limitations specific to the individual techniques and the statistical methods used are discussed 
in the relevant sections. With respect to this study, it should be reiterated that the patients 
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included in the analysis overlap those studied for previous analyses. In addition, the PUI in vivo 
was calculated in 77% of the patients in Chapter 5, as the diallylic resonance was small and 
could not always be fitted. In this chapter, only those patients in whom all measurements were 
available were included. Therefore, while this serves as a useful comparison between markers, it 
does not constitute an independent validation of the techniques used. 
7.5.2 Potential solutions 
This study would be improved by a number of means. If a greater proportion of patients had had 
satisfactory measurement of all markers, there would be greater confidence in the comparison 
between tests. Optimal combinations could be suggested on the basis of such an analysis and 
should be validated using a separate cohort. The number of patients that have been recruited 
prohibits such an analysis. More even numbers of patients for each fibrosis stage would enable 
improved goodness-of-fit for the ordinal regression model of fibrosis stage. 
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7.6 Conclusions 
This analysis suggests that the MR indices PUI and CLR are able to predict fibrosis category 
with accuracy comparable to other non-invasive markers. In combination, these MR indices 
complement APRI and TE. On the basis of the current study, neither PUI nor CLR can be 
recommended as a surrogate marker of hepatic fibrosis in the context of other currently 
available markers. However, the assessment of lipid composition and, specifically, PUI may be 
a biologically and pathologically-relevant adjunct to other techniques for the non-invasive 
assessment of chronic liver disease. 
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8 FUTURE DIRECTIONS 
This thesis has addressed the feasibility and relevance of 'H MRS for the assessment of chronic 
liver diseases and provides the basis for much future work. Further work may be divided into 
further technical development to improve the techniques used and applications of the techniques 
to validate them biologically and clinically. 
8.1 Technical development 
8.1.1 MAS NMR spectroscopy 
The limitations of 'H MAS NMR spectroscopy for the analysis of intact tissue include sampling 
variability and the effects of sample degradation. The sensitivity (defined by signal-to-noise) 
and resolution (defined by linewidth) could be improved by using stronger magnetic field 
strengths (up to 18T). As described in section 2.2, increased numbers of spectral acquisitions 
would also improve sensitivity, but to the potential detriment of spectral resolution and sample 
degradation. Spectral noise could be reduced by cooling the probe electronics, requiring 
upgraded hardware. Vibration control and atmospheric conditions should be tightly controlled 
by housing the magnet in a purpose-built room with an airlock, climate-control and an inflatable 
airbed. To ensure that the signal obtained is optimally quantitative, the sample should be 
confined to the centre of the magnetic field, better achieved using spherical sealing cell cavities. 
8.1.2 Multivariate pattern recognition analysis techniques 
The current approach to analysis of complex spectra with overlapping peaks is to "bucket" 
regions of the spectrum, prior to integration of the area under the curve within the bucket. Co-
resonance of metabolites may lead to resonances being assigned inappropriately. Fitting of 
individual curves using jMRUI is not practical when a large number of resonances is seen. 
Targeted profiling is a new approach which fits the expected lineshape of metabolites to the 
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spectrum of interest, thereby enabling low-concentration metabolites to be distinguished from 
larger overlapping resonances (Weljie et al, 2006). An application of this might be the 
subtraction of known lipid resonances from a spectrum, leaving the smaller metabolites 
unmasked. Sample-specific databases could then be used to fit resonances appropriate and 
relevant to the sample of interest, as the expected ratios of metabolites in tissue differ 
considerably from those seen in urine. 
8.1.3 ' H M R S in vivo 
The major limiting factor in the application of in vivo 'H MRS to chronic liver disease is 
inadequate resolution and SNR, which, in this context, has been shown to lead to the 
underestimation, or occasional failure to curve-fit, smaller resonances (section 5.7.1.3). 
Technical developments should, therefore, focus on increasing SNR and resolution. In theory, 
the SNR should increase proportionally to the increase in field strength (Edelstein et al, 1986). 
'H MRS could be performed at 3T or higher and the spectral information obtained should be 
compared directly to that obtained at 1.5T. Additional factors include control of patient motion 
artefact, distorting magnetic susceptibility effects and hardware contraints, such as electronic 
"noise". The demonstration that 'H MRS is a biologically and clinically relevant tool may 
encourage manufacturers to invest in scanner development, with attention to these areas. 
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8.2 Biological 
8.2.1 Lipid polyunsaturation and oxidative stress 
Polyunsaturated fatty acids are consumed in conditions of oxidative stress to produce lipid 
peroxidation adducts. Oxidative stress is central to mechanisms of hepatic injury, steatosis and 
fibrosis, as discussed in section 1.5.3. In this thesis, evidence has been provided that indices of 
lipid polyunsaturation may be detected both in vitro and, non-invasively, in vivo. Moreover, 
polyunsaturation decreases with increasing fibrosis and steatosis, providing indirect evidence of 
a role in chronic liver disease. For PUI to be considered a potential non-invasive marker of 
oxidative stress in chronic liver disease, further work is required to relate directly PUFA levels 
with lipid peroxidation. To address this issue, a number of experiments could be performed. 
Firstly, semi-quantitative immunohistochemical staining for HNE and MDA adducts in liver 
tissue from biopsy adjacent to that used for 'H MAS NMR spectroscopy could be correlated 
with the PUI, in collaboration with a histopathologist. However, such a study would be limited 
by the sampling variability inherent in any histologically-based study, by the semi-quantitative 
nature of immunohistochemistry and by the volatility of lipid peroxidation products, which may 
lead to poor sensitivity in biopsy samples, which have not been processed immediately upon 
acquisition. 
Colorimetric assays for the quantitative assessment of lipid peroxidation products are available 
(Oxford Biomedical Research Inc. Oxford, MI, USA), although such assays are destructive, 
making the use of limited quantities of human tissue in such circumstances inappropriate. 
Furthermore, such assays would not be possible following 'H MAS NMR spectroscopy analysis 
on account of the sample degradation. Such techniques could be employed, however, in the 
assessment of tissue from animal models of liver disease that are particularly associated with 
oxidative stress, such as carbon tetrachloride-induced liver injury. These experiments could also 
enable a dose-response curve of liver injury to lipid polyunsaturation to be established. 
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Controlled studies would enable changes associated with commencement and resolution of 
injury to be detected. 
8.2.2 Lipid composition of hepatocyte models of HCV replication 
Much work on viral mechanisms of replication and hepatic steatosis is performed using cell 
lines (Kapadia and Chisari, 2005; Miyanari et al., 2007). Quantification of lipid is performed by 
electron or light microscopy, or by using chromatography techniques on cell extracts. 'H MAS 
NMR spectroscopy of the intact cell fraction in cell-culture experiments would provide a rapid 
quantitative technique for the assessment of lipid composition, in which viral and culture-
medium factors may be altered in a controlled fashion. Presentation of work contained in this 
thesis has resulted in an ongoing collaboration with virologists at Imperial College London to 
assess intracellular lipid in infected immortalised hepatocyte cell-lines infected with modified 
HCV, using 'H MAS NMR spectroscopy. 
8.2.3 Profiling of liver tissue subject to toxic, genetic and metabolic insults 
In this thesis, metabolic profiling of intact liver tissue has been applied in murine models of 
NAFLD and in human liver biopsy samples in chronic hepatitis C. The development of robust 
and reliable protocols for data acquisition has formed the basis of new collaborations with GSK 
and the Biological Imaging Centre at Imperial College London for the investigation of the 
effects of a-naphthylisothiocyanate (ANIT), a toxin that causes biliary epithelial damage and 
cholestasis, on rat liver. 'H MAS NMR spectroscopy of tissue forms part of a multi-modality, 
multi-system approach to the investigation of models of liver toxicity and biliary hyperplasia. 
Another collaboration arising from this thesis is the study of tissue from murine models of 
obstetric cholestasis. The effect of pregnancy hormones on bile acid homeostasis is being 
investigated in murine models deficient in the nuclear receptor, farnesoid X (FXR), compared to 
controls in pregnant and non-pregnant mice fed on diets with or without cholic acid 
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supplementation (Van Mil et al., 2007). Preliminary results have demonstrated marked 
differences in the lipid, choline and glucose regions between groups. 
Further animal models of NAFLD are being developed using combinations of chemical 
mutagenesis and dietary manipulation. 'H MAS NMR spectroscopy of liver tissue provides a 
rapid assessment tool that may aid high through-put phenotyping of the resultant models, in 
conjunction with biochemical and histological measures, and the proteomic and metabonomic 
profiling of biofluids. 
8.2.4 Interventional studies 
This thesis has demonstrated that the non-invasive assessment of lipid composition is feasible, 
in addition to measures of total hepatic lipid. As part of a study based at the University of 
Newcastle and in collaboration with investigators at Imperial College London, the effect of 
modulation of lipids with lipid-lowering agents and PUFA-rich fish oils is being studied in 
patients with chronic hepatitis C, who have failed to eradicate the virus with conventional 
antiviral therapy. A subset of these patients is undergoing hepatic 'H MRS before and after lipid 
modulation. The effect of these interventions on lipid composition will be investigated 
longitudinally. The demonstration of changes in hepatic lipid in response to these interventions 
will further validate the technique. Furthermore, differences in hepatic and plasma lipids may be 
correlated with viral load and indicators of liver function. 
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8.3 Clinical applications 
Hepatic lipid quantification using 'H MRS has already been applied to thousands of patients in 
studies of the prevalence of hepatic steatosis in the USA (Browning et al., 2004; Szczepaniak et 
al., 2005). However, the relationship between simple hepatic steatosis and the development of 
progressive liver disease is still unclear. Thus widespread hepatic lipid quantification in the 
general population is not currently indicated. 
It has been argued that the measurement of hepatic lipid composition is of importance in the 
pathogenesis of chronic liver disease. However, this needs to be demonstrated in prospective 
clinical studies. 
Of the markers of hepatic fibrosis studied in this thesis, some, such as APRI and TE, are now 
widely available, have been extensively studied over the last 5 years, and are entering clinical 
practice. Their precise role will evolve with experience. 
8.3.1 Validation of MR indices in CLD of differing aetiologies 
The non-invasive assessment of hepatic lipid composition using 'H MRS has been assessed in 
this thesis in a cohort of patients with hepatitis C-related chronic liver disease. Other 
investigators have recently assessed lipid composition in lean and obese subjects, although 
evidence of liver injury, in terms of inflammation or fibrosis, was not assessed and, as has been 
explained, their assignment of metabolites was incorrect (section 5.2.1). 
The technique should be applied to patients groups in whom hepatic steatosis is thought to be a 
prominent factor in the development of disease. Thus, cohorts of patients with NAFLD and 
alcoholic liver disease should also be studied. 
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8.3.2 Combination of 'H MRS with other MR sequences 
MR techniques are being developed for the staging of chronic liver disease and show promise 
(Talwalkar et al., 2008). As discussed in section 1.7.3, MRE to measure liver stiffness has 
demonstrated high accuracy for the assessment of fibrosis compared to biopsy, while producing 
a map of the spatial distribution of high stiffness regions (Huwart et al., 2008). DWI stages 
fibrosis by assessing proton diffusion, thought to be reduced in fibrotic disease (Lewin et al., 
2007), while ^'P MRS has been shown to grade the severity of cirrhotic and precirrhotic liver 
disease by assessing phosphorus-containing membrane metabolites and energy intermediates 
(Lim et al., 2003b). 'H MRS sequences are quick and available on most clinical MR systems. 
Therefore, a multi-faceted assessment of chronic liver disease might be achieved by combining 
the assessment of lipid composition using 'H MRS with MR sequences that provide information 
on cell membrane components, liver stiffness or measures of diffusion. 
8.3.3 Development of therapeutic strategies for chronic liver disease 
The elucidation of mechanisms of fibrogenesis has demonstrated a number of potential targets 
for drugs to slow, halt or reverse fibrosis and, potentially, cirrhosis. The lack of validated 
markers is a barrier to clinical studies of the effectiveness of novel therapies. In slowly 
progressive disorders, such as chronic liver disease, it may take many years for patients to 
develop the complications of cirrhosis, which are considered "hard" endpoints for clinical 
studies. 
The pharmaceutical industry is under increasing pressure to reduce the costs of drug 
development as, currently, many drugs are developed but fail to progress through clinical trials. 
There is need to develop markers of "early signs of efficacy". Such markers should be sensitive 
to change, but do not necessarily need to be mechanism-specific. The purpose of such markers 
is to enable drugs that do not show signs of efficacy to be excluded at an early stage in 
development, thus saving costs. Candidate drugs passing this hurdle can then be assessed in 
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longer term clinical studies using validated endpoints (Drs W. Vennart & B. Souberbeille, Pfizer 
UK Ltd. personal communication). 
Longer term studies are also required that compare markers with hard endpoints, such as 
repeated histological assessment (with appreciation that histological assessment of liver biopsy 
is also a surrogate marker of liver disease) and the development of complications of cirrhosis, 
such as portal hypertension, the onset of hepatic encephalopathy and the development of 
hepatocellular carcinoma. 
8.3.4 Markers of response to antiviral therapy 
As part of the drive to develop early markers of efficacy, a subset of the patients studied in this 
thesis is currently being assessed longitudinally, over a period of 2 years, in response to antiviral 
therapy with pegylated interferon and ribavirin. The study is due for completion in October 
2009. Having assessed marker performance cross-sectionally in Chapters 6 & 7, markers will 
also be compared in their ability to detect change associated with a response to antiviral therapy. 
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9 CONCLUSIONS 
9.1 Development 
9.1.1 In vitro NMR optimisation studies 
Physical and NMR parameters have been optimised for the acquisition of reliable, high-
resolution 'H m a s NMR spectra from intact liver tissue, using the 11.7T JEOL system at the 
Hammersmith Hospital Campus, Imperial College London. MR parameters were set for 
subsequent experiments. Use of larger samples in the smallest cell able to contain them, was 
considered optimal. A spin speed of 4000Hz and acquisition temperature of 4°C were selected. 
Sample disruption increased spectral resolution but also increased spectral changes with time. 
9.1.2 Phenotyping murine models of NAFLD 
A novel approach to the investigation and classification of murine models of NAFLD on the 
basis of environmental, genetic and histopathological features using 'H MAS NMR 
spectroscopy of intact liver tissue in conjunction with multivariate modelling techniques was 
established. Class membership was predicted with high accuracy and it was possible to 
distinguish reliably between samples, even where histological appearances were 
indistinguishable. Partial least squares discriminant analysis enabled the identification of 
biologically-relevant metabolites contributing to the differences between models. 
Lipid content, measured using 'H MAS NMR spectroscopy, was found to correlate with 
histological assessment of hepatocellular lipid droplets. Moreover, an exponential relationship 
between mouse mass and NMR-defmed hepatic lipid load was established. Lipid composition 
(including indices of fatty acid polyunsaturation) differed according to dietary constituents and, 
independently, according to disease severity. 
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9.2 Translation 
9.2.1 'H m a s NMR spectroscopy of liver tissue in patients with chronic hepatitis C 
High resolution 'H MAS NMR spectroscopy of liver biopsy samples was used to examine the 
metabolic profile in patients with chronic hepatitis C. Multivariate pattern-recognition analysis 
demonstrated that lipid and choline resonances accounted for much of the NMR spectral 
differences between groups; an increase in total lipid and a decrease in lipid polyunsaturation 
were observed with increasing hepatic fibrosis, while increased intrahepatic lipid was observed 
non-invasively in patients with genotype 3. This was the first study to apply these techniques to 
chronic hepatitis C and the largest such study of chronic liver diseases. Moreover, this is the 
first study using 'H MAS NMR to demonstrate decreasing levels of hepatic polyunsaturated 
fatty acids with increasing degrees of liver fibrosis. On the basis of these studies, robust indices 
were proposed, which demonstrated potential to be translated to the in vivo setting. 
9.2.2 In vitro data informs analysis and interpretation of MRS in vivo 
Recently published work was criticised with respect to incorrect peak assignment. A 
physiologically-appropriate method to inforni the analysis of in vivo MR spectra was proposed, 
whereby chemical shift information from 'H MAS NMR spectra informs prior knowledge for 
curve-fitting of in vivo MR spectra. 
9.2.3 Application of 'H MRS to chronic hepatitis C in vivo 
The indices examined in vitro were applied to a separate cohort of patients with chronic 
hepatitis C in vivo. The trends observed in the lipid composition indices in vitro were confirmed 
in vivo; specifically, that total lipid was higher in those with genotype 3, compared to those with 
genotype 1 and that PUI and CLR decreased with increasing hepatic fibrosis stage. Thus, 'H 
MRS is a feasible method for the non-invasive assessment of lipid composition in hepatitis C-
related chronic liver disease. 
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9.3 Evaluation 
9.3.1 Comparison of non-invasive markers for the assessment of chronic hepatitis C 
Two imaging-based markers (TE and HTT) and two serum markers (APRI and ELF) were 
compared with histological assessment of liver biopsy in patients with hepatitis C, both head-to-
head and in combination, according to increasing cost and complexity. Individually, TE and 
ELF performed best for the prediction of fibrosis stage. In combination, APRI with either TE or 
ELF was optimal. Addition of further markers did not improve the prediction of fibrosis stage 
significantly. HTT perfonned least well for the prediction of fibrosis. Neither HTT, nor ELF 
had previously been evaluated in the context of other non-invasive markers of chronic liver 
disease. 
9.3.2 Evaluation of 'H MRS-derived indices compared to other markers 
As the 'H MRS-derived indices correlated with fibrosis stage, their ability to diagnose cirrhosis 
or predict fibrosis stage was compared to that of APRI and TE. Although both PUI and CLR 
predicted fibrosis stage, they perfonned less well than either APRI or TE individually. 
However, in combination with APRI or TE, they contributed significantly to the regression 
model to predict fibrosis, demonstrating that these indices are complementary to other markers 
when used in combination. 
9.3.3 'H MRS in the assessment of chronic liver disease 
In conclusion, the analysis of lipid composition is of pathogenic importance in chronic liver 
disease and the non-invasive assessment of hepatic lipid composition using 'H MRS provides a 
novel perspective. 
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